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Abstract
Inflammatory bowel disease is a chronic inflammation disorder affecting mainly the
colon and the small intestine. A common concomitant feature of this disease is the
formation of colorectal cancer, causing worldwide about 38000 deaths per year. To
date, the pathomechanisms underlying this disease are only partially known. Besides
environmental factors and genetic alterations, an inadequate immune response to the
host’s microbiome significantly contributes to the onset as well to the progression of the
disease. Furthermore, macrophages have been identified as a cell type, highly involved
in the pathophysiology of inflammatory bowel disease and colorectal carcinogenesis.
The immediate early response gene Ier3, whose expression is highly up-regulated in
patients suffering from inflammatory bowel disease, plays an important role in the
cellular response to stress stimuli. Ier3 not only influences the regulation of apoptosis and
proliferation but also affects several immunologic pathways, for instance by interacting
with the NF-κB signaling cascade. In this project we analyzed the effects of a cell type
specific depletion of Ier3 on the outcome of colitis and colitis associated carcinogenesis
using an AOM/DSS mouse model. We were able to show, that a macrophage specific
depletion of Ier3 significantly attenuates the severity of an AOM/DSS induced colitis
as well as the formation of colorectal tumors. This protective effect was much less
pronounced in an epithelial cell specific or genome wide depletion of Ier3. Furthermore,
we observed a reduced responsiveness of Ier3 deficient macrophages to immunogenic
stimuli like bacterial LPS, which manifests in a significantly decreased expression of the
inducible nitric oxide synthase and a diminished release of reactive nitrogen species. As
a result, these macrophages affect the integrity of the intestinal epithelial cell barrier to a
much lesser extent when compared to activated Ier3 proficient macrophages. This relates
to a differential effect on the transepithelial permeability caused by an altered expression
and intracellular distribution of the cellular junction associated proteins E-cadherin and
β-catenin as we could demonstrate in vivo and in vitro. In summary, our results reveal
a novel mechanism how IER3 contributes to inflammatory bowel disease and colitis
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associated carcinogenesis.
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Abstract (German)
Zusammenfassung
Chronisch-entzündliche Darmerkrankungen und die daraus resultierende Entstehung ko-
lorektaler Karzinome fordern weltweit etwa 38000 Tote pro Jahr. Die Pathomechanismen,
die dieser Krankheit zugrunde liegen sind bisher nur zum Teil verstanden. Neben diver-
sen genetischen- und Umweltfaktoren trägt vor allem eine inadäquate Immunreaktion
gegenüber dem intestinalen Mikrobiom zur Initiation und Progression der Erkrankung
bei. Des Weiteren konnten Makrophagen als ein Zelltyp identifiziert werden, welcher
im hohen Maße an der Pathophysiologie chronisch-entzündlicher Darmerkrankungen
und kolorektaler Karzinome beteiligt ist. Das immediate early response Gen Ier3, dessen
Expression in dieser Patientengruppe deutlich hochreguliert ist, spielt eine wichtige Rolle
in der zellulären Antwort auf eine Vielzahl von Stress-Stimuli. Ier3 wirkt sich nicht nur
auf die Regulation der Apoptose und Proliferation aus, sondern interagiert auch mit
diversen immunologisch relevanten Signalwegen, wie zum Beispiel der NF-κB Kaskade.
In dieser Arbeit wurden die Effekte einer Zelltyp-spezifischen Deletion von Ier3 auf
den Verlauf einer Kolitis und der damit einhergehenden kolorektalen Karzinogenese
im AOM/DSS Mausmodell untersucht. Wir konnten zeigen, dass eine Makrophagen-
spezifische Ier3 Defizienz, die Schwere einer AOM/DSS-induzierten Kolitis signifikant
abschwächt, sowie die Bildung kolorektaler Tumore signifikant reduziert. Dieser pro-
tektive Effekt war bei einer Epithel-spezifischen oder genomweiten Depletion von Ier3
deutlich geringer ausgeprägt. Des Weiteren beobachteten wir eine reduzierte Responsivi-
tät Ier3-defizitärer Makrophagen gegenüber immunologischen Stimuli, wie zum Beispiel
bakteriellem LPS, welche sich in einer verringerten iNOS-Expression sowie in einer
verminderten Freisetzung reaktiver Stickstoffspezies manifestierte. Solche Makrophagen
beeinflussten im Vergleich zu Ier3-profizienten Makrophagen die Integrität der intestina-
len Epithelzellbarriere in signifikant geringerem Maße. Dies äußerte sich vor allem in
einer unterschiedlichen transepithelialen Permeabilität, verursacht durch eine veränderte
Expression sowie intrazellulären Distribution der Zellkontakt-assoziierten Proteine E-
Cadherin und β-Catenin, welche sowohl in vivo wie auch in vitro nachgewiesen wurde.
3
Abstract (German)
Zusammengefasst zeigen diese Befunde einen neuen Mechanismus auf, wie IER3 zur
Pathogenese chronisch-entzündlicher Darmerkrankungen und einer damit verbundenen
kolorektalen Karzinogenese beiträgt.
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Introduction
1 Anatomy and physiology of the gut
1.1 Anatomy
The gut (also intestine or bowel, fig. 1.1) is an organ mainly responsible for the digestion
and resorption of nutrients and water as well as for discharging of indigestible food
components [205]. With an surface area of 32 square meters14 [89], it represents a major
immunological barrier separating the human body from its luminal environment. It
consists of two main segments, namely the small intestine and the large intestine (cecum
and colon), which can be further subdivided in smaller anatomically segments. The
small intestine (SI) is distinguished (from proximal to distal) into duodenum, jejunum
and ileum. The colon, which is preceded by the cecum with its appendix, is divided into
ascending colon15, transverse colon16, descending colon, sigmoid colon17 and rectum.
During the last decades, its role in the regulation of the immunological homeostasis has
gained great attention in physiological and medical research [200, 89].
14Other sources report a surface area of 400 m² [159].
15The mouse equivalent to the ascending colon is termed proximal colon.
16The mouse equivalent to the transverse colon is denoted as middle colon (divided in M1 segment and M2
segment).
17The mouse equivalent to descending colon and sigmoid are denoted as distal colon.
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stomach
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rectum
duodenum
jejunum
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small
intestine
Figure 1.1: Illustration of the intestine and stomach. Modified after BLAUSEN cb [39].
In cross section, both, small and large intestine show the typical tissue layer structure of
the gastrointestinal wall which consists of (from luminal to basal): mucosa, submucosa,
muscularis and serosa. While this main structure is consistent over the whole gastroin-
testinal tract there are distinct differences in its manifestation between small intestine
and colon.
The mucosa consists of a monolayer of polarized, columnar intestinal epithelial cells
(IEC) of different types (sec. 1.3.1), sitting on a thin basal lamina. On its apical face,
this epithelial layer is covered by a mucus layer (sec. 1.3.2). Underneath the basal
lamina, the lamina propria is located, a layer of connective tissue containing blood
capillaries and lymphatic vessels as well as lymphocytes and, to a lesser extend, myeloid
cells. Lymphocytes are diffusely distributed trough the epithelial layer (interepithelial
lymphocytes) and the lamina propria, whereas lymphocyte follicles only appear in the
lamina propria. In the small intestine these follicles can appear in huge condensed
clusters called Peyer’s patch. As part of the gut-associated lymphatic tissue (GALT),
these immune cells play a key role in the maintenance of the intestinal immunological
homeostasis. The lamina muscularis mucosae, which is also a part of the mucosa, is a
thin layer of muscle tissue, sitting underneath the lamina propria. The mucosa is the layer
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with the greatest morphological variation within the gastrointestinal system, accounting
for its specialization in distinct compartments. In the small intestine, the mucosa forms
invaginations (crypts) and protrusions (villi) to increase its surface area, whereas the
colon only contains crypts18.
The submucosa is a layer of connective tissue underneath the mucosa, pervaded by a
dense net of blood and lymph vessels to provide the transport of substances as well
as immune cells from and to the mucosa. Lymphocytes and myeloid cells as well as
lymphocyte follicles and Peyer’s patches also appear in this layer. Furthermore, plexi
(ganglia) of the enteric nerve system (Meissner plexi) are located in submucosa.
The muscularis consists of an inner circular and outer longitudinal muscle layer, responsi-
ble for the guts peristaltic. Plexi of the enteric nerve system (Auerbach plexi) are found
between these muscles layers. The longitudinal muscles are covered by the serosa, a thin
connective tissue layer covered by squamous epithelial cells. Representing the outermost
layer of the intestine, it reduces the friction to other organs during peristaltic movements.
1.2 Microbiota in the gut
In humans, the gut is colonized by estimated 1014, mainly (99 %) anaerobic, bacteria, thus
making up a complex microflora [211, 17]. Compared to the colon, which harbors the
majority of the guts microbiome [82], the colonization of the small intestine is much
lower, displaying a gradual increase towards its distal site (jejunum: 103-104 CFU/ml
chyme, terminal ileum: 107-109 CFU/ml chyme) [163]. The gut’s microflora is composed of
estimated 100-500 different bacterial species [82, 179], whereby 30-40 different species
comprise 99 % of all bacteria [33]. However, their composition varies over the different
intestine segments and is modulated by other factors like dietary or the host’s health
condition [151, 82]. In healthy individuals, the bacteria populate the outer (luminal) layer
18In mice, the proximal colon additionally exhibits transversal folds, while the distal mouse colon has
longitudinal folds.
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of the mucus film (sec. 1.3.2), but do neither infiltrate the inner layer nor have direct
contact to the epithelial surface [86]. Besides their appearance in the outer mucus layer,
they make up 60 % of the dry mass of the feces (1010-1012 CFU/ml fresh specimen) [193].
The gut microbiome establishes during the first two years after birth [188]. In parallel, the
host develops an immunological tolerance to these bacteria, which exist in a commensal
and mutualistic relationship [57, 211, 188]. While providing nutrients for the microbiota
[211], the host benefits from them in several ways. Hence colonization and growth
of pathogenic bacteria is prevented by the commensal microflora [218] and otherwise
indigestible food components are converted into absorbable nutrients [41, 163, 69].
However, an exaggerated population with commensal or mutualistic bacteria can also
lead to diseases [82, 164].
1.3 Intestinal epithelial cells
1.3.1 Types of intestinal epithelial cells
The epithelial cell layer of the mucosa consists of different subtypes of specialized cells,
like enterocytes, goblet cells, enteroendocrine cells, Paneth cells and microfold cells
(M cells) [205]. All those cells differentiate from omnipotent epithelial stem cells located at
the bottom of the crypts. With an average lifetime of 4-5 days, they undergo a continues
process of apoptosis and renewal [205]. They all show a high grade of polarization,
giving rise of an apical side which faces the lumen, and a basal side which faces the
lamina propria. Due to their functional specialization, the different types of intestinal
epithelial cells (IEC) are variably distributed over the distinct segments of the intestinal
system [205].
Enterocytes, which are the main type of intestinal cells are largely distributed over
the whole small intestine and colon. Their main function is the absorption of water,
electrolytes and (digested) nutrients like lipids, sugars and proteins from the gut lumen
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as well as their transfer to the capillary system. For this purpose, they comprise a wide set
of substance specific molecular transporters and ion channels, whereas small lipophilic
molecules can be absorbed passively by diffusion through the cell membrane. Enterocytes
form a vast number of cytoplasmic protrusions on their apical side to increase their
surface area [139]. These protrusions are named microvilli. Because of its microscopic
morphology, this microvilli forming epithelium is also named brush border epithelium.
Besides their absorptive properties, enterocytes also secrete IgA, provided from mucosal
B-cells, into the gut lumen [159].
Goblet cells are single cellular glands, producing and secreting a highly glycosylated
mucus into the gut lumen. While found in the small intestine and in the colon, their
number steadily increases from proximal to distal. Compared to enterocytes, their
microvilli are shorter and smaller in number [102, 205].
As part of the endocrine system, enteroendocrine cells are spread over the whole intestine.
They secrete a wide range of different hormones, mainly modulating the digestion and
uptake of specific nutrients [77, 205].
Paneth cells are secretory cells sitting in the crypts of the small intestine. Their granule
contain a range of defensins and other antimicrobial peptides as well as lysozyme,
contributing to the immunological homeostasis [42, 205].
As part of the follicle associated tissue, M cells are found everywhere Peyer’s patches
appear. At their apical face, they are able to take up antigens from the gut lumen and
deliver them to antigen presenting cells (APC) at their basal side [119, 205].
Tuft cells, named after their unique microvilli morphology, belong to the family of
chemosensory cells. While their exact physiological function is not fully understood
until now, it is assumed that they also play a role in modulating the gut immune
system [68, 205].
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1.3.2 The mucosa’s mucus layer
As mentioned above, at its apical face, the mucosal epithelial cell layer is covered by a
thin film of mucus continuously produced by goblet cells. The gel like mucus consists
of water, glycans as well as different glycoproteins, so called mucins, and serves several
purposes [101]. As lubricant, it reduces the friction during the transport of feces towards
the anus. Furthermore, it acts as an additional immunological border between the gut
microbiome and the epithelial cell surface [101]. The mucus film, can be divided in two
distinct layers. An inner layer, which sits firmly on top of the epithelial cells, consists
of a relative dense mucus and has a thickness of about 50 µm. Under physiological
conditions this layer is free of bacteria. The outer layer (≈100 µm thickness) is organized
more loosely and the habitat for the commensal and mutualistic microbiota [86, 101].
1.3.3 Intercellular junctions
The single IEC of the mucosa’s cell composite are connected by several intercellular
junctions [58] (fig. 1.2), impacting significantly its physical and biological properties [87,
200].
Tight junctions Tight junctions (TJ, fig. 1.2a) seal the intercellular space between IEC
at their lateral side, thus preventing an unintended paracellular exchange of substances
and cells between the apical lumen and lamina propria [87]. They appear as belt like
structure completely surrounding single cells and connect them with adjacent cells [58].
From the lateral view, tight junctions can form several superimposed strands, to improve
their sealing properties. While being composed of over 60 different proteins types [156],
tight junctions, are divided into three main classes: Occludin based, claudin based and
junction adhesion molecule (JAM) based tight junctions.
Occludin (OCC19) is a transmembrane protein of 60-82 kDa (in humans), encoded by the
19Alternative protein abbreviations for occludin are OCLN and OCLDN.
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Ocln gene. Several isoforms of the OCC protein exist due to alternative splicing [142, 124].
Occludin consists of four transmembrane domains as well as of two extracellular and
one intracellular loop. C- and N-termini are located intracellularly [87, 62]. The two
extracellular loops form a bond with the extracellular loops from an OCC protein of an
adjacent cell [81]. Near its C-terminus OCC binds to a variety of other junction related
proteins like members of the zonula occludens family (mostly prominent ZO1), cadherins
and cingulin, forming a huge protein complex [142, 124]. This complex again binds to
cellular actin filaments, providing the tight junction’s mechanical stability [64, 135].
The claudin (CLDN) protein family includes 24 known members of 20-27 kDa pro-
teins [199, 63], which all share structural similarity to occludin [110]. Like OCC, the extra-
cellular loops of claudins form bonds with their counterparts from adjacent cells [65, 110].
Near to their C-termini they also bind a variety of junction related proteins which then
again interact with cellular actin filaments [140, 97, 128].
Junctional adhesion molecules (JAM) are proteins of about 40 kDa belonging the super-
family of immunoglobulins (Ig) [55, 31]. They consist of two Ig-like extracellular domains,
a single-pass transmembrane domain and a cytoplasmic C-terminal domain [55, 31]. The
extracellular domains of JAM can form homo- and heterophilic bonds, while the latter
was only shown for endothelial JAM [32, 27]. At their C-terminus they have binding
motifs for ZO1 and other junction related proteins, which can interact with cellular actin
filaments [81].
Adherens junctions Adherens junctions (fig. 1.2b) belong to the group of anchoring
junctions, improving the mechanical cohesion between the IEC in the mucosal layer [178,
87]. They indirectly connect the cytoskeletal actin filaments of two adjacent cells by
linking them trough a intercellular bridge of E-cadherin20 proteins [84]. In cellular
junctions, the extracellular domains of an E-cadherin dimer form a homophilic bond
with the extracellular E-cadherin domains of an adjacent cell [85]. The intracellular
20For more information on E-cadherin and its function in IBD and CAC see section 3.3.1.
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domains bind to proteins of the catenin and vinculin family, which act as adapters
facilitating the anchoring of actin filaments [157, 85]. While other forms are possible, in
the mucosa’s epithelial layer, adherens junctions appear as a belt like structure, named
zonula adherens [58]. They are located directly underneath the tight junctions [200].
Desmosomes Like adherens junctions, desmosomes (fig. 1.2c) belong to the group of
anchoring junctions. Desmosomes connect either two adjacent cells or, as hemidesmo-
somes, a single cell with the basal lamina [53, 208, 67]. They appear as ball shaped
structures randomly distributed at the lateral or, in case of hemidesmosomes, at the basal
side of the cells plasma membrane [58]. In contrast to adherens junctions, desmosomes
connect the keratin filaments of adjacent cells [107]. While also linking two cells by
cadherins, which protrude into the extracellular space, in desmosomes those cadherins
are of the desmoglein or desmocollin type [150, 67]. At their intracellular end, those
cadherins are anchored into a microscopical visible plaque consisting of desmoplakin,
plakoglobin and proteins of the catenin family [53, 67]. This plaque serves as a linker to
the intracellular keratin filaments [53, 67].
Gap junctions Gap junctions (fig. 1.2d) are clusters of intercellular transmembrane
channels (pores), allowing a direct exchange of small molecules (≈≤ 500 Da) between
cells [71]. Each cell forms a hemichannel (connexon), consisting of a homo or hetero-
hexamer of connexin (Cx) proteins, coupling to a connexon of an adjacent cell [173, 72].
Up to now, more than 20 different connexins are known [185, 186], accounting for the
formation of a great number of different gap junction subtypes with a high substance
specificity [90, 70]. Gap junctions connect cells chemically as well as electrically [132]
and serve primarily the transduction of signals [173, 71]. Substance transport through
gap junctions occurs passively by diffusion [132], but can be regulated by opening and
closing the pores [173]. Typical substances exchanged trough gap junctions are second
messengers like AMP, cGMP, IP3 as well as ions [113, 132].
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(a) Tight junctions. OCC: Occludin, CLDN: Claudins, ZO1:
Zonula occludens 1, JAM: Junction adhesion molecules.
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(b) Adherens junctions. Adherens junctions belong to the
group of anchoring junctions, improving the mechanical co-
hesion between the IEC of the mucosal layer.
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(c) Desmosome. Like adherens junctions, desmosomes be-
long to the group of anchoring junctions. The type
of desmosomal cadherins which consist of desmogleins
and desmocollins differ from type I cadherins like E-
cadherin. The intracellular plaque consists of desmoplakin,
plakoglobin and proteins of the catenin family.
extracellular
space
cytoplasm cytoplasm
cell membrane
Connexin
(d) Gap junction. Gap junctions are clusters of channels con-
necting the cytoplasm of two adjacent cells. Thus, they
allow a direct exchange of small molecules (≈≤ 1 kDa) be-
tween those cells. Each hemichannel (connexon) consist
of 6 connexin proteins. At the site of gap junctions the in-
tercellular gap has a wide of 2-4 nm.
Figure 1.2: Simplified illustrations of the four intercellular junction types in the gut’s IEC layer. See the
continuous text for a more detailed explanation.
However, during inflammatory processes cellular junctions allow the transmigration of
immune cells like neutrophil granulocytes and macrophages from the lamina propria to
the apical epithelial side due to their high plasticity [159].
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2 The gut immune system
2.1 The mucosa as immunological barrier
The intestinal mucosa with its mucus and epithelial single cell layer equipped with tight
junctions represents the border between the body and its luminal environment. On the
one hand, it has to be ensured, that none of the myriad of bacteria can overcome this
border. Due to their high number, even commensal or symbiotic bacteria comprise a high
pathogenic risk if infiltrating the lamina propria [82]. On the other hand, an permanently
exaggerated immune response would also negatively affect the host’s health status [159].
So a well balanced equilibrium between immunologic tolerance and activity is pivotal for
a proper function of the gut immune system.
2.2 Macrophages
2.2.1 General properties and functions
Macrophages (MΦ) are a subtype of leukocytes from the myeloid lineage, playing an
important role in the innate as well in the adaptive immunity by killing pathogens
and presenting microbial fragments on their surface. They appear as mononucleated
cells of about 20 µm diameter and can be found in most tissue compartments of the
human body. MΦ derive in multiple steps from hematopoietic stem cells of the bone
marrow under the influence of the growth factor “macrophage colony stimulating factor”
(M-CSF). Their direct precursor cells circulate as monocytes up to four days in the blood
system before migrating into the tissue where they differentiate into mature MΦ . This
differentiation is again mainly triggered by M-CSF, produced by cells of the respectively
tissue compartment (e.g. by fibroblasts). During immunological events, monocytes get
chemotactically attracted to those sites and activated, thus dramatically increasing the
number of MΦ within a reasonable amount of time [143].
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One of their main characteristics is the capability of phagocytosing particles, digest them
and present the resulting fragments on their surface, where they can be recognized by
other immune cells. Such particles can be bacterias and other pathogens, endogenous cells,
cell debris as well as a variety of other exogenous or endogenous particles. After engulfing
the particles in the phagosome, it fuses with the lysosome forming the phagolysosome.
Besides its low pH value, the lysosome contains a broad variety of digestive enzymes as
well as reactive oxygen and nitrogen species allowing an effective digestion respectively
killing of the phagocytosed particles. The digested fragments are then coupled to major
histocompatibility complex class II (MHC II) receptors and presented on the MΦ’s surface
where they can be recognized by T-cells. This ability, which they share with dendritic
cells (DC), characterizes MΦ as professional antigen presenting cells (APC) [143].
MΦ can be activated by a variety of exogenous and endogenous stimuli like the bacterial
antigens lipopolysaccharides (LPS) and muramyl dipeptide (MDP) or cytokines like IFN-
γ, TNF, IL-1β and IL-6 produced by other immune cells. After activation, MΦ increase
their phagocytotic activity, expression of the nitric oxides (NOx) producing protein
inducible nitric oxide synthase (iNOS) and the release of cytokines [143].
The ability to produce reactive nitrogen species (RNS), which can freely diffuse trough
their cell membrane, allows MΦ to kill not only phagocytosed pathogens but also
microorganisms in their direct neighborhood. On the other hand, this also bears the risk
of damaging the surrounding tissue and endogenous cells [143].
On protein expression level, human MΦ are characterized by high amounts of CD11b
and CD68 while CD11c expression is typically low [143]. Murine MΦ additionally
express high levels of F4/80 [126]. There exist several attempts to identify additional
subpopulations of MΦ, either by differences in the expression pattern of certain marker
proteins or by an altered response to immunogenic stimuli as well as an altered cytokine
release profile [74, 73]. There are two main classes of MΦ described in the literature:
Classically activated macrophages (M1 MΦ) exhibit a typical pro-inflammatory pro-
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file [148, 134]. They show an elevated phagocytosis rate combined with high iNOS
expression and an increased release of NOx as well as pro-inflammatory cytokines like
IFN-γ, TNF, IL-β and IL-6 [134, 143]. M1 polarized macrophages represent the typical
MΦ prototype during the host defense against pathogens.
In contrast, alternatively activated macrophages (M2 MΦ) are characterized by their
anti-inflammatory and immune suppressing properties [134, 143]. Compared to M1 MΦ,
their iNOS expression is much lower or even absent, while they produce high levels of
the anti inflammatory cytokines IL-10 and TGF-β.
While some authors divide the above mentioned two classes of MΦ in further sub-
classes [125, 170], the concept of M1/M2 macrophages itself is subject of an ongo-
ing controversial debate. Some authors argue, that there only exists one type of
MΦ, which underlies a certain plasticity regarding its pro- anti-inflammatory prop-
erties [144, 123, 83, 182, 117].
2.2.2 Intestinal macrophages
Though appearing in all segments of the gut, the highest number of MΦ is found
in the colon [145, 54]. From all tissue layers, the lamina propria and the submucosa
comprise the highest density of MΦ [94], while some MΦ are also found to a much
lesser extent, in the muscle layers [133, 195]. One has to distinguish between resident
and infiltrating mucosal MΦ. While the former resident in the mucosa permanently, the
latter infiltrate the mucosa only in response to an immunological challenge. Resident
MΦ comprise both, M1 and M2 features. As a result of their close localization to the
guts microbiome they developed a high tolerance to bacterial antigens regarding their
cytokine expression profile [28, 184, 88]. This could be explained by the continuous
secretion of TGF-β and other anti-inflammatory cytokines from the adjacent stroma
cells [29, 184, 88]. On the other hand, these MΦ comprise a high bactericidal activity
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against infiltrating microbiota [184]. In contrast, infiltrating MΦ exhibit the typical M1
profile of classical activated macrophages [29].
3 Inflammatory bowel disease
Inflammatory bowel disease (IBD) describes a chronic inflammatory disorder affecting
mainly the colon and small intestine, which results worldwide in about 38000 deaths per
year [19]. It manifests in two major forms: Ulcerative colitis (UC) and Crohn’s disease
(CD) [15].
Crohn’s disease was first noticed by the German surgeon Wilhelm Fabry in 1623 and
later described by and named after the US physician Burril B. Crohn in 1932 [47, 2].
The onset of CD occurs mostly at an age of 14 and 30 years. First symptoms are
abdominal pain, bloody diarrhea, fever and weight loss. Ileum and colon are the two
sections of the gastrointestinal tract which are mostly affected by CD in a discontinuous
pattern (fig. 3.1a) [161]. Extra-intestinal manifestations can also occur. Typical for CD
is the transmural inflammation, affecting all layers of the gut, often accompanied by
granulomas, strictures and fistulas [215].
Ulcerative colitis was first described by the British physician Sir Samuel Wilks in
1859 [210]. Its peek incidence is between the 15th and 25th year of age. Guiding symptoms
are mucous bloody diarrhea accompanied by rectal tenesmus. Fever and weight loss are
much more rare than in CD. The disease is marked by continuously inflammation pattern
ascending from the rectum (figure 3.1b) [215]. On histological level, the inflammation
is mostly confined to the mucosa. While granulomas, strictures and fistulas are rather
untypical findings in UC, emerging of ulcers is an often observed characteristic [215].
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(a) Typical inflammation
pattern of Crohn’s
disease.
(b) Typical inflammation
pattern of ulcerative
colitis.
Figure 3.1: Inflammatory bowel disease manifests in two major forms, Crohn’s disease and ulcerative col-
itis. CROHN’s disease (a) is characterized by a patchy inflammation pattern spreading over the whole
colon and the terminal ileum. By contrast, ulcerative colitis (b) presents a continuously inflammation
pattern ascending from the rectum.
The worldwide highest prevalence rates of IBD are seen in northern Europe (CD: 0.322 %,
UC: 0.505 %) [138] and the United States of America (CD: 0.201 %, UC: 0.238 %) [103].
Lower rates are found in Asia, but with increasing incidence during the last decade [138].
The exact mechanisms leading to the pathophysiology of IBD are only partially elucidated
until today [161]. However, several risk factors could be identified [15]. These are genetic
predispositions and mutations as well as environmental factors like dietary and smoking
status. Microbial-host interactions are getting more and more into the focus of science
during the last years, emphasizing IBD as a disease caused by a disturbed barrier
function along an inappropriate immune response. Besides mutations in Nod2, several
other disease associated genes like e.g. Ibd5 or Atg16l1 have been identified, pointing out
the importance of the innate immune system during diseases progression [30]. Luminal
antigen recognition begins at the epithelial level. Epithelial expressed pattern recognition
receptors (e.g. toll like receptors (TLR)) detect microbiome associated antigen motifs
which trigger several intracellular signaling cascades culminating in the activation of the
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB, fig. 3.2) [30]. Under
physiological conditions, there is a balanced equilibrium between active immune response
and immunological tolerance. In patients suffering from IBD, an exceeded activation
of NF-κB triggers an increased expression of pro-inflammatory cytokines. Amongst
other effects, this causes a diminished barrier function of the epithelium by loosening
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intercellular junctions. Thus, an increased number of antigens is detected by dendritic
cells and macrophages, leading to their forced activation thereby to excessive secretion
of pro-inflammatory chemo- and cytokines. The succeeded homing and activation of
further immune-cells results in a pronounced inflammatory phenotype [15, 30].
Figure 3.2: Signaling pathways of TLR and NOD proteins. All signaling cascades result in the activation of
NF-κB. MDP=muramyl dipeptide, MyD=myeloid differentiation primary response protein, IRAK=IL-
1-receptor associated kinase, TRAF=TNF-receptor-associated factor, TAK=TGF-β-activated kinase,
IKK=inhibitor of NF-κB kinase, RICK= receptor-interacting ser/thr-kinase. For further abbreviations see
the list at page XVII. Adapted from BAUMGART et al. [30].
In an experimental study it was shown, that some bacterial species of the luminal
flora influence the intraepithelial expression of cyto- and chemokines [147]. Thus, their
coexistence and interaction with the epithelial barrier and innate immune cells relies on a
delicate balance governed by pattern recognition receptors (e. g. Toll like receptors (TLR))
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expressed on epithelial and immune cells. These receptors detect antigens expressed
by intestinal bacteria and upon their activation then induce several pro-inflammatory
intracellular signaling cascades [30] that maintain the proper barrier function and keep
the microbial-host interaction under tight control. As described above, an exceeding
activation of this cascades is an initial event triggering the onset of IBD.
In all these complex interaction between genetic, luminal and environmental factors
that normally warrant an appropriate mucosal immune response but are out of balance
during IBD, the loss of integrity of the intestinal barrier has a pathologic key role [122].
Smoking is one environmental factor, diminishing the inflammatory phenotype of UC.
Experimental studies suggest that the beneficial effect of nicotine, in respect to the
inflammatory phenotype of IBD, is a result of an increased mucus production in the gut,
strengthening the epithelial barrier function [45, 96].
3.1 IBD and colorectal cancer
Inflammatory bowel disease goes along with an increased risk for developing colitis-
associated cancer (CAC). Such a colitis driven carcinogenesis is the main reason for
mortality in patients suffering from IBD [60]. Although, the molecular mechanisms
underlying CAC are not fully understood yet, it is assumed that they differ from the
typical development pattern of sporadic colorectal carcinomas (CRC) (figure 3.3) [168, 59].
While β-catenin mutations are found in more than 90 % of all sporadic CRC, they occur
rarely in CAC. The CRC-typical Apc mutations emerge in CAC at a much later time point
than in sporadically developing neoplasms, whereas p53 and k-ras mutations appear
rather early. Reactive oxygen species (ROS) contribute to the development of CAC in
a much more pronounced manner than they do during sporadic CRC. The continuous
depletion of epithelial cells during IBD leads to an increased proliferation rate in the
remaining tissue, while increased levels of NF-κB counteract apoptosis in epithelial
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cells. Bacterial translocation across the epithelial barrier is also discussed being a factor
promoting the development of CAC [168].
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(a) Progression model sporadic colorectal cancer by VOGELSTEIN et al [59].
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(b) Progression model of colitis-associated cancer by ROGLER et al [168].
Figure 3.3: Typical mutations occurring during sporadic and colitis-associated colorectal carcinogenesis.
↑ indicates a gain of function or increased levels, while ↓ indicates a loss of function.
3.2 M1 Macrophages in IBD in CAC
The infiltration of the LP with M1 MΦ is a critical step not only during the initial phase
of acute and chronic colitis but also during the inflammation’s progression. This pertains
for human colitis and CAC as well as for murine DSS induced colitis (sec. 3.4) [192, 28].
These MΦ actively contribute to IBD by damaging the epithelial cell layer integrity
and disrupting its barrier function [116]. While there was some controversy in the past,
in which extend the expression of the iNOS and the release of RNS contributes to the
pathogenesis of IBD in humans, newer studies clearly emphasize its importance for the
onset as well for the progression of the disease [190, 56, 116].
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Pro-inflammatory M1 polarized MΦ play an important role, especially during the onset
phase of colitis associated carcinogenesis [171]. In later stages of colorectal cancer, tumor
associated M2 polarized macrophages also contribute to the progression of the disease,
mainly by suppressing the somatic antitumorigenic immune response.
3.3 The role of cellular E-cadherin and β-catenin in IBD and CAC
3.3.1 E-Cadherin
E-Cadherin, which belongs to the type I cadherins, is a single-pass transmembrane
protein of 728 aa. It consists of five extracellular, one transmembrane and one intracellular
domain, whereby the latter comprises its C-terminal end [197, 196]. In humans it is
encoded by the Cdh1 gene. Like all cadherins, E-cadherin is a calcium dependent protein,
meaning it needs Ca2+ ions as cofactor to exert its functional properties. In its quaternary
structure it appears as homodimer [197, 196]. Besides its function in intercellular junctions
(sec. 1.3.3), E-cadherin is also involved in a variety of signal transduction processes [50,
105, 36, 37]. Several authors reported a dysregulation of E-cadherin in the intestinal
mucosa during inflammatory processes and CAC [98, 130, 50, 36].
3.3.2 β-Catenin
β-Catenin is a protein of 85 kDa (781 aa) encoded by the Ctnnb1 gene [109]. Besides its
function in intercellular junctions (sec. 1.3.3) it plays an important role in signal transduc-
tion processes and as transcriptional cofactor [204]. Most notable is its involvement in
the Wnt pathway, which plays an important role during embryonal development and
carcinogenesis [120]. A number of studies reported an altered expression as well as an
altered intracellular localization of β-catenin during IBD and CAC [130, 98, 36, 99].
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3.4 The AOM/DSS-mouse-model
During the last decades several animal models were developed to study the pathogenesis
of IBD and CAC. Although these models can not cover all aspects of the disease mecha-
nisms in human IBD, they are valuable tools for investigating disease contributing factors
[213, 212]. The application of dextran sodium sulfate (DSS) is a well-established model
that has been used for over two decades to study mucosal inflammation [213]. However,
the mechanisms underlying the effects of DSS have only been partially elucidated [51].
DSS is the sodium salt of the sulfated polysaccharide dextran (figure 3.4a). Usually,
it is administered ad libitum, solved in drinking water in a concentration range from
0.5 g/l up to 50 g/l [158]. The main effect by which orally applied DSS induces a colitis,
is its acute toxicity to the intestinal epithelium. Within 24 h, the epithelial expression
of pro-inflammatory cytokines (e.g. TNF, IL-1β and IFN-γ) increases and the epithelial
barrier starts to disintegrate as indicated by the growing loss of of proteins from the
zonula occludens family [158]. First histological changes in the form of basal crypt loss
and an increased mucosal infiltration by immune cells can be seen from day three [158].
These morphological changes are accompanied by an altered expression of tight junction
proteins, such as occludin, claudin-1, -3, -4 and -5 as well as altered rates of proliferation
and apoptosis in endothelial cells. DSS-induced tumorigenesis can be observed after
about 30 weeks as consequence of sustaining inflammation [51].
Interestingly, germ free animals present only a very mild response to DSS, indicating a
contribution of the commensal gut microbiome to diseases progression [93, 149].
DSS can be used to induce an acute or chronic inflammation, depending on its concentra-
tion and application intervals [158]. For instance, a DSS-administration over seven days
at a high dose21 causes an acute inflammation, while the administration of a low dose in
three 7-day-cycles interrupted by recovery phases of seven days each, triggers a chronic
inflammation. Whether the phenotype of a chronic inflammation corresponds more to
21Exactly concentrations depending among other factors on the used mouse-strain.
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the clinical manifestation of Crohn’s disease or ulcerative colitis, strongly depends on
the molecular weight of the DSS used22 [104, 91]. While DSS of 5 kDa triggers a CD-like
phenotype, administration of DSS with a molecular weight of 40 kDa provokes a UC-like
phenotype.
Besides concentration and application intervals, many other factors influence the out-
come of a DSS-induced colitis and carcinogenesis [158]. Commercially available DSS
is purchased in batches with a molecular weight between 5 kDa and 1 400 kDa. Most
severe colitis in BALB/c mice was observed in animals treated with DSS of 40 kDa, while
the application of 5 kDa DSS resulted in a less pronounced colitis [91, 104]. Animals
treated with DSS of 500 kDa or more exhibited no lesions in the large intestine. Mice
with different genetic background or gender show a distinct response to DSS. The same
is true for different housing conditions and concomitant differences in the composition
of the intestinal microbiome [121, 131].
One measure to increase the tumorigenicity of DSS is the additional administration of
azoxymethane (AOM, figure 3.4b) [51]. AOM, which itself exhibits an own tumorigenic
effect, is a metabolite of 1,2-dimethylydrazine, a precursor of biomolecules found in cycad
flour [115]. After administration to the host, AOM requires further metabolic activation
steps to induce DNA-reactive adducts. The main effect of AOM-derived metabolites
is the methylation of guanine at its O6- or N7-position, resulting in the formation of
promutagen lesions [52, 51]. Thus, the combined administration of AOM and DSS usually
reduces latency time for tumor formation to 10 weeks compared to about 30 weeks in a
pure DSS-model [51].
22The exact experimental conditions applied in this project are described in section 10.
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(a) DSS (b) AOM
Figure 3.4: Structural formulas of (a) DSS and (b) AOM.
Typically, AOM is applied as single or repeated dose by intra-peritoneal (i.p.) injection at
a concentration of 20 µg/g body weight prior to and/or during the DSS-administration
[51].
Numerous different AOM/DSS-protocols have been described in the literature [169, 155,
38, 152, 35, 34, 198], accounting for the great variations of this model with respect to
intrinsic or extrinsic factors which could influence the experimental outcome. Thus, it is
necessary to develop an individual protocol adjusted to the specific experimental setup
and questions posed.
4 IER3
In 1993 Charles et al. [40] identified a new growth factor-inducible immediate-early
gene, encoding a short-living glycosylated protein in mice. Later it came up, that this
gene was the murine orthologue of a human X-ray inducible immediate early gene
cloned by Kontratyev et al. in 1996 [106]. The same year, Schaefer et al. cloned its rat
orthologue [176]. While this gene initially named Gly96, Iex-1, Prg2 or Dif2, it is since
2002 officially termed as immediate early respone-3 (Ier3) [141].
Structurally, IER3 is highly conserved between different eutheria. Human IER3 comprises
156 amino acids (aa), while its murine and rat orthologues have a length of 153 and 160 aa,
respectively. Interestingly, the sequence motif of Ier3 shows no similarity with other
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known vertebra genes [26]. Thus, it is not possible to identify putative cellular functions
by comparing its tertiary structure to other proteins. However, several domains, like a
putative transmembrane domain [106], a potential glycosylation site [106], a Ser/Thr
phosphorylation site [66], a nuclear localization site as well a PEST like sequence [111]
could be identified in all orthologues.
The human Ier3-gene consist of two exons interrupted by an 112 bp intron [26]. There is
only one spliced mRNA variant expressed in vivo [174], while other reported expression
variants [214] turned out as artifacts. A great number of binding motifs for regulated
transcription factors could be identified in the promoter region of ier3, indicating its
involvement in various cellular responses to quite distinct stimuli [26].
Ier3 expression is triggered in response to variety of different cellular stress related
stimuli like radiation, increased levels of reactive oxygen species, immunogenic cytokines
or apoptotic stimuli [26]. Several studies demonstrated the interdependency between
IER3- and NF-κB expression [24, 25]. The Ier3 promoter sequence not only contains a
binding motif for NF-κB itself, but also binding motifs for other transcription factors
under control of NF-κB [26]. In turn, IER3 acts as an NF-κB inhibitor as part of a tightly
regulated negative feedback loop (figure 4.1a) [26]. Furthermore, a mutual modulation
of IER3 and proteins involved in the regulation of proliferation and apoptosis like ERK,
AKT, P53 or cMYC was reported [92, 95, 167]. However, there is some controversy in
which way IER3 contributes to cellular proliferation and survival in different cell types.
While Rocher et al. [167] demonstrated an IER3 mediated sustaining of ERK signaling in
promegakaryoblasts in response to growth stimuli (fig. 4.1b), Osawa et al. [154] reported
an negative interference between IER3 and AKT in hepatocytes.
IER3-triggered apoptosis in response to different apoptotic stimuli was shown for a wide
range of cell types [22, 23, 25, 80, 177, 26]. Another study identified IER3 as part of
P53 mediated apoptosis in response to DNA damage [175]. In contrast, anti-apoptotic
effects of IER3 were shown in T-cells from transgenic mice [220] and in some laboratory
cell-lines [181].
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(a) Negative feedback loop regulation between NF-κB and
IER3 described by ARLT et al. [24, 25]. While being a di-
rect expression target of NF-κB mediated transcription, IER3
inhibits the activity of NF-κB (p65/p50) by two distinct mech-
anisms. First, nuclear IER3 interacts with the transactivation
domain of p65, thereby suppressing the NF-κB mediated ac-
tivation of certain gene promoters. Furthermore, IER3 indi-
rectly attenuates the proteasomal activity by negatively inter-
fering with the expression of proteasomal genes, resulting in
a decreased IkBα degradation.
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(b) IER3 mediated sustaining of ERK signaling in
promegakaryoblasts described by Rocher et
al. [167]. As a direct downstream target of P-ERK,
P-IER3 interacts directly with PP2A and P-ERK,
causing to a phosphorylation of the PP2A’s B56
subunit leading to its inactivation. As conesquence
the PP2A mediated P-ERK dephosphorylation is
attenuated, resulting in an increased phosporylation of
further P-ERK targets like AKT.
Figure 4.1: Exemplary illustration of the involvement of IER3 in different cellular signaling pathways.
Adapted and modified after ARLT et SCHAEFER [26]. For abbreviations see list on page XVII.
Summarizing these results, IER3 seems to exhibit both, pro- as well as anti-apoptotic
effects. The outcome of the actions of IER3 is influenced by several factors like the
expression of other pro- or anti-apoptotic stimuli and the cellular context. Another
important role have compartment specific effects of IER3, depending on the tissue type
in which it is expressed [26].
4.1 IER3 in colitis and colitis associated cancer
A genome-wide microarray based mRNA-expression-analysis (figure 4.2) identified
ier3 as one of the most overexpressed genes in patients suffering from CD or UC, the
both major manifestations of IBD [46]. The possible effect of this overexpression is
a matter of some debate: One theory postulates, that the Ier3-overexpression is an
initially or disease triggered event, actively contributing to the disease progression [18].
The other theory argues, that the ier3-overexpression is a physiological response to
the exaggerated inflammation that finally manifests as a permanent but futile attempt
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to reduce the inflammatory burden [183]. Both theories are supported by obviously
contrary experimental results. A recent study conducted by Sina et al. [183] used a
constitutive Ier3-knockout mouse-model. After exposing the animals to several cycles of
dextran sodium sulfate (DSS) solved in drinking water, mice with ablated IER3 showed a
pronounced disease phenotype compared to the wild-type cohort. This came up with
severe erosions of the diseased colon epithelium, indicated by the loss of a regular crypt
architecture and considerable infiltration of inflammatory cells such as macrophages.
A striking feature along with the forced inflammatory response in IER3-deficient mice
was the enhanced release of pro-inflammatory cytokines and greater activation of NF-κB.
This was particularly shown for macrophages. Contrary, Ustyugova et al. [202] reported,
that IER3-deficient mice are characterized by an ameliorated inflammatory response in
a combined azoxymethane/DSS-model, along with a declined incidence of colorectal
cancer.
(a) Ier3-expression in CD. (b) Ier3-expression in UC.
Figure 4.2: Microarray based mRNA-expression-analysis in colon tissue from (a) CD- and (b) UC-patients.
Green fields indicate a relative underexpression while red fields indicate an overexpression. Row of
ier3-expression is marked by an orange box and arrow. Adapted from Costello et al. [46].
There are several possibilities which could explain the discrepancy between those findings,
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e.g. mice-strains used for both experiments consisted of different genetic backgrounds
and housing conditions. It was shown, that these both factors have a considerable impact
on the progression of DSS-induced colitis and colitis associated carcinogenesis [158].
Furthermore, the mice used by Wu et al. comprised besides the IER3 deficiency also a
depletion of the rag-gene. Thus, Ier3 depletion in distinct cellular compartments seems
to differently affect the outcome in DSS colitis and for this reason these two contrary
studies are not comparable. Accordingly, an important conclusion from the discrepant
results was that only a compartment specific depletion of IER3 can unveil its contribution
to IBD and colitis associated colorectal cancer. For this purpose, our group generated a
conditional Ier3 knock-out mouse model based on the Cre/loxP-system23 (see section 4.2)
that allows a compartment specific deletion of this gene.
4.2 Specific depletion of IER3 in the myeloid or enterocyte compartment
As mentioned above, macrophages, which belong to the lineage of myeloid-derived
cells [201, 129], are one cell-type contributing in a distinct manner to the progression of
IBD and CAC. For this study, we used the Cre/loxP-system [165, 112] to investigate the
impact of the specific knockout of ier3 in these cells.
The enzyme Cre-recombinase (Cre) is a λ-integrase of 38 kDa encoded in the genome
of the bacteriophage P1. It plays an important role in the life cycle of the bacterio-
phage by catalyzing DNA rearrangements between its own and the hosts genome in
a topoisomerase-like manner [16, 146, 206]. Cre recognizes a specific DNA-sequence
of 34 bp denoted as loxP (locus of X-over P1). In an arbitrary genomic DNA-sequence
flanked by a loxP-sequence each at its 5’- and 3’-site24, Cre causes a site specific re-
combination event, depending on the orientation of the loxP-sequences [194]. If both
loxP-sites are orientated in the same direction, the intermediary DNA-sequence gets cut
23The generation was conducted in cooperation with Genoway.
24Such a site is commonly termed as “floxed”.
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out together with one of the loxP-sequences, while the other loxP-sequence remains in
the genome (figure 4.3) [194].
Cre IER3
Cre Cre
lysM-promoter cre ier3loxP loxP
ier3loxP loxP
loxP
loxP
ier3
Figure 4.3: Exemplary illustration of the Cre/loxP-system using the example of a lysM-promoter-regulated
Cre-expression and ier3 as target-gene flanked by similar orientated loxP-sequences. For detailed
information, see the continuous text.
In 1992 Orban et al. [153] reported of a mouse-model based up on the Cre/loxP-system
to perform a tissue-specific gene-knockout, by putting the Cre-expression under the
control of a tissue specific gene promoter.
Lysozyme M (LysM) is a murine derived hydrolase encoded by the Lyz-gene, exclusively
expressed in cells of the myeloid lineage [48]. By crossing mice whose Ier3-gene is flanked
on both sides by similar orientated loxP-sequences (Ier3-flox) with mice containing the
Cre-gene under control of the LysM-promoter (LysM-Cre) we were able to generate mice
with a specific depletion of IER3 in the myeloid compartment (Ier3-flox+/+ LysM-Cre+/+).
As one of the tissue compartments mostly affected by IBD and CAC, we also investigated
the effects of an enterocyte specific IER3 depletion. For this purpose we used an Ier3-
flox/Cre mouse model with the Cre-gene under control of the enterocyte specific villin
promoter (Vil-Cre).
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5 Aim
Aim of this project was to study the effects of myeloid Ier3-deficiency (thus in macrophages)
on the onset and progression of colitis as well as on colitis associated carcinogenesis
in vivo. These findings were compared to the effects of Ier3 depletion in other tissue
compartments.
Additionally, the molecular and cellular mechanisms underlying these effects were
elucidated in detail by in vivo and in vitro experiments.
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Materials and Methods
6 Devices
Table 6.1 lists the devices used in this project.
Table 6.1: List of used devices.
Device Model Company
Autoclave 5075 ELVC Tuttnauer, (Breda,
Netherlands)
Centrifuge I MegafugeTM 1.0 Heraeus (Hanau, Germany)
Centrifuge II 5804R Eppendorf (Hamburg,
Germany)
Compartment dryer B 6200 Heraeus (Hanau, Germany)
ECL imaging system ChemiDocXRSTM BioRad (Munich, Germany)
Flow cytometer FACS-VerseTM BD (Franklin Lakes, USA)
Fluorimeter F200 Tecan (Maennedorf,
Switzerland)
Grinding mill MM400 Retsch (Haan, Germany)
Incubator BBD 6220 Thermo (Waltham, USA)
Laboratory scale PT1200 Sartorius (Goettingen,
Germany)
Continuation on next page.
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Continuation of table 6.1
Device Model Company
Laminar flow cabinet HerasafeTM Heraeus (Hanau, Germany)
Magnetic stirrer Ikamag RCT IKA (Staufen, Germany)
Micro scale CP1245-0CE Sartorius (Goettingen,
Germany)
Microscope 1 (transmission light) AxiovertTM 25 Carl Zeiss (Jena, Germany)
Microscope 2 (transmission light +
reflected light fluorescence)
AxioplanTM 2 Carl Zeiss (Jena, Germany)
Microscope 3 (LSM) LSM800 Carl Zeiss (Jena, Germany)
Microscope 4 (scanning system) BZ-II Keyence (Osaka, Japan)
Microtome HM 430 Micron (Boise, USA)
Microwave oven M686 Miele (Guetersloh, Germany)
PCR cycler 2720 Thermo (former ABS,
Waltham, USA)
PCR gradient cycler T3000 Biometra (Goettingen,
Germany)
Plate photometer Opsys MR Dynex (Denkendorf,
Germany)
Power supply #1 P25 Biometra (Goettingen,
Germany)
Continuation on next page.
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Continuation of table 6.1
Device Model Company
Power supply #2 500 Desaga (Wiesloch, Germany)
pH-meter pH537 WTW (Weilheim, Germany)
Realtime PCR device CFX-ConnectTM BioRad, (Hercules, USA)
Roller mixer SRT6D Bibby (former Stuart),
Staffordshire, UK)
Spectrophotometer NanodropTM
ND-1000
Peqlab (Erlangen, Germany)
Thermomixer 5436 Eppendorf (Hamburg,
Germany)
Thermostat RM20 Lauda (Lauda-Koenigshofen,
Germany)
Tumbling table WT17 Biometra (Goettingen,
Germany)
UV imaging system Multiimage I Alpha-Innotec (Kasendorf,
Germany)
Vortex mixer MS1 IKA (Staufen, Germany)
Water bath U3 Julabo (Seelbach, Germany)
Water purification device LabostarTM Siemens (Berlin, Germany)
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7 Consumables
7.1 Cell culture vessels
Vessels used for cell culture are listed in table 7.1. They were either purchased from AFC
(Courbevoie, France), Sarstedt (Nuembrecht, Germany) or VWR (Darmstadt, Germany).
Table 7.1: Cell culture vessels.
Label Company Order no.
T75 culture flask for adherent cells exc. MΦ Sarstedt 83.3910.002
T75 culture flask for sensitive adherent cells Sarstedt 83.3911.302
T75 culture flask for RAW264.7 and suspension cells Sarstedt 83.3911.502
VueLifeTM FEP bags (C series) AFC 2PF-0032-C
Petri dish ∅=92 mm (untreated PS) Sarstedt 82.1473.001
6-well culture dish for adherent cells exc. MΦ Sarstedt 83.3920
6-well culture dish for sensitive adherent cells Sarstedt 83.3920.300
6-well culture dish for RAW264.7 and suspension cells Sarstedt 83.3920.500
6-well culture dish for MΦ (untreated PS) VWR 734-2777
6-well Transwell TC inserts, pore size: 0.4 µm Sarstedt 83.3930.041
12-well culture dish for adherent cells exc. MΦ Sarstedt 83.3921
12-well culture dish for MΦ (untreated PS) VWR 734-2778
12-well Transwell TC inserts, pore size: 0.4 µm Sarstedt 83.3931.041
24-well culture dish for adherent cells exc. MΦ Sarstedt 83.3922
24-well culture dish for sensitive adherent cells Sarstedt 83.3922.300
24-well Transwell TC inserts, pore size: 0.4 µm Sarstedt 83.3932.041
96-well culture dish for adherent cells exc. MΦ Sarstedt 83.3924.300
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7.2 Kits
A list of the kits used for this project is given in table 7.2.
Table 7.2: List of used kits.
Application Product name Company Order no.
Flow cytometry staining Fixation /
Permeabilization kitTM
for flow cytometry
BD (Franklin
Lakes, USA)
554714
Protein quantification assay DCTM protein assay BioRad
(Hercules, USA)
500-0116
ECL substrate/reaction kit I for wb ECL clarityTM kit BioRad
(Hercules, USA)
170-5061
ECL substrate/reaction kit II for wb ECL super signalTM kit Thermo
(Waltham, USA)
34096
Occult blood detection kit HaemoccultTM kit Beckman
(Brea, USA)
PZN:
01933716
PCR PeqGoldTM
Taq-DNA-Polymerase
kit
VWR (Darmstadt,
Germany)
PEQL
01-1020
RNA extraction and purification kit RNeasyTM kit Qiagen
(Hilden, USA)
74106
RT-PCR RevertAidTM Reverse
Transcriptase kit
Thermo
(Waltham, USA)
EP0442
7.3 Further consumables
PVDF membranes for western blot were purchased from Roth (Karlsruhe, Germany;
order no. T830.1). Further consumable materials were purchased from B. Braun (Melsun-
gen, Germany), Eppendorf (Hamburg, Germany), Roth (Karlsruhe, Germany), Sarstedt
(Nuembrecht, Germany), Thermo (Waltham, USA) and VWR (Darmstadt, Germany).
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8 Reagents
8.1 Water
8.1.1 Ultrapure water
Ultrapure water was generated by using a laboratory own purification device (Siemens
LabostarTM) based on ion exchange, reverse osmosis and ultrafiltration.
8.1.2 Sterile and nuclease free water
Sterile, RNase as well DNase free ultra pure water (Merck order no.: L0015) was used for
DNA and RNA treatment as well as for sterile applications.
8.1.3 Drinking water for experimental mice
Autoclaved taped water served as drinking water for the experimental mice. This water
was also used to prepare the DSS drinking solutions.
8.2 Commercially available reagents, solutions, buffers and cell culture media
Reagents, solutions, buffers and cell culture media were purchased from Biochrom (Berlin,
Germany), Biomol (Hamburg, Germany), Biozym (Hamburg, Germany), Corning (New
York, USA), Dako (Jena, Germany), Fermentas (Waltham, USA), Gibco (Carlsbad, USA),
Invitrogen (Carlsbad, USA), Menarini (Florence, Italy), Merck (Darmstadt, Germany), MP
Biomedicals (Eschwege, Germany), Peprotech (Hamburg, Germany), Ratiopharm (Ulm,
Germany), R&D Systems (Minneapolis, USA), Roth (Karlsruhe, Germnay), Sigma-Aldrich
(St. Louis, USA), Thermo (Waltham, USA) and Tocris (Bristol, UK).
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8.2.1 Growth factors, cytokines and stimulants
Growth factors, cytokines and stimulants used in cell culture are listed in table 8.1.
Table 8.2 lists the stock solutions of the exogenous nitric oxide donor S-nitroso-N-
acetylpenicillamin (SNAP) as well as the iNOS inhibitor 1400W used for in vitro cell
culture experiments. Their structural formulas are given in figure 8.1.
Table 8.1: Growth factors and stimulants for cell culture.
Label Company Order no. Stock solution
Rec. mouse EGF Gibco PMG8044 100 µg/ml in PBS containing 1 g/l
BSA; sterile; aliquots á 50 µl,
stored at -80 °C.
Rec. mouse GM-CSF Peprotech SRP3201 20 µg/ml in aqueous sucrose
solution 50 g/l; sterile, aliquots á
50 µl; stored at -80 °C.
Rec. mouse IFN-γ R&D Systems 485-MI-100 100 µg/ml25 in PBS containing
1 g/l BSA; sterile; aliquots á
50 µl; stored at -80 °C.
LPS Sigma-Aldrich L7895 1 mg/ml in water; sterile; aliquots
á 50 µl; stored at -20 °C.
Rec. mouse M-CSF Peprotech SRP3221 20 µg/ml in aqueous sucrose
solution 50 g/l; sterile; aliquots á
50 µl; stored at -80 °C.
Rec. mouse Noggin Peprotech 250-38 100 µg/ml in PBS containing 1 g/l
BSA; sterile; aliquots á 50 µl;
stored at -80 °C.
Rec. human normal insulin Menarini PZN: -0722122426 100 IU/ml ready to use
formulation; sterile; stored at
4 °C.
Rec. mouse R-Spondin-1 Peprotech 315-32 100 µg/ml in PBS containing 1 g/l
BSA; sterile; aliquots á 50 µl;
stored at -80 °C.
Rec. mouse Wnt-3a Peprotech 315-20 50 µg/ml in PBS containing 1 g/l
BSA; sterile; aliquots á 50 µl,
stored at -80 °C.
Y-27632⋅2 HCl Tocris 1254 10 mmol/l in PBS; sterile; aliquots
á 50 µl, stored at -20 °C.
25
=̂843 ⋅ 103 IU/ml.
26This formulation is free of preservatives.
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Table 8.2: Nitric oxide donor and iNOS inhibitor.
Name Company Order no. Stock solution
SNAP Sigma-
Aldrich
N3398 100 mmol/l in dried DMSO, sterile, light protected, aliquots á 50 µl,
stored at -80 °C, not re-frozen/ re-thawed.
1400W Sigma-
Aldrich
W4262 4 mmol/l in dried DMSO, sterile, aliquots á 20 µl, stored at -80 °C.
(a) SNAP (b) 1400W
Figure 8.1: Structural formulas of the nitric oxide donor SNAP and the iNOS inhibitor 1400W.
8.2.2 Animal experiment reagents
Reagents used for animal experiments are listed in table 8.3.
Table 8.3: Reagents used for animal experiments.
Label Company Order no.
AOM Sigma-Aldrich A5486
DSS (M=36 kDa-50 kDa) MP Biomedicals 216011090
8.2.3 FITC conjugated dextrans
FITC-conjugated dextrans (fig. 8.2) used for permeability experiments are listed in
table 8.4.
Table 8.4: FITC conjugated dextrans used for permeability experiments.
Label Approx.
MW
Approx. Stokes
radius
Company Order
no.
FD4 4000 g/mol 14 Å Sigma-Aldrich FD-4
FD10 10000 g/mol 23 Å Sigma-Aldrich FD-10S
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Figure 8.2: Structural formula of FITC dextran. *: The site of attachment of FITC is randomly associated with
any free hydroxyl group. Adapted from [11].
8.2.4 Further commercially available reagents, solutions, buffers and cell culture
media
Table 8.5 lists further commercially available reagents, solutions, buffers and cell culture
media. Additional chemicals and reagents, which are not listed here, were purchased
from the companies listed above. Their degree of purity conformed at least as pro analysis
or equal.
Table 8.5: List of commercially available reagents, solutions and cell culture media.
Label Company Order no.
General reagents, solutions and buffers:
BSA Biomol 01400
FCS Biochrom S0115
HBSS Biochrom L2045
PBS (Dulbecco), sterile Biochrom L1842
Cell culture:
AccutaseTM Merck SCR005
CellStripperTM solution Corning 25-056-CI
Continuation on next page.
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Continuation of table 8.5.
Label Company Order no.
DMEM27 Biochrom F0435
DMEMw/o PR Biochrom F0475
DMEM/F-12 (1:1) Biochrom F4815
Gentamycine solution Ratiopharm PZN: 3942435
Glutamine solution Biochrom K0283
HEPES solution Gibco 15630-056
Na-pyruvate solution Biochrom L0473
P/S soulution Biochrom A2213
RPMI 1640 Biochrom F1640
Trypsin/EDTA solution Biochrom L2143
DNA-PAGE, SDS-PAGE and western blot:
100 bp DNA ladder Invitrogen 15628-019
Acrylamide solution (RothiphoreseTM) 40 % Roth T802.1
Antibody stripping solution Merck 2504
Aprotinin solution Sigma-
Aldrich
A6279
APS Merck 1.01201
Ethidium bromide stock solution Roth 161-0433
PageRulerTM protein ladder Thermo 26619
Phosphatase inhibitor cocktail #2 Sigma-
Aldrich
P5726
Phosphatase inhibitor cocktail #3 Sigma-
Aldrich
P0044
Skim milk powder Roth T145.3
TEMED Roth 2367.3
Genotyping, PCR, RT-PCR and qPCR:
10x RXN buffer Invitrogen Y02028
Biozym Blue S’Green qPCR mix Biozym 331416
dNTP’s 10 mmol/l Fermentas R0192
Magnesium chloride solution Invitrogen Y02016
Oligo(dT)18 primer Thermo S0132
Quick Extract DNA solution 1.0 Biozym QE0905
RiboLockTM RNase inhibitor Thermo EO0381
Taq DNA polymerase Invitrogen 18038-042
Continuation on next page.
27This DMEM formulation contains 4.5 g/l glucose, 3.7 g/l NaHCO3 and no pyruvate. Without the addition of further
buffers, it requires a atmospheric CO2concentration of 10 % (v/v) to acquire a pH-value of 7.4.
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Continuation of table 8.5.
Label Company Order no.
ICC and IHC:
AEC substrate chromogen Dako K3464
Buffered formaline, ≥37 %, stabilized, acid free Merck 1.039993
EnVision+TM anti mouse polymer (HRP-conjugated) Dako K4000
EnVision+TM anti rabbit polymer (HRP-conjugated) Dako K4002
Eosin Y solution Merck 1.09844
FluorSaveTM mounting medium Merck 345789
Hoechst bisbenzimide H33258 Calibochem 382061
Immersion oil for microscopy Roth X899.1
Kaiser’s glycerol gelatine Merck 109242
Mayer’s haematoxylin Merck 1.09249
Proteinase K solution (600 mAnU/ml) Merck 1.07393
8.3 Self prepared solutions, buffers and cell culture media
Self prepared solutions, buffers and cell culture media are listed in table 8.6. If not
mentioned else, cell culture media were stable for approximate 14 days when stored at
4 °C. All other solutions were stored at RT if not mentioned else.
Table 8.6: List of self prepared solutions, buffers and cell culture media.
Label Composition
General buffers:
Glycine buffer 0.5 mol/l Glycine
stock soln. 1 in water
Glycine buffer 0.5 mol/l Na-Glycinate
stock soln. 2 in water
Glycine buffer ≈1.0 VP Stock soln. 1 PH adjusted by mixing
stock soln. in correct
ratio.
0.5 mol/l, pH 9.6 ≈1.0 VP Stock soln. 2
Continuation on next page.
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Continuation of tab. 8.6.
Label Composition
MACS buffer 5.0 g/l BSA
Always prepared fresh.2.0 mmol/l Na2-EDTA
in PBS, pH 7.4
PBS pH 7.428 8.1 g/l NaCl
0.2 g/l KCl
1.44 g/l Na2HPO4
0.25 g/l KH2PO4
in water
adjusted to pH 7.4 with HCl/NaOH soln.
10x TRIS / borate / 0.45 mol/l TRIS base
EDTA-buffer 0.45 mol/l H3BO4
(10x TBE) 5.0 mmol/l EDTA
in water
TRIS buffered saline 2.0 TRIS base
(TBS) 14.0 mmol/l NaCl
in water
adjusted with HCl-soln. to pH 7.6
Cell culture media:
CaCo-2 medium 20.0 % (v/v) FCS
2.0 mmol/l L-Glutamine
1.0 mmol/l Na-Pyruvat
5.0 mmol/l HEPES
in DMEM
HT-29 medium 10.0 % (v/v) FCS
2.0 mmol/l L-Glutamine
in Mc Coy’s 5A modified medium
IEC-6 medium 5.0 % (v/v) FCS heat inactivated29
2.0 mmol/l L-Glutamine
1.0 mmol/l Na-Pyruvat
0.1 IU/ml Rec. human normal insulin
in DMEM / F-12
Continuation on next page.
28For sterile or nuclease / proteinase sensitive applications a commercial ready-to-use solution was used.
2956 °C for 30 min.
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Continuation of tab. 8.6.
Label Composition
Macrophage basal 2.5 % (v/v) FCS
medium (MΦ-M.) 2.0 mmol/l L-Glutamine
1.0 mmol/l Na-Pyruvat
100.0 IU/ml Penicillin
0.1 g/l Streptomycin
40.0 mg/l Gentamycin
in DMEM / F-12
Macrophage 50.0 ng/ml mM-CSF Added just before
application.differentiation 50.0 IU/ml mIFN-γ
medium(MΦdiff.-M.) in macrophage basal medium
Macrophage 20.0 ng/ml mM-CSF Added just before
application.cultivation 50.0 IU/ml mIFN-γ
medium (MΦcult.-M.) in macrophage basal medium
Neutralization 10.0 % (v/v) FCS
medium in DMEM
Raji medium 10.0 % (v/v) FCS
2.0 mmol/l L-Glutamine
in RPMI 1640
RAW264.7 medium 10.0 % (v/v) FCS
4.0 mmol/l L-Glutamine
5.0 mmol/l HEPES
in DMEM
YAMC basal medium 5.0 % (v/v) FCS
Stable for 5 days at 4 °C.
2.0 mmol/l L-Glutamine
0.5 IU/ml Rec. human normal insulin
5.5 mg/l Transferrin
6.7 µg/l Na2SeO3
10.0 µmol/l 1-Thioglycerol
1.0 µmol/l Hydrocortisone
100.0 IU/ml Penicillin
0.1 g/l Streptomycin
in RPMI 1640
YAMC culture 5.0 IU/ml mIFN-γ Added just before
application.medium in YAMC basal medium
Continuation on next page.
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Continuation of tab. 8.6.
Label Composition
Protein extracts:
RIPA stock solution 150.0 mmol/l NaCl
Storage in aliquots at
-20 °C. Thawing on ice.
No re-freezing/thawing.
50.0 mmol/l TRIS/TRIS-HCl, pH 7.8
1.0 g/l SDS
5.0 g/l Na-Deoxycholat
1.0 % (v/v) Triton X-100
5.0 mmol/l Na2-EDTA
1.0 mmol/l EGTA
1.0 tbl./10 ml Protease inhibitor
in water
RIPA working 1.0 mmol/l PMSF Stock solutions stored at
-20 °C. Addition just
before application.
solution 1.0 mmol/l DTT
1.0 mmol/l Na3VO4
optional 1.0 % (v/v) PIC No2 Addition just before
application.optional 1.0 % (v/v) PIC No3
in RIPA stock solution
SDS-PAGE and western blot:
4x Laemmli 250.0 mmol/l TRIS/TRIS⋅HCl pH 6,8
Storage at -20 °C.
loading dye30 80.0 g/l SDS
20.0 % (v/v) 2-Mercaptoethanol
30.0 % (v/v) Glycerol
200.0 mg/l Bromophenol blue
in water
WB separating gel 1.5 mol/l TRIS base
buffer, pH 8.8 4.0 g/l SDS
in water
adjusted with HCl-soln. to pH 8.8
WB stacking gel 1.5 mol/l TRIS base
buffer, pH 6.8 4.0 g/l SDS
in water
adjusted with HCl-soln. to pH 8.8
Continuation on next page.
30This solution differs in composition distinctly from Laemmli’s original formulation.
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Continuation of tab. 8.6.
Label Composition
1x SDS-PAGE 25.0 mmol/l TRIS base
electrophoresis 192.0 mmol/l glycine
running buffer 1.0 g/l SDS
in water
WB blotting buffer A 300.0 mmol/l TRIS base
20.0 % (v/v) Methanol
in water
WB blotting buffer B 25.0 mmol/l TRIS base
20.0 % (v/v) Methanol
in water
WB blotting buffer C 25.0 mmol/l TRIS base
20.0 % (v/v) Methanol
5.0 g/l Amino caproic acid
in water
TBS-T for WB 0.05 % (v/v) Tween-20
in TBS
Skim milk powder 50.0 g/l Skim milk powder
Always prepared fresh.
based blocking and in TBS-T
incubation solution
for wb
BSA based 50.0 g/l BSA
Always prepared fresh.
incubation in TBS-T
solution for wb
PCR and DNA-PAGE31
Sucrose solution 300.0 g/l Sucrose
Storage at -20 °C.
in water
Continuation on next page.
31PCR master mix and PAGE gel compositions are given in section 23.3 together with the respectively primer sequences
and PCR-conditions.
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Continuation of tab. 8.6.
Label Composition
SucRed solution 1.5 g/l Cresol red
Storage at -20 °C.
0.10 % (v/v) TRIS/TRIS⋅HCl buffer, c=1.0 mol/l,
pH 9.0
300.0 g/l Sucrose
in water
Ethidium bromide 1.0 mg/l Ethidium bromide
Stable for 1 week at RT.
staining buffer in 1x TBE
ICC & IHC:
Carnoy’s fixative 6.0 % (v/v) Dried methanol
modified after 3.0 % (v/v) Trichloromethane
Putchler 1.0 % (v/v) Dried acetic acid
Lillie’s formol 3.6 % (m/m) Neutral formaline
Always prepared fresh.
in PBS
Citrate antigen 0.01 mol/l Citric acid
Storage at 4 °C.
retrieval stock soln. A in water
Citrate antigen 0.01 mol/l Na3-Citrate Storage at 4 °C.
retrieval stock soln. B in water
Citrate antigen ≈9.0 % (v/v) Stock solution A Storage at 4 °C. Pre-warm
to RT before use. PH
adjusted by mixing stock
soln. in correct ratio.
retrieval solution ≈41.0 % (v/v) Stock solution B
for histology, pH 6.0
TRIS/EDTA antigen 10.0 mmol/l TRIS/TRIS⋅HCl, pH 9.0
retrieval solution 1.0 mmol/l Na2-EDTA
for histology, pH 9.0 in water
TBS-T for histology 0.10 % (v/v) Tween-20
in TBS
Permeabilization 0.20 % (v/v) Triton X-100
solution for IHC in TBS
Blocking solution 20.0 g/l BSA
Always prepared fresh.
for ICC in TBS-T
Continuation on next page.
48
Materials & Methods
Continuation of tab. 8.6.
Label Composition
Blocking solution 40.0 g/l BSA
Always prepared fresh.
for IHC in TBS-T
Ab diluent for 10.0 g/l BSA
Always prepared fresh.
ICC and IHC in TBS-T
Acidic alum 1.74 g/l K2SO4 Storage at 4 °C.
Pre-warmed to RT before
use.
solution 6.48 g/l Al2(SO4)3 ⋅ 17H2O
in water
Scott’s solution 10.0 g/l NaHCO3
20.0 g/l MgCl2
in water
Griess test
Griess reagent I 30.0 g/l Sulfanilamide in 5 % (m/m) H3PO4 Usable as long as
solutions stay colorless.Griess reagent II 3.0 g/l NED in 5 % (m/m) H3PO4
9 Animals
9.1 Housing and breeding
All animals were housed and bred under S1 conditions in the central animal housing
facility of the Christian Albrechts University Kiel (Building U39, UKSH Campus Kiel)
pursuant to the German animal welfare regulations.
9.1.1 Constitutive Ier3 ko-mice
Ier3-/--mice genetically based on a Sv129 background [189] were used at backcross
generation >10 [183]. Heterozygous parental animals were intercrossed to yield Ier3+/+
and Ier3-/- offspring. Those mice served as constitutive Ier3 wt- and Ier3 ko-mice.
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9.1.2 Conditional Ier3 ko-mice
Ier3-flox -/+ and LysM-Cre -/+ mice genetically based on a C57BL/6 background
(Genoway, Lyon, France) were mated to generate Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-
Cre+/+ mice at later generations.
Ier3-flox -/+ and Vil-Cre -/+ mice genetically based on a C57BL/6 background (Genoway,
Lyon, France) were mated to generate Ier3-flox+/+ Vil-Cre-/- and Ier3-flox+/+ Vil-Cre+/+ mice
at later generations.
9.2 Genotyping of constitutive and conditional ier3-knockout mice
During breeding, all mice were routinely genotyped regarding their Ier3 status by PCR
and subsequently DNA-PAGE. Additionally, all mice used for experiments were tested
again after termination of the experiments for validation.
Constitutive Ier3 wt/ko-mice were tested for the genomic Ier3-sequence. The PCR
amplification led to a product size of 1160 bp (wt-allele) or 960 bp (ko-allele).
Conditional Ier3 wt/ko-mice were genotyped for the lysM-cre or vil-cre sequence as
well as for the Ier3-containing loxP cassette (Ier3-flox). The amplification product of the
Ier3-flox cassette had a size of 542 bp while the Ier3 wt-allele led to a product size of
413 bp.
The existence of the LysM-Cre allele was performed by two different PCRs. In presence
of the LysM-Cre allele, one PCR amplified a product of approximate 700 bp (=positive),
while the allels’s absence led to no PCR-product. The ohter PCR provided a product
of approximate 350 bp in the absence of the LysM-Cre sequence (=negative) while it’s
presence generated no amplicon.
The Vil-Cre allele generated an amplicon of 1000 bp (=positive), while its absence led to
no PCR product.
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9.2.1 DNA extraction from source tissue
Genomic DNA was extracted from tail tips, harvested during weaning. Additionally, a
tail tip from each experimental animal was harvested directly after sacrifice. Until DNA
extraction they were stored at -20 °C.
DNA extraction was performed using Quick Extract DNA solution 1.0TM (QEDS, BioRad)
with an adjusted protocol. After thawing QEDS aliquots on ice, 25 µl were added to
each tail clip containing micro reaction tube. After vigorous vortexing for 15 s, the tubes
were spun down shortly and incubated in a prewarmed thermomixer for 30 min at 65 °C
and 750 rpm. Following the incubation, the tubes were vortexed again for 15 s. After
spinning down the liquid, the tubes were incubated in a prewarmed thermomixer for
5 min at 98 °C (without shaking) and cooled on ice subsequently. The DNA containing
solution was aspirated and applied directly for PCR or alternatively stored at -20 °C still
containing the tail tip remains.
9.2.2 PCR
Primer for mouse genotyping Primer for mouse genotyping were purchased from
Eurofins Genomics (Ebersberg, Germany). After receiving, they were solved in nuclease
free water to a concentration of 100 pmol/µl and stored at -20 °C. Primer sequences are
listed in table 9.1.
PCR conditions PCR was performed using the PeqGOLDTM Taq DNA polymerase kit
(Peqlab) with an adjusted buffer system. For the reaction (total volume per batch 23 µl),
3 µL DNA solution were added to 20 µL PCR-mastermix into a PCR micro tube. PCR
reaction was performed straight afterwards using an ABS 2720 thermal cyler. The master
mix composition is given in table 9.2, while the composition of self prepared master mix
ingredients is listed in table 8.6. The respective PCR conditions are given in Table 9.3.
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Table 9.1: Mouse genotyping primer sequences.
Label Sequence
Constitutive Ier3 allele:
gly96 fwd: 5’- G C A G T T T T G T G T C C G T G T G C T C -3’
gly96 rev: 5’- T T C T T C G G A C T G T G A C C C A T C G -3’
Neo rev: 5’- G G G C T G A C C G C T T C C T C G T G C T T T -3’
Ier3-flox allele:
45flp fwd: 5’- G G A A A G C G G T C T C T C A A G C A T T A C G -3’
46flp rev: 5’- G T G A A G T C C A G C A A G A T C A A G G G A C C -3’
LysM-Cre allele:
398 fwd: 5’- C C C A G A A A T G C C A G A T T A C G -3’
399 rev: 5’- C T T G G G C T G C C A G A A T T T C T C -3’
400 rev: 5’- T T A C A G T C G G C C A G G C T G A C -3’
Vil-Cre allele:
vil-cre78 fwd: 5’- G T G T G G G A C A G A G A A C A A A C C -3’
vil-cre79 rev: 5’- A C A T C T T C A G G T T C T G C G G G -3’
Table 9.2: PCR mastermix for mouse genotyping.
Volume Component included in kit
2.353 µl Buffer “S” 10x yes
2.353 µl Sucrose soln 300 g/l no
2.353 µl SucRed soln no
0.471 µl dNTP mix 10 mmol/l, each no
0.882 µl each Primer 10 µmol/l no
0.147 µl PeqGOLDTM Taq DNA polymerase yes
ad H2O 20 µl no
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Table 9.3: PCR conditions for mouse genotyping.
Amplicon Primer label
PCR conditions Product size
temperature time cycles
ier3- gly96 fwd 95 °C 300 s wt: 1160 bp
allele gly96 rev (wt) 95 °C 60 s ko: 960 bp
(constitutive) Neo rev (ko) 58 °C 60 s ⟲ 45×
72 °C 120 s
72 °C 600 s
ier3-flox- 45flp 95 °C 300 s neg: 413 bp
allele 46flp 95 °C 45 s pos: 542 bp
63 °C 45 s ⟲ 38×
72 °C 60 s
72 °C 600 s
lysM-cre- 398 94 °C 300 s pos: ≈700 bp
allele 399 94 °C 30 s
positive 56 °C 45 s ⟲ 45×
72 °C 60 s
72 °C 600 s
lysM-cre- 399 95 °C 300 s neg: ≈350 bp
allele 400 95 °C 60 s
negative 65 °C 40 s ⟲ 3×
72 °C 40 s
↓
95 °C 60 s
64 °C 40 s ⟲ 3×
72 °C 40 s
↓
95 °C 60 s
63 °C 40 s ⟲ 3×
72 °C 40 s
↓
95 °C 60 s
62 °C 30 s ⟲ 36×
72 °C 40 s
72 °C 600 s
vil-cre- vil-cre78 94 °C 300 s pos: ≈1000 bp
allele vil-cre79 94 °C 30 s
positive 62 °C 45 s ⟲ 45×
72 °C 75 s
72 °C 600 s
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Detection of PCR products PCR products were separated by polyacrylamide gel elec-
trophoresis, subsequently stained with ethidium bromide and detected under UV-light:
10 µl PCR product were directly loaded onto a 8 % (m/m) PAA gel32 (tab. 9.4). Additionally,
one lane was loaded with 2.5 µL 100 bp DNA ladder (Fermentas). Electrophoresis was
performed in 1x TBE at 200 V for 90 minutes.
Afterwards, the gel was incubated in 1x TBE containing 1 µg/ml ethidium bromide
for 5 minutes. Detection of bands was conducted under UV-light (365 nm) using the
Multiimage ITM imaging system (Alpha-Innotec).
Table 9.4: Composition of PAA gels for DNA-PAGE.
Label Composition
Separating gel 8 % 20.0 % (v/v) RotiphoreseTM solution 40 %
10.0 % (v/v) TBE buffer 10x
0.1 % (v/v) TEMED
1.0 g/l APS
solved in water
10 DSS and AOM/DSS animal experiments
Several dextran sodium sulphate (DSS) or azoxymethane (AOM)/DSS animal experi-
ments were conducted to study putative effects of IER3 in different tissue compartments
in the context of acute and chronic colitis as well as colitis associated carcinogenesis
(CAC). This experimental design closely mimics the pathogenic processes appearing in
the colons of patients suffering from IBD [166].
All experiments were conducted in accordance with the European and German animal
welfare regulations and were approved by the admission authorities of the Federal State
of Schleswig-Holstein (File no. 155-11/13).
32Due to the PCR mastermix composition, no additional loading buffer was necessary.
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The experiments were conducted in the campus’ central animal housing facility. Only
male mice were used for the experiments to avoid possible perturbations caused by the
hormone system of female mice.
10.1 Induction of acute colitis
To explore effects of IER3 in different tissue compartments during acute colitis, mice with
and average age of 9-10 weeks were supplied with 30 g/l DSS in drinking water ad libitum
over a period of 9-10 days.
10.2 Induction of chronic colitis
The putative effects of constitutive as well as of epithelial expressed IER3 on the progress
of a chronic colitis were studied in several interval DSS experiments. Animals with
an average age of 9 weeks received three 5-day and one 4-day cycles of 15 g/l DSS in
drinking water ad libitum. Each DSS cycle was followed by a 5 day treatment free interval.
10.3 Induction of chronic colitis and colitis associated carcinogenesis
The effects of myeloid IER3 on the progress of chronic colitis and its subsequent colorectal
tumor formation were studied in a long term AOM/DSS experiment (fig. 10.1). Animals
with an average age of 131/2 weeks were injected intraperitoneal (i.p.) with 10 µg/g body
weight (bw) AOM at day -7 to induce an inflammation triggered carcinogenesis at a later
time-point. To induce a chronic inflammation, the animals were treated with 10 g/l DSS in
the drinking water ad libitum in three cycles (interrupted by three treatment free recovery
phases) beginning at day 0. The first DSS cycle endured for seven days, followed by a
14 day lasting treatment free interval. The second cycle was shortened to three days
(day 21-24) to avoid a premature termination of the experiment due to the animals health
condition (see sec. 10.6 for abort criteria). This cycle was followed by an 11 days treatment
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free interval. The last DSS cycle endured again for seven days from day 35-42. The
experiment was terminated at day 85.
Figure 10.1: Experimental design to induce a chronic inflammation and subsequent tumor formation in
Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice. Animals were injected i.p. with AOM
10 µg/g bw at day -7. 10 g/l DSS in drinking water was administered ad libitum from day 0-7, day 21-24
and day 35-42. The experiment was terminated at day 85.
An additional experiment was conducted to closer evaluate the processes during the
initiation phase of a chronic AOM/DSS induced colitis in Ier3-flox+/+ LysM-Cre-/- and
Ier3-flox+/+ LysM-Cre+/+ mice. Accordingly to the long term AOM/DSS experiment, these
animals were injected intraperitoneal (i.p.) with 10 µg/g body weight (bw) AOM at day -7.
DSS was administered in a concentration of 10 g/l in the drinking water ad libitum from
day 0-7. The experiment was aborted at day 13.
10.4 Parameters gathered during the experiments33
During the experiments the following parameters were gathered on a regular basis34:
• vitality score35
• body weight
• rectal bleeding score
• occult blood in stool
• stool consistency
33Not all parameters were gathered in all experiments.
34The intervals of measuring were adjusted to the current condition of the experimental animals.
35For definition of the vitality score see section 10.6.
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Rectal bleeding and blood in feces Rectal bleeding was assessed optical. Occult blood
in feces was detected using the HaemoccultTM-kit (Beckman). The principle of this kit
bases on the guaiac method modified by Greegor [76]. Scores had a range from 0 (no
detection of occlult blood) up to 4 (rectal bleeding).
Stool consistency Stool consistency was rated by a simplified Bristol stool scale in a
range from 0 (normal consistency) up to 4 (practical liquid).
10.5 Parameters and samples gathered after termination
After killing the following parameters were gathered:
• liver weight
• spleen weight
• cecum weight
• colon length
• number and localization of tumors in the colon
• tumor size
• anatomical abnormalities
The following organs and samples were achieved:
• blood / serum36
• colon (formalin or Carnoy fixation as well as cryo conservation (-80 °C))
36Blood was achieved directly before killing by heart puncture. The blood was collected into EDTA
containing tubes and centrifuged at 1000 g for 5 minutes. The supernatant (blood serum) was transferred
into a micro reaction tube and stored at -80 °C until its further use.
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• ileum (cryo conservation (-80 °C))
• cecum(formalin fixation and cryo conservation (-80 °C))
• spleen (formalin fixation and cryo conservation (-80 °C))
• liver (formalin fixation and cryo conservation (-80 °C))
• 3 tumors if available (cryo conservation (-80 °C))
• mesenterial lymph nodes (cryo conservation (-80 °C))
• tail tips37
The colon of each animal was cut longitudinal in two halves. One half was rolled
to a “swiss-roll” and fixated in Lillie’s formaline or modified Carnoy’s solution for
histological analysis. The other half was divided in 4 segments (proximal, M1, M2 and
distal) and cryo-preserved. A scheme of the segmentation is given in figure 10.2.
Figure 10.2: Segmentation of the colon from experimental animals after killing for further analysis.
37Mice were re-genotyped post mortem for reasons of redundancy.
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10.6 Abort criteria
Mice were prematurely excluded from the experiments if matching at least on abortion
criterion:
• Body weight < 75 % compared to body weight at day 0.
• Signs of severe pain.
• A low vitality score.
Severe signs of pain and/or a low vitality score were assessed by at least one of the
following behavioral patterns:
• No elopement after touching the animal with a finger.
• Sitting in a corner of the cage without movement (except shivering).
• Narrowing one’s eyes to slits with or without shivering.
For Kaplan-Meier survival-curve analysis, matching an exclusion criterion was rated to
be equivalent to a treatment caused death of the animal.
11 In vivo permeability to FITC-Dextrans
The guts permeability of 8-12 week old38 Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-
Cre+/+ animals to FITC conjugated dextrans (FD) of different molecular weights was
determined in several in vivo experiments to identify putative differences in the intesti-
nal barrier function between the genotypes. Experiments were conducted with DSS
pretreated as well as with unchallenged, healthy animals.
Four hours after oral administration of a body weight adjusted dose (tab. 11.1), the
FD blood serum concentration was determined photometrically. Two sorts of FD with
different molecular weights (see tab. 8.4) were applied for the experiments.
38Animals were age matched for the particular experiments.
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11.1 Pretreatment with DSS
If applied, animals were pretreated with 10 g/l DSS in drinking water ad libitum for 24 h
before the FD administration.
11.2 Admimistration of FITC dextrans
The FD solutions (tab. 11.1) were always prepared freshly at each experimental day and
stored protected from light. A body weight adjusted amount (tab. 11.1) was administrated
directly to the pylorus trough a bulb-headed stomach probe39.
Table 11.1: FITC dextran solutions for oral administration.
Solution Conc. Solvent Administrated
amount
(referred to FD dry mass)
FD4 100 mg/ml water 0.5 mg/g bw
FD10 100 mg/ml water 1.0 mg/g bw
11.3 Blood sampling and measurement
3:40 h after the FD administration, the animals were narcotized i.p. injection (tab. 11.2).
After pain reflex falsification, blood samples were taken by heart puncture exactly
4:00 h after the FD administration40. The fresh samples were transfered into a polymer
based serum tube (BD MicrotainerTM SST, ord.-no. 365968) and processed pursuant
manufacturers declaration41.
39Before administration, the probe was coated in sugared water for reasons of compliance.
40Animals were killed by cervical dislocation directly after blood sampling.
41The centrifugal forces were limited to 6000 g, to avoid FD precipitation.
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Table 11.2: Narcotization compound for intraperitoneal injection.
Component Dosage
Fentanyl 0.075 mg/kg bw
Medetomidine 0.75 mg/kg bw
Midazolam 7.5 mg/kg bw
The processed blood serum was diluted 1:100 in 0.5 mol/l glycine buffer, pH 9.6 and
pipetted in triplicates into a 96-well microtiter plate (150 µl/well). Fluorescence intensity
was measured in a plate fluorimeter at λEx=485/20 nm and λEm=535/25 nm.
12 Histology
12.1 Specimen preparation
After fixating the the achieved specimen in either Lillie’s formaline for 72 h or modified
Carnoy’s solution for 24 h they were completely dehydrated and embedded into paraffin
blocks. The blocks were cut into slices of 3 µm thickness using a sledge microtome
(Micron) and mounted onto silanized microscopic slides (Labsolute). The slides were
stored upright and incubated for 24 h at 40 °C before further use.
12.2 Deparaffinization and rehydration
The slides were deparffinated and rehydrated in an xylene-alcohole-water sequence
accordingly to table 12.1.
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Table 12.1: Deparaffination and rehydration of thin layer paraffin sections.
Step Solution Incubation time
1 Xylene I 10 min
2 Xylene II 10 min
3 Ethanol absolute I 10 min
4 Ethanol absolute II 10 min
5 Ethanol 95 % (v/v) 5 min
6 Ethanol 70 % (v/v) 2 min
7 Ethanol 50 % (v/v) 2 min
8 Water I 2 min
9 Water II 5 min
12.3 Staining
12.3.1 Haematoxylin / Eosin staining
Specimen were deparaffinated and rehydrated as described in section 12.2. Next, the
specimen were submersed in a 1:2 dilution of Meyer’s Haematoxylin solution42 (Merck)
in water for 5 min to stain the nuclei. The slides were subsequently rinsed in water
and incubated 2 times for 60 s each in acidic potassium aluminium sulfate solution
(c(KAl(SO4)2) = 20 mmol/l) to reduce unspecific cytoplasmic staining. After shortly
rinsing the slides in water, bluing was conducted by incubating them in Scott’s solution
for 3x 10 min, each.
Cytoplasmatic counterstaining was performed by submersing the specimen in a solution
of 1 g/l Eosion Y (Merck) in water for 4 min. Afterwards, the specimen were differentiated
in water and embedded subsequently using Kaiser’s glycerol gelantine.
12.3.2 Conventional Immuno-Staining
Specimen were deparaffinated and rehydrated as described in section 12.2. Unspecific
peroxidase activity was blocked by incubating the slides for 10 min 2 % (m/m) H2O2-
42The Haematoxylin dilution was filtered trough a 5951/2 pleated filter directly before use.
62
Materials & Methods
solution at RT. Afterwards, the slides were shortly rinsed 3x in water. Antigen retrieval
was performed by transferring the slides into a plastic cuvette filled with an antibody
(Ab) depending retrieval solution (tab. 12.4). The cuvette was heated in a microwave
oven at 300 W for 6x 5 min, each. Evaporated retrieval solution was replaced between
the heating steps. After cooling down for 15 min, the specimen were encircled using a
grease pencil. Depending on the antigen, the specimen were incubated in approx. 100 µl
permeabilization buffer for 7 min, if necessary43. Afterwards the slides were rinsed two
times in washing buffer and unspecific bonds were blocked by incubating the specimen
in approximately 100 µl blocking solution for 90 min at RT in a humidified chamber.
After the slides were shortly rinsed in washing buffer, the specimen were covered with
60 µl of the diluted primary antibody or a respectively isotype control. Incubation took
place overnight at 4 °C in a humidified chamber.
The next day, the slides were washed 3 times in wahsing buffer for 5 min, each. Subse-
quently, the specimen were incubated for 60 min at RT with 1-2 drops of a HRP-conjugated
polymer based reagent (Dako), directed against the host species of the primary anti-
body. Afterwards, the slides were washed 3 times in washing buffer for 5 min, each.
Developing of the specimen was performed using an 3-Aminocr-9-ethylcarbazole (AEC)
based substrate (Dako). For this, 1-2 drops of the substrate solution were dripped onto
the specimen and incubated for 10-45 min at RT until the reaction reached its optimal
chromogenic intensity. The reaction was stopped by immersing the slides in water for
10 min.
Counterstaining of the cell nulclei was performed by immersing the slides in a 1:2
dilution of Meyer’s Haematoxylin solution44 (Merck) in water for 5 min. The slides were
subsequently rinsed in water and incubated 2 times for 60 s, each in acidic potassium
aluminium sulfate solution (c(KAl(SO4)2) = 20 mmol/l) to reduce unspecific cytoplasmic
staining. After shortly rinsing the slides in water, bluing was conducted by incubating
43Despite the addition of Tween-20 to the blocking and washing buffer, the usage of a designated triton
X-100 based permeabilization solution has proven for the staining of some intracellular epitops.
44The Haematoxylin dilution was filtered trough a 5951/2 pleated filter directly before use.
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them in Scott’s solution for for 3x 10 min, each. Afterwards, the slides were shortly
rinsed in water and specimen were embedded subsequently using Kaiser’s glycerol
gelatine.
12.3.3 Fluorescence immunohistochemistry (IHC-F)
Specimen were deparaffinized and re-hydrated as described in section 12.2. If fixated in
formalin, specimen were incubated for 10 min in freshly prepared sodium borohydride
solution (10 g/l NaBH4in PBS, pH 7.4) to reduce background fluorescence (Cave: Explosion
hazard due to hydrogen gas formation). Afterwards, the slides were shortly washed 3x
in water. Antigen retrieval was performed by transferring the slides into a plastic cuvette
filled with an antibody depending retrieval soulution (tab. 12.4 on page 66). The cuvette
was heated in a microwave oven at 300 W for 6x 5 min, each. Evaporated retrieval solution
was replaced between the heating steps. After cooling down for 15 min, the specimen
were encircled using a grease pencil. Depending on the antigen, the specimen were
incubated in approximately 100 µl permeabilization buffer for 5-10 min, if necessary45.
Afterwards the slides were rinsed two times in washing buffer and unspecific bonds were
blocked by incubating the specimen in approximately 100 µl blocking solution for 90 min
at RT in a humidified chamber. After the slides were shortly rinsed in washing buffer,
the specimen were covered with 60 µl of the diluted primary antibody or a respectively
isotype control. Incubation took place overnight at 4 °C in a humidified chamber.
The next day, the slides were washed 3 times in washing buffer for 5 min, each. The
specimen were covered with 60 µl of the diluted, fluorochrome conjugated secondary
antibodies together with 665 ng/ml Hoechst bisbenzimide H33258 for nucleic counter
staining. After incubation for 40 min in the dark at RT, the slides were washed 3 times in
washing buffer for 5 min, each. Following, the slides were rinsed shortly in water and
subsequently mounted with cover slips using FluorSaveTM (Merck) mounting medium.
45Despite the addition of Tween-20 to the blocking and washing buffer, the usage of a designated triton
X-100 based permeabilization solution has proven for the staining of some intracellular epitops.
64
Materials & Methods
24 h after the mounting, the specimen were sealed with nail polish and stored 4 °C until
analysis.
Table 12.2: Isotype control antibodies for conventional and fluorescence based immunohistochemistry
and immunocytochemistry.
Host
Clonality/
Stock conc.
Company/
Isotype order-no.
m mAb IgG 0.5 mg/ml R&D MAB002
rb pAb IgG 1.0 mg/ml CST 2729
Legend:
Manufacturer: CST: Cell Signaling Tech., R&D: R&D Systems.
For further abbreviations see the list on page XVII.
Table 12.3: Secondary antibodies for ICC-F and IHC-F.
Target Host- Conjugated TSS Stock Dilution Company/
Species
Ab species fluoro- puri- conc. ICC-F & order-no.
Isotype chrome fication IHC-F
m IgG (H+L) donkey AF-488 EAC 2 mg/ml 1: 1000 Thermo A-21202
rb IgG (H+L) goat AF-555 AC 2 mg/ml 1: 750 Thermo A-21428
Legend:
TSS: Target species specificity.
AC: Cross adsorption chromatography; EAC: Enhanced cross adsorption chromatography.
For further abbreviations see the list on page XVII.
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13 Cell culture
Cell lines were either purchased from ATCC or provided by other research groups46. Ta-
ble 13.1 lists the name of the cell line specific culture media, while their exact formulation
is given in table 43.
The differentiation, cultivation and detachment of primary BMC derived MΦ differs in
parts from the methods described here. See section. 13.1 for further informations.
Table 13.1: List of culture media used for the different cell lines.
Cell line Culture
medium
3T3 RAW-M.
CaCo-2 CaCo-M.
HEK-293T RAW-M.
HT29 HT29-M.
IEC-6 IEC-6-M.
Med. for in vitro differentiation of primary MΦ from murine BMC MΦdiff.-M.
Med. for cultivation of in vitro differentiated primary MΦ from murine BMC MΦcult.-M.
MODE-K RAW-M
Primary murine IEC *
Raji Raji-M.
RAW 264.7 RAW-M.
THP-1 RAW-M.
YAMC YAMC-M.
*: For the cultivation as well as for the immortalization of primary IEC, a variety of different culture media formulations
was tested.
See the list on page XVII for abbreviations.
13.1 Seeding an cultivation of cells
If not mentioned else, cells were seeded in a concentration of 1 ⋅ 105 cells/ml. Table 13.2
gives the volumes of cell suspension/culture medium used for the regarding culture
vessels.
46Cell lines were kindly provided by the groups of Prof. Frey, Prof. Reiss, Dr. Tiwari and Prof. Zeissig.
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Table 13.2: Volumes of cell suspension / culture medium for different culture vessels.
Vessel Volume
24-well plate 0.5 ml per well
12-well plate 1.0 ml per well
Transwell insert for 12-well plate 0.5 ml per insert
6-well plate 2.0 ml per well
Culture dish ∅=80 mm 8.0 ml per dish
T75 culture flask 14.0 ml per flask
FEP bag 32-AC 30.0 ml per bag
BMCs for MΦ differentiation were seeded and cultivated on untreated PS surfaces not
suitable for adherent cells. MΦ were seeded and cultivated either in untreated PS or
FEP surfaces. RAW264.7 and undifferentiated THP-1 cells (monocyte stadium) were
seeded and cultivated in PS vessels with a hydrophobic surface treatment (Sarstedt color
code green). Primary cells were cultured on PS surfaces with an enhanced hydrophilic
treatment for sensitive adherent cells (Sarstedt color code yellow). These surfaces were
additionally coated with a combination of collagen and fibronectin before use. All other
cell lines were cultured in PS vessels with a hydrophilic surface treatment, suitable for
cell adherence (Sarstedt color code red).
For ICC experiments, cells were cultivated on coverslips, optionally precoated with
collagen and fibronectin if necessary.
Coating of surfaces with collagen and fibronectin As mentioned above, for some ex-
periments it was necessary to pre-coat the surfaces of the culture vessels or cover slips
with a combination of collagen and fibronectin for optimal cell adherence.
Surfaces were coated with 10 µg/cm² collagen and 2 µg/cm² fibronectin. The necessary
amount of the stock solution was solved in an appropriate volume water. The volume of
water was chosen pursuant, the solution had a coating thickness of approximate 1-2 mm
when covering the surface of the culture vessel.
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The surfaces were allowed to dry overnight under a running47 lamina flow cabinet. The
next day, the surfaces were carefully rinsed with PBS48 before seeding the cells.
13.2 Culture conditions
13.2.1 General culture conditions
Except from YAMC, which require a temperature of 33 °C for proliferation49, all cell
lines as well as primary murine BMC/MΦ were cultured in an incubator at 37 °C in
an atmosphere of 85 % (v/v) relative humidity and 5 % (v/v) CO250 (in this thesis these
conditions are designated as standard conditions).
13.2.2 Generation of IEC monolayers
To establish dense IEC monolayers, the cells were cultivated over a period of 10-20 days
without passaging. During this period, the culture medium was exchanged every second
day.
13.3 Passaging & harvesting of cultivated cells
If not mentioned else, cells were passaged 2-3 times a week, according to their prolifera-
tion rate and confluence.
After aspirating the supernatant, the cells were rinsed shortly with prewarmed PBS con-
taining 2 mmol/l Na2-EDTA. Next, the cells were covered with Trypsin/EDTA solution51
47The constant vibrations ensured an equal wetting during the drying process.
48This step was necessary to remove putative HCl residues from the collagen stock solution as well as to
rehydrate the collagen fibers.
49The differentiation of YAMC into cells with a putative epithelial like phenotype appears at 37 °C.
50Even cells cultivated in pure DMEM normally require a CO2 concentration of 10 % (v/v) for an optimal
pH-value of the culture medium, they could be cultivated at 5 % (v/v) CO2 due to the addition of HEPES
and/or FCS to the culture medium.
51For some applications, which required the integrity of trypsin sensitive surface antigens, alternative
detachment solutions were utilized.
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(Biochrom) and incubated at 37 °C for 3-15 minutes depending on their specific adherence.
The cells were intermittently resuspended with a serological pipette to facilitate their
detachment. After all cells were detached, the suspension was transfered into a reaction
tube and mixed with an equal volume neutralization medium.
The cell suspension was centrifuged at 350 g for 10 min. Afterwards, the supernatant was
aspirated and discarded. For passaging, the remaining pellet was resuspended in an
appropriate volume of the culture medium or in an appropriate volume buffer if meant
to be used for other experiments. After determining the cell concentration, they were
re-seeded into a new culture vessel in the desired concentration or utilized for other
applications.
14 Primary Macrophages from bone marrow cells
Primary murine macrophages (MΦ) were generated from bone marrow cells (BMC) of
8-14 weeks old52 Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals.
14.1 Harvesting of BMC
BMC were harvested from the animal’s femurs and tibias. After killing the mice by
cervical dislocation, they were disinfected by wetting them with 70 % v/v ethanol. Next,
the animals were skinned. The musculus quadriceps as well as it’s attached tendons and
ligaments were intersected completely. The femur head was luxated by simultaneous
dislocating and pulling the femur against its socket. Femur and tibia were removed by
cutting trough the intra-articular space. The bones were stored in sterile, ice cold PBS
until further use.
52Animals for each particular experiment were age matched.
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The bones were pruned of all tissue remains using a scalpel and cleaning tissues. After
shortly immerse them in 70 % v/v ethanol, the bones were stored in sterile, ice cold PBS
until further use.
All following steps were conducted under a laminar flow cabinet. Femur and tibia were
cut trough in the middle. The bone fragments were threaded onto a hypodermic needle
(27 G⋅3/4) attached to a syringe filled with sterile, ice cold PBS. Subsequently, the bone
marrow cells were flushed out into a petri dish. The suspension was transfered into a
50 ml tube and remaining cell aggregates were dislodged by repeated resuspending of
the suspension using a serological 10 ml pipette. After centrifugation for 10 min at 350 g
and 4 °C, the supernatant was discarded. The remaining pellet was resuspended in an
adequate volume MΦdiff.-M. and stored on ice until further use.
14.2 Differentiation of BMC into MΦ
After counting the cells, they were adjusted to a concentration of 1 ⋅ 106 cells/ml using
MΦdiff.-M.. They were seeded in PET cell culture vessels with an untreated surface53, only
and cultured under standard conditions at 37 °C. At day 3 after seeding, the supernatant
was discarded and the cells were gently washed twice using prewarmed PBS to remove
not adherent cells and debris. The culture medium was exchanged against fresh MΦdiff.-
M.. At day 7, the cells were completely differentiated into MΦ.
Further experiments were were conducted using mGM-CSF and/or mIFN-γ in different
concentrations to differentiate BMCs into MΦ (Results not shown).
53Standard culture vessels for adherent cells showed up to be inappropriate.
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14.3 Culture of differentiated BMC derived MΦ
14.3.1 Culture medium
For the long-term culture of fully differentiated macrophages, the supplementation of
the macrophage basal medium (MΦ-M.) with 20 ng/ml mM-CSF and 50 IU/ml mIFN-
γ (MΦcult.-M.) has proven successful. The culture medium was exchanged every 3rd
day. Fully differentiated MΦ were conducted for experiments from day 7 to day 10
after BMC harvesting. Although not applied for experiments anymore at this time point,
MΦ survived up to 20 days without morphological changes under these conditions.
14.3.2 FEP culture bags
Additional to the culture in PET vessels with an untreated surface, for some applications
fully differentiated MΦ were also cultivated in specialized FEP culture bags (VueLifeTM,
AFC) with reduced adhesion potential. However, the approach of differentiating BMC
into MΦ directly in these bags led to a relatively low yield.
14.4 Detachment and harvesting of MΦ
14.4.1 Detaching MΦ from PET vessels
Due to their strong surface adherence, harvesting of BMC derived MΦ differed from the
standard protocol for harvesting adherent cells. First, the culture medium was discarded
and the cells were washed 3 times using prewarmed PBS containing 2 mmol/l Na2-EDTA.
Afterwards, the cells were covered with AccutaseTM solution and incubated for 30 min at
37 °C. Subsequent to the incubation, 1/2 volume freshly AccutaseTM solution was added
and the cells were incubated for additional 10 min on a plate shaker at 200 rpm and RT.
After all cells were detached (microscopic control), the suspension was mixed with an
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equal volume DMEM containing 10 % v/v FCS. After centrifugation for 10 min at 350 g
and 4 °C, the supernatant was discarded and the cell pellet could be used for further
experiments.
14.4.2 Detaching MΦ from FEP bags
To detach MΦ from FEP bags, the bags were immersed into an ice/water bath for
30 min. Next, the bag was scrubbed multiple times over a round edge with a low radius.
Afterwards, the now detached cells could be transfered into a reaction tube. Remaining
cells were collected by flushing the bag with ice cold PBS. After centrifugation for 10 min
at 350 g and 4 °C, the supernatant was discarded and the cell pellet could be used for
further experiments.
15 RNA expression profile of IER3 proficient and deficient MΦ
Putative differences in the RNA expression profile of immunologically relevant genes
in fully differentiated primary MΦ derived from the bone marrow of Ier3-flox+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice (sec. 14) were analyzed by qPCR. The MΦ were
optionally stimulated with different concentrations of LPS (0.5 ng/ml or 1.0 ng/ml) as
immunological activator, simulating the contact with gram negative bacterias. Cells
were harvested 6 h after LPS stimulation and RNA extraction was performed as de-
scribed in section 23. The RNAs of the ribosomal protein L13a (RPL13a) as well as of
the hypoxanthine-guanine phosphoribosyltransferase (HPRT) coding genes proved as
rather constantly expressed during these experiments and served as housekeepers for
normalization of the qPCR results.
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16 Protein expression profile of IER3 proficient and deficient MΦ
Putative differences in the Protein expression profile of immunological relevant genes
in fully differentiated primary MΦ derived from the bone marrow of Ier3-flox+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice (sec. 14) were analyzed by western blot (sec. 22).
The MΦ were optionally stimulated with different concentrations of LPS (2.0 ng/ml or
4.0 ng/ml) as immunological activator, simulating the contact with gram negative bacte-
rias. Cells were harvested 6 h after LPS stimulation and RIPA lysates were generated
subsequently as described in section 22.1.
17 Griess test
17.1 Background
The production and release of reactive nitrogen species (RNS) of MΦ derived from
the bone marrow of Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice (sec. 14)
was quantified indirectly in a photometrically assay based on a specific azo coupling
reaction firstly described by Griess [79]. A stoichiometric fraction of the iNOS produced
nitric oxide radicals (NO·) as well as their nitrogen dioxide radical intermediates (NO ·2 )
can freely diffuse trough the cellular membrane [136]. Under in vitro conditions, these
radicals immediately react with components of the culture medium to form nitric anions
(NO –2 ). During the Griess reaction, the nitric anions react with the reagents to form a
photometrically detectable azo dye.
17.2 Stimulation
BMC derived MΦ from IER3 proficient and deficient mice were cultured in 12-well
culture plates as described above in a concentration of 1 ⋅ 106 cells/ml. The cells were
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optionally stimulated for 6 h with different concentrations of LPS (0.5 ng/ml or 1.0 ng/ml) as
immunological activator. After the LPS incubation, the culture medium was exchanged
against LPS free MΦcult.-M. and the cells were incubated for further 18 h.
17.3 Griess Test
At the end of the incubation, the medium was aspirated54 and centrifuged for 20 min at
400 g and 4 °C. The supernatant was transfered into new micro reaction tubes and stored
on ice. The Griess test was performed subsequently in a 96-well microtiter plate. All
samples as well as a sodium nitrite standard series were measured as triplicates. 250 µl
sample solution was pipetted into each well. Next, 25 µl Griess reagent I (sulfanilamide)
were added to each well and the plate was incubated protected from light for 8 min at
RT on a plate shaker at 500 rpm. Afterwards, 25 µl Griess reagent II (NED) were added
added to each well and the plate was incubated for 15 min at RT on a plate shaker at
500 rpm. During 15 min after the incubation has ended, the optical absorbance was
measured on a plate photometer (Dynex) at λEx=550 nm. The composition of the reagents
is listed in table 8.6.
17.4 Normalization
The determined concentrations of nitrite were normalized against the MΦ number.
The cell number was determined fluorimetrically by staining the nuclei with Hoechst
bisbenzimide H33258 and determining the overall fluorescence intensity per well. In
brief, the MΦ in the culture plates were fixated with 4 % (m/m) phosphate buffered
formaline for 20 min. After a permeabilization step with 0.2 % (v/v) Triton X-100 in
PBS for 5 min, cells were washed 3 times with PBS. For nuclei staining, the cells were
incubated protected from light in 2 µg/ml Hoechst H33258 in PBS for 15 min. After washing
washing the cells 5 times with PBS, each cell layer was covered with 0.5 ml PBS to prevent
54The cells were covered in PBS directly after the aspiration.
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desiccation. Fluorescence intensity was measured subsequently on a plate fluorimeter
(Tecan) at λEx=340/10 nm and λEm=460/35 nm with 144 data points per well.
18 Immunocytochemistry
For fluorescence based immunocytochemistry (ICC-F), cells were cultivated on coverslips
as described in section 13.1. For the staining procedure, the supernatant was aspirated
and the cells were shortly rinsed with PBS. Next, the PBS was aspirated most thoroughly.
For fixation, the cells were covered with dried, pre-cooled (-20 °) methanol and incubated
at -20 °C for 15 min. After the fixation, the methanol was aspirated and the cells were
rinsed shortly with PBS. After aspirating the PBS, cells were covered with blocking
solution and incubated at RT for 60 min.
During the incubation, a glass plate was covered with parafilm and placed in a humidified
chamber. Per specimen, 50 µl of primary antibodies (tab. 18.1) or respectively isotype
controls (tab. 12.2) diluted in incubation solution were pipetted onto the parafilm. After
blocking unspecific binding sites, the coverslips were shortly dripped off and placed on
top the antibody dilution. Incubation took place in a humidified chamber overnight at
4 °C.
The next day coverslips were washed 3 times for 5 min, each with PBS (RT). A parafilm
covered glass plate was prepared as described above. Per specimen, appropriate, fluo-
rochrome conjugated secondary antibodies (tab. 12.3) were diluted in 50 µl incubation
solution together with 665 ng/ml Hoechst bisbenzimide H33258 and pipetted onto the
parafilm. After shortly dripping off the coverslips, they were placed on top the antibody
dilution and incubated in the dark for 40 min at RT.
Next, the coverslips were washed 3 times for 5 min, each with PBS (RT). After rinsing the
specimen two times shortly with water, they were dripped off and subsequently mounted
onto a microscope slide using FluorSave mounting medium (Merck).
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24 h after the mounting, the specimen were sealed with nail polish and stored 4 °C until
analysis.
Table 18.1: List of primary antibodies for fluorescence based Immunocytochemistry.
Antigen Species- Host Clonality/ Stock conc. Dillution Company/
reactivity Isotype order-no.
β-Catenin h, m, rt rb ∗50 µg/ml 1:200 CST 9562
E-Cadherin h, m, rt m mAb IgG2a 250 µg/ml 1:150 BD 610182
OCC h, m, rt rb pAb IgG 250 µg/ml 1:100 Thermo 40-4700
ZO1 h, m, rt rb pAb IgG 400 µg/ml 1:250 GTX GTX108613
Legend:
Species reactivity: letters: manufacturer recommendation, underlined: successfully applied.
∗: Concentration Lot depending.
Manufacturer abbreviations: BD: Becton Dickinson, CST: Cell Signaling Technologies, GTX: GeneTex
For further abbreviations see the list on page XVII.
19 Protein and mRNA expression of IEC monolayers during
direct co-culture with primary MΦ
Putative effects of in vitro generated primary MΦ derived from BMCs of Ier3-flox+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre-/- animals to the protein and mRNA-expression in IEC
monolayers were investigated in direct co-culture experiments.
Monolayers of intestinal epithelial cell lines were generated in 6-well culture plates over
a period of 14 days as described in section 8.6. In parallel, BMCs from Ier3-flox+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals were harvested and differentiated in vitro into
MΦ as described in section 14.
After harvesting the fully differentiated MΦ (sec. 14.1), they were adjusted to a concen-
tration of 5 ⋅ 105 cells/ml using MΦcult.-M. The supernatant of the IEC monolayers was
aspirated and exchanged against the MΦ containing cell suspension. Subsequently the
co-culture was optionally stimulated with 5 ng/ml LPS. NC experiments were conducted
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with MΦ free MΦcult.-M.±LPS. Macrophages and IEC monolayers were co-cultured
for 24 h or 48 h. Following the incubation, protein or RNA extracts were generated as
described in sections 22.1 and 23.1.
20 Protein and mRNA expression of IEC monolayers in response
to exogenous nitric oxide
To investigate putative effects of nitric oxide on the protein and mRNA-expression in IEC
monolayers, they were cultured in presence of the NO-donor S-nitroso-N-acetylpenicillamine
(SNAP).
IECs were either seeded in 6-well plates (for western blot and qPCR analysis) or on
coverslips in 12-well plates (for ICC-F) as describe in section 13.1. The IECs were
cultivated over a period of 14 days, during which they formed a dense monolayer. At
day 14, the culture medium was exchanged against freshly prepared medium containing
either 2.5 mmol/l or 5.0 mmol/l SNAP or an equal amount of DMSO in the negative control.
The monolayers were incubated under standard conditions for 24 h or 48 h.
Afterwards, either RIPA protein lysates for wb (sec. 22.1) or mRNA lysates for qPCR
(sec. 23.1) were generated. Alternatively, the IEC monolayers were processed for ICC-F
staining of cellular junction related proteins as described in section 18.
21 In vitro permeability of epithelial cell monolayers to
FITC-dextran
21.1 Permeability in co-culture with primary MΦ
Putative IER3 depending effects of activated primary MΦ from Ier3-flox+/+ LysM-Cre-/- and
Ier3-flox+/+ LysM-Cre+/+ animals on the permeability of IEC monolayers to small molecules
78
Materials & Methods
were investigated in these experiments.
Intestinal epithelial cells were seeded on transwell inserts and monolayers were estab-
lished over a period of 14 days as described in sections 13.1 and 13.2. In parallel, BMC
from Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals were harvested and
differentiated in vitro into MΦ as described in section 14.
24 h before the start of the experiment, the respectively culture medium in the IEC culture
was exchanged against a culture medium of identical formulation, except the containing
of phenol red (M.w/o PR).
For the experiment, the fully differentiated MΦ were harvested as described in sec-
tion 14.4 and washed 1x with the respective IEC-M.w/o PR. Next, the MΦ were adjusted to
a concentration of 5 ⋅ 105 cells/ml suspended in the respective IEC-M.w/o PR supplemented
with 5 mg/ml FD4 and 5 ng/ml LPS.
The culture medium in the lower and upper compartments of the IEC culture were
aspirated and discarded. The medium in the lower compartment was replaced with fresh
IEC-M.w/o PR, while the medium in the upper compartment was exchanged against the
FD4 and LPS containing MΦ suspension.
The co-culture was incubated for 24 h or 48 h at 37 °C under standard conditions before
determining the trans epithelial permeability.
21.1.1 Analysis
Fluorescence intensity After the incubation, the medium from the upper and lower
compartments were transfered into a micro reaction tube and centrifuged for 10 min at
350 g to precipitate potential debris. The supernatant was transfered into fresh micro
reaction tubes. Next, the samples from the upper compartment were diluted 1:10000
while the samples from the lower compartment were diluted 1:10 in 0.5 mol/l glycine
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buffer pH 9.6. 150 µl aliquots of the diluted sample solution were pipetted in triplicates
into the wells of 96-well microtiter plate.
The fluorescence intensity of the diluted samples was measured in a plate fluorimeter
(Tecan) at λEx=485/20 nm and λEm=535/25 nm.
Calculation of trans epithelial permeability The experimental design sufficiently fulfills
the following conditions:
1. cupper ≫ clower
2. cupper (t0) ≈ cupper (t1)
cupper (t0) : FITC-dextran concentration in the upper compartment at the begin of the experiment.
clower (t0) : FITC-dextran concentration in the lower compartment at the begin of the experiment.
cupper (t1) : FITC-dextran concentration in the upper compartment at the time point of analysis.
clower (t1) : FITC-dextran concentration in the lower compartment at the time point of analysis.
Hence, differences in transepithelial permeability µ between different experimental setups
can be approximated by the following equation:
µ̄ (t) = clower(t1)cupper(t1)
µ̄ (t) : Average time depending transepithelial permeability of the monolayer to
FITC-dextran between begin of the experiment and the time point of analysis.
21.2 Nitric oxide induced permeability
In these experiments putative effects of nitric oxide on the permeability of IEC monolayers
to small molecules were investigated. For this, confluent IEC monolayers were cultured
in presence of the nitric oxide donor S-Nitroso-N-acetyl-DL-penicillamine (SNAP).
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21.2.1 Experimental design
Intestinal epithelial cells were seeded on transwell inserts and monolayers were estab-
lished over a period of 14 days as described in section 13.2.2. 24 h before the start of the
experiment, the respectively culture medium was exchanged against a culture medium
of identical formulation, except the containing of phenol red (M.w/o PR).
For the experiment, the medium in lower compartment was exchanged against freshly
prepared mediumw/o PR containing 2.5 mmol/l, 5.0 mmol/l SNAP or an equal amount DMSO
in the NC. The culture medium in the upper compartment was also exchanged against
freshly prepared mediumw/o PR with an SNAP/DMSO concentration identical to the one
in the lower compartment but with the addition of 5 mg/ml FD455. Afterwards the cells
were incubated under standard conditions for 24 h or 48 h.
After the incubation, the transepithelial permeability was determined as described in
sec 21.1.1.
22 SDS-PAGE and western blot
22.1 RIPA protein extracts
For the generation of RIPA protein extracts, only protease free materials and reagents
were used. The cell culture medium was aspirated and cells were washed twice using
PBS (RT). All following procedures were conducted on ice. Remaining traces of PBS were
aspirated thoroughly. Subsequently, an appropriate volume56 freshly prepared, ice cold
RIPA buffer was added. The cells were scraped off and the suspension was transfered
into an pre-coold micro reaction tube. Afterwards, the tubes were vortexed for 40 min at
55An additional mediumw/o PR/SNAP batch w/o FD4 served as blank value during the analysis.
56E. g. 250 µl for a confluent grown well of a 6-well culture plate.
81
Materials & Methods
1400 rpm and 4 °C. Following this, the suspension was centrifuged for 20 min at 13000 g57
and 4 °C. Subsequently, the protein containing supernatant was transfered into a fresh
pre-cooled micro reaction tube and directly used for experiments or stored at -20 °C.
22.2 Measurement of total protein concentration in cell extracts
Total protein concentration in whole cell lysates was measured colorimetric using the
DCTM 58 protein assay kit (BioRad) based on the Lowry method [118] according to
the manufacturer’s manual. A five-point calibration curve was generated using a BSA
standard in a concentration range from 0.1mg/ml up to 1.0 mg/ml, diluted in RIPA buffer.
Detection was performed at 630 nm using a Opsys MRTM plate photometer (Dynex).
While standards were measured in triplicates, samples were measured in duplicates to
reduce random errors.
22.3 SDS-PAGE
Three volumes protein solution adjusted59 exactly to a total protein concentration of
approximate 0.5-1.5 µg/µl60 were mixed with 1 volume 4x Laemmli loading buffer and
incubated at 95 °C for 7 minutes. Afterwards, the samples were spun down shortly and
cooled on ice.
The samples were loaded onto a SDS-PAGE stacking gel (10 µl/lane). The PAA concentra-
tion of the separating gel was 10 %, 12.5 % or 15 % PAA, depending on the molecular
weight of the target proteins. The composition of the gels is given in table 22.1. One
lane of each gel was loaded with 2 µL PageRuler plus TM protein ladder (Fermentas) for
57Optimal conditions for centrifugation have to be determined in reference to the used cell line and proteins
of interest.
58DC: Detergent compatible.
59Protein concentration adjustment was performed using RIPA buffer.
60All samples of a particular experiment were adjusted to equal concentrations.
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molecular weight verification of the detected proteins. The PAGE was performed in SDS
running buffer at 35 mA per gel.
Table 22.1: Composition of PAA gels for SDS-PAGE.
Label Composition
Separating gel 25.0 % (v/v) WB separating gel buffer pH 8.8
10 %/12.5 %/15 % PAA 25.0/31.3/37.5 % (v/v) RotiphoreseTM solution 40 %
0.075 % (v/v) TEMED
0.35 g/l APS
solved in water
Stacking gel 4 % 25.0 % (v/v) WB stacking gel buffer pH 6.8
10.0 % (v/v) RotiphoreseTM solution 40 %
0.1 % (v/v) TEMED
0.5 g/l APS
solved in water
22.4 Western blot
22.4.1 Electro blot
Western blot was performed using the semi-dry technique. The proteins from a SDS-
PAGE gel were blotted onto a PVDF membrane (Roth). Lamination of the single layers
of the blotting system is given in figure 22.1. Buffer composition is listed in table 8.6.
Electro blots were performed at 1.5 mA/cm2 for 50 minutes.
22.4.2 Detection of blotted proteins
After finishing the electro blot, the membrane was washed in in TBS-T for 5 minutes.
Subsequently, it was blocked in wb blocking solution for 2 h at room temperature. Then
the membrane was transferred into a 50 ml reaction tube containing 5 ml of a primary
antibody diluted in its appropriate diluent61. A comprehensive list of the applied
61If the diluent of the primary Ab was BSA based, the blot was washed 3x for 5 min, each prior incubation.
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Figure 22.1: Design layout of the semi-dry electro-blotting system. Buffer compositions are listed in table 8.6.
antibodies including their characteristics and incubation parameters (species reactivity,
dilutions, etc.) is given in table 22.2. Incubation was performed on a roller mixer
overnight at 4 °C. Following the incubation, 3 washing cycles in TBS-T for 10 minutes
each at room temperature were performed. Afterwards, the membrane was incubated
with a corresponding, HRP-conjugated secondary antibody (sec. 22.4.3) diluted in 5 ml
skim milk powder (smp) based blocking solution for 2 h at room temperature on a roller
mixer. Next, the membrane was washed 3 times with TBS-T for 10 minutes each at
room temperature. Afterwards the membrane was incubated in ECL developing solution
(BioRad) for 5 minutes at room temperature. The chemoluminescence reaction was
detected using the ChemiDocXRSTM scanning system (BioRad).
To allow staining of several epitopes on a membrane, the membrane was washed 3 times
in TBS-T after each detection. Then the staining with another primary antibody was
performed like described above. Between different stainings, an antibody stripping was
performed if necessary. For this, the membrane was incubated in 5 ml 1x Re-Blot PlusTM
antibody stripping solution (Millipore) on a shaker at room temperature for 20 minutes
followed by a repeated 2 h incubation in wb blocking solution.
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22.4.3 Western blot antibodies
Table 22.2 lists the primary antibodies used for detection of blotted proteins. The HRP
conjungated secondary antibodies (anti-mouse IgG: CST ord.-no.: 7076, anti-rabbit: ord.-
no.: 7074) were diluted 1:3000 in 5 ml SMP-based blocking solution (50 g/l SMP in TBS-T).
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23 RNA extraction and quantitative real time PCR
23.1 RNA extraction and purification
Cell harvesting with subsequent RNA extraction and purification was performed using
the column based RNeasyTM mini RNA extraction Kit (Qiagen) in combination with
QiaShredderTM columns accordingly manufacturers instructions. An additional DNAse
digestion was conducted during the purification process. The processed samples were
stored at -80 °C until further use.
Purity and RNA concentration of generated samples was verified photometrically using
the NanodropTM ND1000 photometer (Peqlab).
23.2 Reverse transcription of RNA into complementary DNA
An 0.5 – 1.5 µg total RNA containing volume RNA-solution was adjusted with water
to a total volume of 11.5 µl. After addition of 1 µL oligo dT primers (Fermentas,
100 µmol/l) the solution was incubated at 65 °C for 5 minutes. After cooling down on ice,
7.5 µl mastermix were added. The composition of the mastermix is listed in table 23.1.
The reverse transcription was performed by incubating the reaction mix at 42 °C for
60 minutes. Afterwards, the reaction mix was heated up to 70 °C for 5 minutes to
deactivate the reverse transcriptase. The processed samples were diluted 1:5 in water.
Purity and complementary DNA (cDNA) concentration of the generated samples was
verified photometrically using the NanodropTM ND1000 photometer (Peqlab). The
samples were stored at -20 °C until further use.
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Table 23.1: Master mix composition for RT-PCR.
Volume Component
4.0 µl 5x RT reaction buffer
2.0 µl dNTP solution (c=10 mmol/l, each)
0.5 µl RiboLockTM RNase inhibitor (c=40 U/µl)
1.0 µl RevertAidTM mMLV reverse transcriptase (c=200 U/µl)
23.3 Quantitative real time PCR
23.3.1 General
Quantitative real-time PCR (qPCR) was performed using the Blue S’GreenTM qPCR mix
kit (Biozym) in combination with a CFXTM 96-well qPCR cycler (BioRad). 2 µl cDNA
containing sample were transfered as duplicates or triplicates into a well of a 96-well
reaction plate. Next, 10 µl freshly prepared mastermix (composition is listed in table 23.2)
were added. The plate was sealed, shaken and the samples were spun down shortly.
Subsequently, the qPCR reaction was performed. The qPCR conditions are listed in
table 23.3. Primer sequences for the respectively target genes as well as their optimal
annealing temperatures are listed in table 23.4.
Table 23.2: Master mix composition for qPCR.
Volume Component
6.000 µl 5x Blue S’GreenTM reaction buffer
0.048 µl Fwd primer (100 µmol/l)
0.048 µl Rev primer (100 µmol/l)
3.904 µl water
23.3.2 qPCR primer sequences and corresponding annealing temperatures
Primer sequences for qPCR (tab. 23.4) were designed using the NCBI PrimerBlastTM
software. All primers were purchased from Eurofins and adjusted with water to a stock
concentration of 100 µmol/l. They were stored at -20 °C. Optimal annealing temperatures
were established experimentally.
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23.3.3 qPCR quality control
The following measures were implemented to ensure the quality of the generated qPCR
data:
• All samples were measured as duplicates or triplicates.
• Melting curves of all qPCR products were achieved.
• For all applied Primer/cDNA combinations, a gel electrophoresis of the qPCR
product was performed at least once to verify the molecular size and purity of the
product.
• For each cDNA sample at least two different housekeeping genes were used for
normalization.
Table 23.3: qPCR conditions.
Step
PCR conditions
temperature time cycles
Initial melting step 95 °C 120 s
Melting 95 °C 5 s
Annealing * °C 10 s ⟲ 40×
Elongation 65 °C 20 s
Melting curve 65-95 °C
*: The optimal annealing temperature for each sample/primer combination
was determined theoretical as well as experimental. The distinct temperatures
are listed in table 23.4 together with the primer sequences.
89
Materials & Methods
Table 23.4: qPCR primer sequences and their corresponding annealing temperatures.
Gene Primer sequence
Annealing
temp.
mHprt
fwd: 5’- G C T G A C C T G C T G G A T T A C A T -3’ 64 °C
rev: 5’- T T G G G G C T G T A C T G C T T A A C -3’
mIer3
fwd: 5’- G A T A T G C C T C C C C T G C T G T A A -3’ 62 °C
rev: 5’- A A G G G T C T T C C A A A G C C T T A -3’
mIl-1β
fwd: 5’- C C C A A C T G G T A C A T C C A G C A C -3’ 62 °C
rev: 5’- T C T G C T C A T T C A C G A A A A G G -3’
mIl-6
fwd: 5’- T A G T C C T T C C T A C C C C A A T T T C C -3’ 65 °C
rev: 5’- T T G G T C C T T A G C C A C T C C T T C -3’
mIl-10
fwd: 5’- G G C G C T G T C A T C G A T T T C T C -3’ 64 °C
rev: 5’- A T G G C C T T G T A G A C A C C T T G G -3’
mNos2 (iNos)
fwd: 5’- T C C C T T C C T T G C A T G T G C C C -3’ 62 °C
rev: 5’- T G A C C A T C T C G G G T G C G G T A -3’
mRpl13a
fwd: 5’- A T G A C A A G A A A A A G C G G A T G -3’ 64 °C
rev: 5’- C T T T T C T G C C T G T T T C C G T A -3’
mTgf-β
fwd: 5’- A G C T G C G C T T G C A G A G A T T A -3’ 62 °C
rev: 5’- A G C C C T G T A T T C C G T C T C C T -3’
mTnf
fwd: 5’- C C C A C T C T G A C C C C T T T A C T -3’ 62 °C
rev: 5’- T T T G A G T C C T T G A T G G T G G T -3’
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24 Flow cytometry
24.1 Cell detachment and harversting
Adherent cells were detached and harvested by the respectively standard protocol (see
sections 13.3 and 14.1). For the staining of some extracellular antigens, the detach-
ment process had to be adjusted, due to the enzymatic shedding activity of the actual
detachment reagent.
24.2 Staining
• All antigen staining were performed using fluorophor conjugated REATMantibodies
(Miltenyi) exclusively, according to manufacturer’s recommendations. A list of
the applied antibodies is given in table 24.1. Table 24.2 lists the respective isotype
controls.
• Due to the specific design of REATMantibodies (Miltenyi), it was not necessary to
perform an FC-receptor block before staining
62.
• Following staining batch combinations were performed for each experiment:
– Unstained (for optimal PMT-Voltage adjustment).
– Single staining of each antigen (for channel compensation).
– Combined staining of with all isotype control antibodies (for negative/positive
gating)
– Combined staining of all antigens in one batch (actually sample).
62Nevertheless, for each new experiment an FC-receptor block was performed once for validation.
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Table 24.1: Fluorochrome conjugated REA* antibodies applied for flow cytometry analysis.
Antigen
Species-
Host
clonality/ Fluoro- Stock
Dilution
Order-
reactivity Isotype chrome conc. no.∗∗∗
conjugate
CD11b m Rec. (h) mAb IgG1 (REA*) APC 150 µg/ml 1:50 130-113-802
CD11c m Rec. (h) mAb IgG1 (REA*) PE 150 µg/ml 1:50 130-110-701
CD68 m Rec. (h) mAb IgG1 (REA*) VioBlue** 150 µg/ml 1:50 130-112-861
CD200R m Rec. (h) mAb IgG1 (REA*) APC 150 µg/ml 1:50 130-112-531
F4/80 m Rec. (h) mAb IgG1 (REA*) FITC 30 µg/ml 1:10 130-102-988
MHC II m Rec. (h) mAb IgG1 (REA*) PE 150 µg/ml 1:50 130-104-625
Legend:
*: REA is a trademark of recombinant antibodies from Miltenyi.
**: VioBlue is a fluorochome distributed by Miltenyi, with a em/ex-spectrum comparable to AF-405.
***: All antibodies were purchased from Miltenyi.
For further abbreviations see the list at page XVII.
Table 24.2: Fluorochrome conjugated REA isotype control antibodies applied for flow cytometry analysis.
Host Clonality/ Fluorochrmome Stock conc. Order
isotype conjugate no.∗∗∗
Rec. (h) mAb IgG1 (REA∗) APC 30 µg/ml 130-104-630
Rec. (h) mAb IgG1 (REA∗) FITC 30 µg/ml 130-104-626
Rec. (h) mAb IgG1 (REA∗) PE 30 µg/ml 130-104-628
Rec. (h) mAb IgG1 (REA∗) VioBlue∗∗ 30 µg/ml 130-104-625
Legend:
∗: REA is a trademark of recombinant antibodies from Miltenyi.
∗∗: VioBlue is a fluorochome distributed by Miltenyi, with a em/ex-spectrum comparable to AF-405.
∗∗∗: All antibodies were purchased from Miltenyi.
For further abbreviations see the list at page XVII.
24.3 Gating strategy
First, the optimal FSC and SSC PMT-voltages were adjusted to detect the majority of all
events. After excluding all debris from the parental population by inverse gating, the
optimal PMT-voltage for each single channel was adjusted in a live color/SSC dot plot
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diagram as well in a histogram using unstained (sic!) cells63. Next, a channel bleeding
compensation was performed using single stained samples. Gates to discriminate between
negative and positive events were set in reference to the fluorescence intensity of the
isotype controls.
25 Statistics
The statistical significance of the results was calculated either by an adjusted two-sided
Wilcoxon-Mann-Whitney test or by two-sided Student’s t-test, depending on the
experimental design. A p-value ≤ 0.05 was considered as statistical significant (*), while
a p-value ≤ 0.01 was considered as statistical highly significant (**). Calculations were
performed using the Gnumeric software application [203] in version 1.12.28.
63The goal of this approach is to to set the mean fluorescence intensity for each channel to zero without
overcompensating the respectively channel. This ensures a optimal channel sensitivity while avoiding
the risk of detecting false positive events despite correct gating.
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26 Phenotype comparison between Ier3-flox+/+ LysM-Cre-/- and
Ier3-flox+/+ LysM-Cre+/+ mice
Before starting experimental colitis experiments with mice exhibiting Ier3 proficiency
and deficiency in the myeloid compartment, their basal status was analyzed.
26.1 Body weight and organs
Body weight and parameters of immunological relevant organs of from male Ier3-
flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice (neach GT ≥ 5) with an average age of
14 weeks (±6 days) were compared (fig. 26.1). With a median body weight of 34.0 g, Ier3-
flox+/+ LysM-Cre+/+ animals were on average 23 % heavier than Ier3-flox+/+ LysM-Cre-/- mice
(27.6 g; fig. 26.1a; p=0.050). Both genotypes showed no significant differences in their
median colon length (fig. 26.1b), liver weight (fig. 26.1d) and spleen weight (fig. 26.1e),
while their medial cecum weight differed significant (p=0.014) from 16.72 mg/g body weight
in the Ier3-flox+/+ LysM-Cre-/- cohort to 14.81 mg/g body weight (fig. 26.1c).
26.2 Histology
Histologically, there were no morphological differences observable between both geno-
types (fig. 26.2). Furthermore, tissue and cell morphology did not deviate from the one
of healthy non-transgenic wild-type mice, including the presence of a moderate number
of F4/80-positive MΦ.
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*
(a) Absolute, median body weight.
n.s.
(b) Absolute, median colon length.
*
(c) Relative, median cecum weight, normalized to
body weight.
n.s.
(d) Relative, median liver weight, normalized to
body weight.
n.s.
(e) Relative, median spleen weight, normalized to
body weight.
Figure 26.1: Comparison of body weight and immunological relevant organs from Ier3-flox+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice. Animals had an age of 14 weeks (±6 days) on the
day they were sacrificed (neach GT ≥ 5). Shown are median values of the analyzed parameters
(crossbar within the box). Boxes cover the 25 % and 75 % quantiles. Whisker length corresponds to
values with a maximal medial deviation of the 1.5-folds interquartile range, while extreme values are
indicated as bullets. Statistical significance in the difference between the two cohorts was determined
by adjusted WILCOXON-MANN-WHITNEY-test. A p-value ≤ 0.05 is considered as statistically significant
(*).
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Figure 26.2: IHC staining of MΦ in the colons of healthy Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-
Cre+/+ mice with an average age of 14 weeks (±6 days). Colons were removed immediately
after killing the animals and the specimen were processed subsequently as described in sec. 12.1.
Conventional immunostaining was performed as described in sec. 12.3.2. MΦ were stained using
an anti F4/80 antibody (CST) or an respectively isotype control Ab. Detection was performed by
chromogenic AEC reaction (red) using a HRP-conjugated secondary antibody. Areas of increased
MΦ accumulation are additionally indicated by black arrow heads. Cell nuclei were counterstained
using MEYER’S haematoxylin (blue). Shown are representative pictures.
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27 In vivo effects of myeloid IER3-deficiency in response to DSS
and AOM
Several dextran sodium sulphate (DSS) or azoxymethane (AOM)/DSS animal experi-
ments were conducted to study putative effects of myeloid IER3 in the context of acute
as well chronic colitis and colitis associated carcinogenesis (CAC) in vivo.
27.1 Myeloid Ier3 knockout mitigates acute DSS colitis
27.1.1 Weight loss and survival
The role of myeloid IER3 in acute colitis was investigated in two independent animal
experiments by applying high DSS (30 g/l) in drinking water ad libitum over a period
of 9-10 days. Animals of both genotypes started to loose body weight from day 4-
5 after having started the DSS treatment (fig. 27.1). Until day 6, weight loss in the
Ier3-flox+/+ LysM-Cre+/+ cohort was slightly greater compared to the Ier3-flox+/+ LysM-
Cre-/- group (exp. #1: -9 % vs. -8 %; exp. #2: -7 % vs. -5 %). This trend started to reverse
between day 6 and 7. While weight loss in both genotypes continued until the end of
the experiments, it was markedly more pronounced in Ier3-flox+/+ LysM-Cre-/- animals.
Moreover, the weight difference between both genotypes increased during time. At
the endpoint, Ier3-flox+/+ LysM-Cre-/- animals in exp. #1 on average had lost 23 % body
weight (exp. #2: 17 %), while Ier3-flox+/+ LysM-Cre+/+ animals in exp. #1 lost 17 % (exp. #2:
9 %). Even though both experiments similarly show differential weight loss patterns,
differences within each experiment were statistically not significant. Weight loss in both
genotypes was accompanied by diarrhea and the appearance of occult blood in the feces,
though without distinct differences between both genotypes.
In both experiments, all Ier3-flox+/+ LysM-Cre+/+ mice survived until the scheduled
endpoint (fig. 27.2), whereas one animal from the Ier3-flox+/+ LysM-Cre-/- cohorts had to
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(a) Experiment #1. neach GT = 8.
DSS
(b) Experiment #2. nLysM-Cre−/− = 8. nLysM-Cre+/+ = 9.
Figure 27.1: Comparison of body-weight loss between Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-
Cre+/+ animals during acute DSS colitis. 9 week (±3 days) old Ier3-flox+/+ LysM-Cre-/- and
Ier3-flox+/+ LysM-Cre+/+ mice received 30 g/l DSS in drinking water ad libitum over a period of 9 days
(exp. #1) or 10 days (exp. #2). Mice were prematurely excluded from the experiment if matching at
least one abort criterion. Shown is the mean relative body-weight of each cohort in relation to the
absolute body-weight at day 0. Error bars represent relative standard deviation.
be excluded prematurely (exp. #1: day seven, fig. 27.2a; exp. #2: day nine, fig. 27.2b) due
to its poor health condition.
DSS
(a) Experiment #1. neach GT = 8.
DSS
(b) Experiment #2. nLysM-Cre−/− = 8. nLysM-Cre+/+ = 9.
Figure 27.2: Kaplan Meyer survival curve of Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals during
the onset of acute DSS colitis. Experimental design as described in figure 27.1.
27.1.2 Post mortem analysis of immunological relevant organs
At the end point of the experiments, there were no differences in colon length (fig. 27.3a)
as well in the cecum weight (fig. 27.3b) between both genotypes. Interestingly, in
experiment #1, Ier3-flox+/+ LysM-Cre+/+ animals showed a significant higher liver weight
compared to Ier3-flox+/+ LysM-Cre-/- animals (p=0.049, fig. 27.3c). In addition, the spleen
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weights were significantly lower in Ier3-flox+/+ LysM-Cre+/+ mice than in Ier3-flox+/+ LysM-
Cre-/- mice (p ≤ 0.002, fig. 27.3d). However, those differences were not observed in
experiment #2 (fig. 27.3a-27.3d).
Ier3-flox++
LysM-Cre-
Ier3-flox++
LysM-Cre-
Ier3-flox++
LysM-Cre++
Ier3-flox++
LysM-Cre++
experiment #1 experiment #2
n.s. n.s.
(a) Absolute, median colon length.
Ier3-flox++
LysM-Cre-
Ier3-flox++
LysM-Cre++
experiment #1
n.s.
(b) Relative, median cecum weight, normalized to body
weight.
Ier3-flox++
LysM-Cre-
Ier3-flox++
LysM-Cre-
Ier3-flox++
LysM-Cre++
Ier3-flox++
LysM-Cre++
experiment #1 experiment #2
* n.s.
(c) Relative, median liver weight, normalized to body weight.
Ier3-flox++
LysM-Cre-
Ier3-flox++
LysM-Cre-
Ier3-flox++
LysM-Cre++
Ier3-flox++
LysM-Cre++
experiment #1 experiment #2
** n.s.
(d) Relative, median spleen weight, normalized to body
weight.
Figure 27.3: Comparison of immunological relevant organs from Ier3-flox+/+ LysM-Cre-/- and Ier3-
flox+/+ LysM-Cre+/+ mice after induction of acute AOM/DSS colitis. Animals had an age of
14 weeks (±6 days) on the day they were sacrificed (neach GT ≥ 5). Experimental design as de-
scribed in figure 27.1. Shown are median values of the analyzed parameters (crossbar within the
box) from seven Ier3-flox+/+ LysM-Cre-/- and nine Ier3-flox+/+ LysM-Cre+/+ animals (experiment #1),
respectively seven Ier3-flox+/+ LysM-Cre-/- and eight Ier3-flox+/+ LysM-Cre+/+ animals (experiment #2)
after experimental termination. Boxes cover the 25 % and 75 % quantiles. Whisker length corresponds
to values with a maximal medial deviation of the 1.5-folds interquartile range, while extreme values are
indicated as bullets. Statistical significance in the difference between the two cohorts was determined
by adjusted WILCOXON-MANN-WHITNEY-test. A p-value ≤ 0.05 is considered as statistically significant
(*), while a p-value ≤ 0.01 is considered as statistically highly significant (**).
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27.2 Myeloid IER3-deficiency protects during initiation phase of chronic DSS
colitis
27.2.1 Weight loss and survival
Mice were injected intraperitoneally (i.p.) with 10 µg/g bw AOM at day -7. DSS was
applied at at a concentration of 10 g/l in drinking water ad libitum from day 0 until
day seven to induce a colitis. Ier3-flox+/+ LysM-Cre-/- animals started to loose weight
up from day 6 (fig. 27.4a). Weight loss in Ier3-flox+/+ LysM-Cre-/- animals continued
until day ten, where it reached its maximum of -16 % (Ier3-flox+/+ LysM-Cre+/+: ±0 %).
Ier3-flox+/+ LysM-Cre-/- mice started to recover their body weight from day 11 until they
fully gained their initial weight at day 13. However, this is due the fact, that some Ier3-
flox+/+ LysM-Cre-/- animals had to be excluded already earlier from the experiment due
to their poor health condition (fig. 27.4b). In contrast, all Ier3-flox+/+ LysM-Cre+/+ animals
showed no significant weight loss during the whole experiment. Strikingly, the individual
weight distribution within the Ier3-flox+/+ LysM-Cre-/- cohort was much higher compared
to the Ier3-flox+/+ LysM-Cre+/+ cohort.
As mentioned above, some animals of the Ier3-flox+/+ LysM-Cre-/- cohort matched at least
one abortion criterion during the experiment. One animal was excluded on day 11, while
two further animals had to be excluded at day 12 (fig. 27.4b). This led to an overall
13 days survival rate of 50 % in the Ier3-flox+/+ LysM-Cre-/- group compared 100 % in the
Ier3-flox+/+ LysM-Cre+/+ cohort.
27.2.2 Post mortem analysis of organs
At the time point of termination, none of the animals from both genotypes showed any
signs of neoplasms. There were no significant differences in the colon length between
both cohorts (fig. 27.5a). The same was seen for cecum weights (fig. 27.5b). Interestingly,
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AOM
(a) Body-weight alterations between Ier3-flox+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals in response
to AOM/DSS. Shown is the mean relative body-weight
of each cohort in relation to the absolute body-weight at
day 0. Error bars represent relative standard deviation.
Significance of body-weight differences between both
cohorts was determined by two-sided Student’s t-test. A
p-value ≤ 0.05 is considered as statistically significant (*).
DSSAOM
(b) Kaplan Meyer survival curve of Ier3-flox+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals in response to
AOM/DSS.
Figure 27.4: Onset of chronic AOM/DSS colitis. Six Ier3-flox+/+ LysM-Cre-/- and five Ier3-flox+/+ LysM-
Cre+/+ mice with an average age of 10 1/2 weeks (±10 days) were injected i.p. with AOM
(10 µg/g body weight) at day -7. Animals received 10 g/l DSS in drinking water ad libitum from day
0-7. The experiment was terminated at day 13. Mice were excluded earlier from the experiment if
matching at least one abortion criterion.
the livers (p = 0.034, fig. 27.5c) and spleens (p = 0.025, fig. 27.5d) of Ier3-flox+/+ LysM-
Cre-/- mice were significant greater compared to Ier3-flox+/+ LysM-Cre+/+ animals.
27.2.3 Tissue damage and pathology
Pictures of the whole colon stained with HE from each animal were generated (fig. 27.6) to
estimate tissue damage and the extend of inflammatory infiltrates. It can be appreciated,
that colons from both genotypes similarly contained both, unobtrusive areas with the
typical tissue morphology of healthy animals, as well as areas with tissue damages
characteristic for DSS colitis. This includes surface epithelium erosions and an increased
mucosal infiltration with cells, presumptive (!) of the leukocyte lineage.
However, morphological tissue damages in Ier3-flox+/+ LysM-Cre-/- animals were slightly
increased in both, number and severity, when compared to Ier3-flox+/+ LysM-Cre+/+ mice.
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n.s.
(a) Absolute, median colon length.
n.s.
(b) Relative, median cecum weight, normalized to
body weight.
*
(c) Relative, median liver weight, normalized to
body weight.
*
(d) Relative, median spleen weight, normalized to
body weight.
Figure 27.5: Comparison of immunological relevant organs from Ier3-flox+/+ LysM-Cre-/- and Ier3-
flox+/+ LysM-Cre+/+ mice after induction of chronically AOM/DSS colitis. Experimental design
as described in figure 27.4. Shown are median values of the analyzed parameters (crossbar within
the box) from three Ier3-flox+/+ LysM-Cre-/- and five Ier3-flox+/+ LysM-Cre+/+ animals after experiment
termination at day 13. Boxes cover the 25 % and 75 % quantiles. Whisker length corresponds to
values with a maximal medial deviation of the 1.5-folds interquartile range, while extreme values are
indicated as bullets. Statistical significance in the difference between the two cohorts was determined
by adjusted WILCOXON-MANN-WHITNEY-test. A p-value ≤ 0.05 is considered as statistically significant
(*).
27.2.4 Macrophage infiltration
Macrophage infiltration into the mucosa was determined histologically by conventional
AEC based immunostaining against F4/80 (fig 27.7). The specificity of the staining was
verified by an appropriate isotype control. Specimen from both genotypes exhibited
a massive infiltration of MΦ into all layers of the mucosa. There was no difference
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(a) Ier3-flox+/+ LysM-Cre-/- (b) Ier3-flox+/+ LysM-Cre+/+
Figure 27.6: Exemplary HE staining of colons from Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre-/- an-
imals treated with AOM/DSS. Experimental design as described in figure 27.4. After termination,
colons were dissected, rinsed with PBS and cut open longitudinally. Histological specimen were
processed as described in sec. 12.1. HE staining was performed as described in sec. 12.3.1.
seen in the grade of infiltration between Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-
Cre+/+ animals.
27.2.5 Expression of cellular junction related proteins
As the disintegrity of cellular junctions (CJ) is an critical aspect during the pathogenesis
of IBD and CAC in humans (sec. 3.3), respectively during AOM/DSS colitis in mice, we
analyzed the in vivo expression of several CJ related proteins.
The expression of the CJ related proteins E-cadherin and β-catenin in the colonic mucosa
was determined by fluorescence based immunostaining (fig. 27.8). The specificity of the
staining was verified by an appropriate isotype control (not shown).
In both genotypes, there were high fluctuations in the expressional intensity of the two
proteins within a single colon. Nevertheless, the overall expression of E-cadherin as well
as of β-catenin was much higher in Ier3-flox+/+ LysM-Cre+/+ animals when compared to
Ier3-flox+/+ LysM-Cre-/- mice.
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Figure 27.7: MΦ infiltration in the colonic mucosa of Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-
Cre+/+ animals after AOM/DSS-treatment. Experimental design as described in figure 27.4. After
termination, colons were dissected, rinsed with PBS and cut open longitudinally. Histological specimen
were processed as described in sec. 12.1. Conventional immunostaining was performed as described
in sec. 12.3.2. MΦ were stained using an anti F4/80 antibody (CST) or an respectively isotype
control Ab. Detection was performed by chromogenic AEC reaction (red) using a HRP-conjugated
secondary antibody. Cell nuclei were counterstained using MEYER’S Haematoxylin (blue). Shown are
representative pictures of colons from Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice at
day 13.
Furthermore, there was a decreasing gradient in the expressional intensity of both
proteins from the lumen facing site towards the crypts. In some colon segments of
Ier3-flox+/+ LysM-Cre-/- mice this resulted in a distinctly weakened protein expression in
the apical surface, whereas β-catenin and especially E-cadherin, were barely detectable in
the crypts of these segments.
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Figure 27.8: Expression of E-cadherin and β-catenin – IHC-F. Experimental design as described in figure 27.4.
After termination, colons were dissected, rinsed with PBS and cut open longitudinally. Histological
specimen were processed as described in sec. 12.1. IHC-F staining was performed as described in
sec. 12.3.3. E-Cadherin appears green, while β-catenin appears red. Appropriate isotype controls
were performed for all specimen (not shown). Cell nuclei were counterstained with Hoechst bisbenz-
imide H33258 (blue). Shown are representative pictures from colons of Ier3-flox+/+ LysM-Cre-/- and
Ier3-flox+/+ LysM-Cre+/+ mice.
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27.3 Myeloid depletion of IER3 protects mice from colitis associated
carcinogenesis
The pathogenesis of UC and subsequent carcinogenesis was explored by employing long
term AOM/DSS treatment.
27.3.1 Weight loss
Figure 27.9 illustrates the body weight course of both cohorts during the experiment.
Ier3-flox+/+ LysM-Cre-/- animals started to loose weight at the beginning of the first DSS
cycle. Until day four, they lost on average 11 % body weight before sustaining on this
level. In contrast, Ier3-flox+/+ LysM-Cre+/+ mice showed no weight loss during or after the
first DSS cycle. The difference in body weight between both cohorts was highly significant
from day two until day 11. Ier3-flox+/+ LysM-Cre-/- animals started to regain weight up
from day 11 until they reached their initial weight at day 21. The second DSS cycle was
shortened to 3 days to prevent premature discontinuation of the experiment64. However,
this cycle had no impact on the body weight of neither the cohorts. Animals from
both genotypes started again to loose body weight from day 42, which was the seventh
day of the third DSS cycle. Weight loss continued until day 44 in the Ier3-flox+/+ LysM-
Cre-/- group (-13 %) and day 45 in the Ier3-flox+/+ LysM-Cre+/+ group (-17 %) respectively.
After the third DSS cycle, Ier3-flox+/+ LysM-Cre-/- animals recovered faster compared to
Ier3-flox+/+ LysM-Cre+/+ mice, so that there was a significant difference in the body weight
between both cohorts from day 48 until day 57. Ier3-flox+/+ LysM-Cre-/- animals fully
regained their initial weight until day 48 (99 %), while for Ier3-flox+/+ LysM-Cre+/+ animals
this was not before day 63 (100 %). Animals in both cohorts slightly continued to gain
body weight until the scheduled end of the experiment at day 85.
64Compare to abortion criteria listed in section 10.6.
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Figure 27.9: Long term comparison of body-weight alterations between Ier3-flox+/+ LysM-Cre-/- and Ier3-
flox+/+ LysM-Cre+/+ animals in response to AOM/DSS. Ten Ier3-flox+/+ LysM-Cre-/- and nine
Ier3-flox+/+ LysM-Cre+/+ mice with an average age of 13 1/2 weeks were injected i.p. with AOM
(10 µg/g body weight) at day -7. DSS (10 g/l in drinking water ad libitum) was applied from day 0-7, day
21-24 and day 35-42. The experiment was terminated at day 85. Mice were prematurely excluded
from the experiment if matching at least one abort criterion. Shown is the mean relative body-weight
of each cohort in relation to the absolute body-weight at day 0. Error bars represent relative standard
deviation. Significance of body-weight differences between both cohorts was determined by two-sided
Student’s t-test. A p-value ≤ 0.05 is considered as statistically significant (*), while a p-value ≤ 0.01 is
considered as statistically highly significant (**).
27.3.2 Stool consistency and rectal bleeding
Stool consistency was rated by a simplified Bristol stool scale in a range from 0 (normal
consistency) up to 4 (practical liquid). Furthermore, the appearance of occult or fresh
blood in the feces as well as rectal bleeding was rated in a scale from 0 (no detection
of occult blood) up to 4 (rectal bleeding). At experimental day 16, animals from both
cohorts suffered from diarrhea. However, symptoms were more pronounced in the Ier3-
flox+/+ LysM-Cre-/- group. While symptoms in both groups alleviated between the second
and the third DSS cycle (day 30), they impaired shortly after the begin of the third DSS
cycle at day 35. Again, they were more pronounced in the Ier3-flox+/+ LysM-Cre-/- group.
When having reached the half period of the third DSS cycle at day 39, none of animals
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from the Ier3-flox+/+ LysM-Cre+/+ group had an score higher than 1, while all mice in
the Ier3-flox+/+ LysM-Cre-/- group were rated with a score of 2 or 3. The severity of
diarrhea in both cohorts further increased, even after the end of the third DSS cycle at
day 42. At days 44 and 45, Ier3-flox+/+ LysM-Cre+/+ animals had a score between 2 and 4,
while the majority of the Ier3-flox+/+ LysM-Cre-/- mice were rated with a score of 3. Stool
consistency in both cohorts improved between day 45 and 63, so that on the latter only
one Ier3-flox+/+ LysM-Cre-/- animal was rated with a score of 2, while all other animals
were rated with a score of 1. Interestingly, during the last two weeks of the experiment
stool consistency in both genotypes partially aggravated without being challenged by
DSS.
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Figure 27.10: Stool consistency of Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice during
AOM/DSS colitis. Experimental design as described in figure 27.9. Stool consistency was an-
alyzed at selected days and rated by a simplified bristol stool scale. Scores ranged from 0 (normal
consistency) up to 4 (practical liquid). Variations in sample sizes between days are explained by the
fact, that it was not always possible to obtain samples from all animals at each probing day.
At experimental day 16, occult blood was detectable only in the feces from four Ier3-
flox+/+ LysM-Cre-/- animals but not in any of the Ier3-flox+/+ LysM-Cre+/+ mice (fig. 27.11).
Likewise, creneg mice likewise were more affected by the second DSS cycle, resulting in
increased bleeding scores in over the half of the evaluable Ier3-flox+/+ LysM-Cre-/- animals
at day 30. In contrast, only one out of seven Ier3-flox+/+ LysM-Cre+/+ animals had an
increased bleeding score. While bleeding scores increased in both genotypes during the
third DSS cycle (day 35-42), they rose faster in the Ier3-flox+/+ LysM-Cre-/- cohort. However,
at day 39 all evaluable animals suffered from severe rectal bleeding. crepos animals
recovered mostly until day 48. In contrast, the majority of Ier3-flox+/+ LysM-Cre-/- mice
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kept suffering from rectal bleeding or bloody feces until the end of the experiment.
Notably, bleeding scores in both cohorts raised during the last 14 days of the experiment
without being challenged with DSS again.
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Figure 27.11: Occult blood and rectal bleeding in Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice
during AOM/DSS colitis. Experimental design as described in figure 27.9. Appearance of occult or
fresh blood in feces as well as rectal bleeding was analyzed at selected days. Traces of blood in
feces were detected using a commercial guaiac based test kit. Scoring ranged from 0 points (no
detection of occult blood) up to 4 points (rectal bleeding). Variations in sample sizes between days
are explained by the fact, that it was not always possible to obtain samples from all animals at each
probing day.
27.3.3 survival
Even tough animals in both cohorts suffered from diarrhea and rectal bleeding none of
them died or had to be excluded during the first five weeks of the experiment (fig. 27.12).
At day 38, which was the third day of the third DSS cycle, two Ier3-flox+/+ LysM-Cre-/- mice
died, respectively had to be excluded due to their poor health conditions. At day 44
another two and at day 47 one of the Ier3-flox+/+ LysM-Cre-/- animals had to be excluded,
too. From the Ier3-flox+/+ LysM-Cre+/+ animals, only two mice had to be excluded at day
45 and 46.
The remaining animals survived until the scheduled termination at day 85, resulting
in an overall 85-day survival rate of 50 % and 71 %65 in the Ier3-flox+/+ LysM-Cre-/-and
Ier3-flox+/+ LysM-Cre+/+ cohort respectively.
65Two moderately affected animals from the Ier3-flox+/+ LysM-Cre+/+ cohort, which did not match any
abortion criteria, were also excluded at day 38 for histological comparison.
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Figure 27.12: Kaplan Meyer survival curve of Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals
during chronic AOM/DSS colitis. Experimental design as described in figure 27.9.
27.3.4 Post mortem analysis of organs
Compared to Ier3-flox+/+ LysM-Cre+/+ animals, colons of Ier3-flox+/+ LysM-Cre-/- animals
were shorter by trend (fig. 27.13a), although not significantly (p=0.05004). The median
cecum weights (fig. 27.13b) in Ier3-flox+/+ LysM-Cre-/- mice were slightly higher than
in Ier3-flox+/+ LysM-Cre+/+ animals (p=0.084), while their livers weighted significant
more (p = 0.021, fig. 27.13c), thus indicating a higher inflammation score. In contrast,
their spleen weights (fig. 27.13d) were significantly lower (p = 0.014) compared to
Ier3-flox+/+ LysM-Cre+/+ animals.
27.3.5 Colorectal Carcinogenesis
At the endpoint of the experiment, colons of all animals were examined for neoplasm
formation (fig. 27.14). Colons from Ier3-flox+/+ LysM-Cre-/- mice showed on median eight
local neoplasms per animal (fig. 27.15a), while Ier3-flox+/+ LysM-Cre+/+ mice suffered from
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n.s.
(a) Absolute, median colon length.
n.s.
(b) Relative, median cecum weight, normalized to
body weight.
*
(c) Relative, median liver weight, normalized to
body weight.
*
(d) Relative, median spleen weight, normalized to
body weight.
Figure 27.13: Comparison of immunological relevant organs from Ier3-flox+/+ LysM-Cre-/- and Ier3-
flox+/+ LysM-Cre+/+ mice after chronically AOM/DSS colitis. Experimental design as described
in figure 27.9. Shown are median values of the analyzed parameters (crossbar within the box) from
five Ier3-flox+/+ LysM-Cre-/- and five Ier3-flox+/+ LysM-Cre+/+ animals after experimental termination
at day 85. Boxes cover the 25 % and 75 % quantiles. Whisker length corresponds to values with a
maximal medial deviation of the 1.5-folds interquartile range, while extreme values are indicated as
bullets. Statistical significance in the difference between the two cohorts was determined by adjusted
WILCOXON-MANN-WHITNEY-test. A p-value ≤ 0.05 is considered as statistically significant (*).
three neoplasms (p = 0.009). In both cohorts, tumors were mostly located in the distal
and M2 segments of the colon. Occasionally, tumors were detected in the M1 quartile
but not in further proximal regions. The neoplasms itself were mostly free of MΦ but
surrounded by high numbers of them (fig. 27.16). Interestingly, with an median tumor
diameter of 3 mm, the median tumor size between both cohorts did not differ (p = 0.328,
fig. 27.15b).
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(a) Colons from Ier3-flox+/+ LysM-Cre-/- animals. (b) Colons from Ier3-flox+/+ LysM-Cre+/+ animals.
Figure 27.14: Colorectal neoplasms in Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals after
AOM/DSS-treatment. Experimental design as described in figure 27.9. After termination, colons
were dissected, rinsed with PBS and cut open longitudinally. Shown are representative pictures from
colons of Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice at day 85. Red arrows indicate
neoplasms.
**
(a) Tumor number per animal.
n.s.
(b) Average Tumor diameter .
Figure 27.15: Tumor number and size after AOM/DSS induced carcinogenesis in Ier3-flox+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals. Experimental design as described in figure 27.9.
Shown are median values of the analyzed parameters (crossbar within the box) from five Ier3-
flox+/+ LysM-Cre-/- and five Ier3-flox+/+ LysM-Cre+/+ animals after experimental termination at
day 85. Boxes cover the 25 % and 75 % quantiles. Whisker length corresponds to values with a
maximal medial deviation of the 1.5-folds interquartile range, while extreme values are indicated as
bullets. Statistical significance in the difference between the two cohorts was determined by adjusted
WILCOXON-MANN-WHITNEY-test. A p-value ≤ 0.01 is considered as statistically highly significant
(**).
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27.3.6 Macrophage Infiltration
The mucosa of both Ier3-flox+/+ LysM-Cre-/- as well Ier3-flox+/+ LysM-Cre+/+ animal was
highly infiltrated by macrophages (fig. 27.16). There could be no differences determined
in the overall number of infiltrating MΦ between both genotypes. However, MΦ were
not consistently distributed over all colon segments in both genotypes. As described
above, neoplasms (Tu) themselves were mostly free of MΦ but surrounded by high
numbers of them.
27.3.7 Expression of E-cadherin and β-catenin
The expression and distribution of the CJ related proteins E-cadherin andβ-catenin as
well as their colocalization with MΦ infiltrates in the colons of AOM/DSS treated Ier3-
flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals was analyzed by IHC-F (fig. 27.17).
There were considerable differences in the expression intensity of E-cadherin and β-
catenin in different colon segments, independently of the animals genotype. In most
cases, the expression of both proteins, correlated inversely with the morphological grade
of tissue damage. Interestingly, in Ier3-flox+/+ LysM-Cre-/- animals, an inverse correlation
between the number of infiltrating MΦ and the expression of E-cadherin and β-catenin
was observed, whereas no such correlation was seen in Ier3-flox+/+ LysM-Cre+/+ animals.
Hence, in colon segments with comparable grades of tissue integrity and MΦ infiltration,
the expression of E-cadherin and β-catenin were significantly down-regulated in Ier3-
flox+/+ LysM-Cre-/- animals compared to Ier3-flox+/+ LysM-Cre+/+ animals, as shown in
figure 27.17. Interestingly, the detection of both proteins was not limited to sites of
intercellular contacts but they were also found in cytoplasmic regions, independently of
the animals genotype.
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Figure 27.16: Macrophage infiltration into the mucosa of Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-
Cre+/+ animals after AOM/DSS-treatment. Experimental design as described in figure 27.9.
After termination, colons were dissected, rinsed with PBS and cut open longitudinally. Histological
specimen were generated as described in sec. 12.1. Conventional immunostaining was performed
as described in sec. 12.3.2. MΦ were stained using an anti F4/80 antibody (CST). or an respec-
tively isotype control Ab. Detection was performed by chromogenic AEC reaction (red) using a
HRP-conjugated secondary antibody. Cell nuclei were counterstained using MEYER’S Haema-
toxylin (blue). Neoplastic tissue is indicated by “Tu”. Shown are representative pictures of colons
Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice at day 85.
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Figure 27.17: Expression of cellular junction related proteins inIer3-flox+/+ LysM-Cre-/- and Ier3-
flox+/+ LysM-Cre+/+ animals after AOM/DSS-treatment. Experimental design as described in
figure 27.9. After termination, colons were dissected, rinsed with PBS and cut open longitudinally.
Histological specimen were generated as described in sec. 12.1. IHC-F staining was performed
as described in sec. 12.3.3. MΦ (red) were stained using an anti F4/80 antibody. E-Cadherin
appears green, while β-catenin is also stained red. Appropriate isotype controls were performed
for all specimen (not shown). or an respectively isotype control Ab. Cell nuclei were counter-
stained with Hoechst bisbenzimide H33258 (blue). Shown are representative pictures from colons of
Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice at day 85.
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27.4 Ier3-flox+/+ LysM-Cre+/+mice exhibit reduced intestinal permeability to
FITC-dextran after DSS challenge
Based on the previous findings, it could be assumed that Ier3 status of macrophages
could affect the intestinal barrier integrity in vivo. To test this assumption, the intestinal
permeability to fluorescein isothiocyanate (FITC) labeled dextrans (FD) of different
molecular weights (FD4: 4000 g/mol, FD10: 10 000 g/mol) was measured by determining
their serum concentrations after oral application.
In healthy animals, there was no significant difference in serum concentrations of FD4
between both genotypes (p=0.40). If challenged with DSS (10 g/l in drinking water
ad libitum) for 24 h before application, Ier3-flox+/+ LysM-Cre-/- animals showed an 2.37-
fold increased permeability to FD4 compared to Ier3-flox+/+ LysM-Cre+/+ mice (p=0.004).
Interestingly, this difference diminished mainly when using FD with an average molecular
weight of 10000 g/mol (p=0.08), whose intestinal permeability was in general much lesser
in both genotypes compared to FD4.
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n.s.
(a) Relative FD4 serum concentrations
in mice not pretreated. neach GT =
9.
**
(b) Relative FD4 serum concentra-
tions in mice pretreated with
DSS. nIer3-flox+/+ LysM-Cre-/- = 18,
nIer3-flox+/+ LysM-Cre+/+ = 17.
n.s.
(c) Relative FD10 serum concentra-
tions in mice pretreated with
DSS. nIer3-flox+/+ LysM-Cre-/- = 14,
nIer3-flox+/+ LysM-Cre+/+ = 13.
Figure 27.18: Intestinal permeability of Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice to FITC-
dextran. 12± 3 week old Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice were optional
pretreated with 10 g/l DSS in drinking water ad libitum for 24 h. FITC-dextrans of different molecular
weights (FD4 or FD10) were directly applied into the pylorus using a buttoned hypodermic needle
(FD4: 0.5 mg/g bw, FD10: 0.2 mg/g bw). Blood samples were taken 4 h after administration and FD
serum concentrations were determined using a fluorescence based assay. Shown are normalized
median serum concentrations (crossbar within the box). Relative serum concentrations in Ier3-
flox+/+ LysM-Cre-/- mice were set to 1. Boxes cover the 25 % and 75 % quantiles. Whisker length
corresponds to values with a maximal medial deviation of the 1.5-folds interquartile range, while
extreme values are indicated as bullets. Statistical significance in the difference between the
two cohorts was determined by adjusted WILCOXON-MANN-WHITNEY-test. A p-value ≤ 0.01 is
considered as statistically highly significant (**).
28 Effects of IER3-deficiency in other compartments in response
to DSS
In order to extend the insight into the role of IER3 deficiency in the pathogenesis of
DSS colitis, it was further explored whether the deletion of the Ier3 gene in other tissue
compartments has also an effect.
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28.1 Epithelial IER3 status has impact on acute but not on chronic DSS colitis
After identifying the myeloid Ier3 status affecting the integrity of the intestinal barrier
in response to DSS, we also wanted to address the question if an epithelial specific
Ier3 depletion has an impact on the inflammatory phenotype during DSS colitis. For
this purpose, two DSS experiments were conducted using an Ier3-flox/Villin-Cre (Vil-Cre)
mouse model based on a C57/BL6 background.
28.1.1 Body weight differences between healthy Ier3-flox+/+ Vil-Cre-/- and
Ier3-flox+/+ Vil-Cre+/+ mice
There were no significant differences in the body weight between healthy Ier3-flox+/+ Vil-
Cre-/- and Ier3-flox+/+ Vil-Cre+/+ mice, as shown in figure 28.1.
n.s.
Figure 28.1: Body weight differences between healthy Ier3-flox+/+ Vil-Cre-/- and Ier3-flox+/+ Vil-Cre+/+ mice.
Shown are median body weights (crossbar within the box) of 9 Ier3-flox+/+ Vil-Cre-/- and 7 Ier3-
flox+/+ Vil-Cre+/+ animals with an average age of 9± 1 weeks. Boxes cover the 25 % and 75 %
quantiles. Whisker length corresponds to values with a maximal medial deviation of the 1.5-folds
interquartile range, while extreme values are indicated as bullets. Statistical significance in the
difference between the two cohorts was determined by adjusted WILCOXON-MANN-WHITNEY-test. A
p-value ≤ 0.05 is considered as statistically significant (*).
28.1.2 Acute DSS colitis in Ier3-flox/Vil-Cre mice
Nine Ier3-flox+/+ Vil-Cre-/- and seven Ier3-flox+/+ Vil-Cre+/+ mice with an average age of 9
weeks (±1 week) were challenged with 30 g/lDSS in drinking water ad libitum for nine
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days to induce an acute colitis (fig. 28.2). Animals in both cohorts started to loose weight
up from day 4 (fig. 28.2a). While weight loss proceeded until the end of the experiment
at day 9 in both genotypes, this decline was more pronounced in the Ier3-flox+/+ Vil-
Cre-/- cohort (p (∆bw) ≤ 0.05 from day 5-8). Maximal weight differences between both
genotypes were observed at day 8, with an average weight loss of −21 ± 7 % in the
Ier3-flox+/+ Vil-Cre-/- group vs. −10± 4 % in the Ier3-flox+/+ Vil-Cre+/+ cohort.
Differences would have been even more distinct, if not 4 animals of the Ier3-flox+/+ Vil-
Cre+/+ group had to be excluded prematurely from the experiment due to a poor general
health condition (fig. 28.2b). This led to an overall 9 day survival rate of 44.4 % in the
Ier3-flox+/+ Vil-Cre-/- group vs. 100 % in the Ier3-flox+/+ Vil-Cre+/+ group (p=0.029).
DSS
*
(a) Body-weight loss in Ier3-flox+/+ Vil-Cre-/- and Ier3-
flox+/+ Vil-Cre+/+ mice during acute DSS colitis. Shown is
the mean relative body-weight of each cohort in relation to
the absolute body-weight at day 0. Error bars represent
relative standard deviation. Significance in of body weight
differences between both cohorts was determined by two-
sided Student’s t-test. a p-value ≤ 0.05 is considered as
statistically significant (*).
DSS
(b) Kaplan Meyer survival curve of Ier3-flox+/+ Vil-Cre-/- and
Ier3-flox+/+ Vil-Cre+/+ mice during acute DSS colitis.
Figure 28.2: Acute DSS colitis in Ier3-flox+/+ Vil-Cre-/- and Ier3-flox+/+ Vil-Cre+/+ mice. Nine Ier3-flox+/+ Vil-
Cre-/- and seven Ier3-flox+/+ Vil-Cre+/+ mice with an average age of 9 weeks (±1 week) received
30 g/l DSS in drinking water ad libitum to induce an acute colitis. Mice were prematurely excluded
from the experiment if matching at least one abort criterion.
28.1.3 Chronic DSS colitis in Ier3-flox/Vil-Cre mice
Eight Ier3-flox+/+ Vil-Cre-/- and seven Ier3-flox+/+ Vil-Cre+/+ mice with an average age of
9 weeks were challenged with three 5 day cycles and one 4 day cycle of 15 g/l DSS
in drinking water ad libitum to induce a chronic colitis. Each cycle was interrupted by
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a 5 day treatment free interval (fig. 28.3). Mice from both genotypes began to loose
weight up from the last day of the first DSS cycle (fig. 28.3a). Weight loss in both groups
continued until day 8 where it reached its maximum (Ier3-flox+/+ Vil-Cre-/-: −12± 6 % vs.
Ier3-flox+/+ Vil-Cre+/+: −18± 12 %). Though, Ier3-flox+/+ Vil-Cre+/+ animals had lost slightly
more weight at this time point, there were no significant weight differences between both
genotypes observed during the whole experiment.
Animals regained weight until the end of the second DSS cycle at day 15 (Ier3-flox+/+ Vil-
Cre-/-: 99 ± 4 % vs. Ier3-flox+/+ Vil-Cre+/+: 98 ± 8 %). A reoccurring weight drop after
the second cycle came off weaker compared to the first cycle. The weight drop after
the second cycle was again followed by a recovery phase until the begin of the third
cycle. This pattern occurred again during and after the third DSS cycle. Animals
kept their weight during the last DSS cycle until the end of the experiment at day 35
(Ier3-flox+/+ Vil-Cre-/-: 100± 5 % vs. Ier3-flox+/+ Vil-Cre+/+: 97± 3 %).
Respectively one animal from each genotype had to be prematurely excluded from the
experiment at day 10 due to a poor general health condition (fig. 28.3b). This led to an
overall 35 day survival rate of 87.5 % in the Ier3-flox+/+ Vil-Cre-/- group vs. 85.7 % in the
Ier3-flox+/+ Vil-Cre+/+ group (p > 0.9).
DSS DSS DSS DSS
(a) Body-weight loss in Ier3-flox+/+ Vil-Cre-/- and Ier3-
flox+/+ Vil-Cre+/+ mice during chronic DSS colitis.
DSS DSS DSS DSS
(b) Kaplan Meyer survival curve of Ier3-flox+/+ Vil-Cre-/- and
Ier3-flox+/+ Vil-Cre+/+ mice during chronic DSS colitis.
Figure 28.3: Chronic DSS colitis in Ier3-flox+/+ Vil-Cre-/- and Ier3-flox+/+ Vil-Cre+/+ mice. Eight Ier3-flox+/+ Vil-
Cre-/- and seven Ier3-flox+/+ Vil-Cre+/+ mice with an average age of 9 weeks (±10 days) received
three 5-day and one 4-day cycles of 15 g/l DSS in drinking water ad libitum. Each DSS cycle was
followed by a 5 day treatment free interval. Mice were prematurely excluded from the experiment if
matching at least one abortion criterion.
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Parameters of immunological relevant organs were exploited after the end of the ex-
periment at day 34. Median Colon length did not differ significantly between both
genotypes (p=0.144, fig. 28.4a). Also, there were no significant differences in the relative
cecum (p=0.732, fig. 28.4b), liver (p=0.131, fig. 28.4c) or spleen weight (p=0.291, fig. 28.4d)
between Ier3-flox+/+ Vil-Cre-/- and Ier3-flox+/+ Vil-Cre+/+ animals detectable.
n.s.
(a) Absolute, median colon length.
n.s.
(b) Relative, median cecum weight, normalized to
body weight.
n.s.
(c) Relative, median liver weight, normalized to
body weight.
n.s.
(d) Relative, median spleen weight, normalized to
body weight.
Figure 28.4: Comparison of immunological relevant organs from Ier3-flox+/+ Vil-Cre-/- and Ier3-flox+/+ Vil-
Cre+/+mice after chronically DSS colitis. Experimental design as described in figure 28.3. Shown
are median values of the analyzed parameters (crossbar within the box) from seven Ier3-flox+/+ Vil-
Cre-/- and five Ier3-flox+/+ Vil-Cre+/+ animals after experimental termination at day 34. Boxes cover the
25 % and 75 % quantiles. Whisker length corresponds to values with a maximal medial deviation of the
1.5-folds interquartile range, while extreme values are indicated as bullets. Statistical significance in
the difference between the two cohorts was determined by adjusted WILCOXON-MANN-WHITNEY-test.
A p-value ≤ 0.05 is considered as statistically significant (*).
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28.2 Constitutive Ier3 knockout
Two experiments were conducted using a mouse strain with an constitutive Ier3 knockout
based on an Sv129 background.
28.2.1 Body weight comparison between healthy Ier3 wt and Ier3 ko mice
There were no significant differences in the body weight between healthy Ier3 wt and
Ier3 ko mice, as shown in figure 28.5.
n.s.
Figure 28.5: Body weight differences between healthy Ier3 wt and Ier3 ko mice. Shown are median body
weights (crossbar within the box) of 8 Ier3 wt and 8 Ier3 ko animals with an average age of 9 weeks
(±10 days). Boxes cover the 25 % and 75 % quantiles. Whisker length corresponds to values with a
maximal medial deviation of the 1.5-folds interquartile range, while extreme values are indicated as
bullets. Statistical significance in the difference between the two cohorts was determined by adjusted
WILCOXON-MANN-WHITNEY-test. A p-value ≤ 0.05 is considered as statistically significant (*).
28.2.2 Acute DSS colitis in constitutive Ier3 wt and ko mice
Five Ier3 wt and six constitutive Ier3 ko mice with an average age of 10 weeks were
challenged with 30 g/l DSS in drinking water ad libitum for nine days to induce an acute
colitis. Animals in both cohorts started to loose weight up from day 4 (fig. 28.6a). Weight
loss continued until the scheduled endpoint at day 9, where animals in both cohorts had
lost on average 14 % of their initial body weight at day 0. No significant body weight
differences between both genotypes were observed during the whole experiment. One
123
Results
animal of the Ier3 wt group had be prematurely excluded at day 8 due to its poor general
health condition (fig. 28.6b).
DSS
(a) Body-weight loss during acute DSS colitis. Shown is the
mean relative body-weight of each cohort in relation to the
absolute body-weight at day 0. Error bars represent relative
standard deviation.
DSS
(b) Kaplan Meyer survival curve of ier wt and ko animals
during acute DSS colitis.
Figure 28.6: Acute DSS colitis in Ier3 wt and Ier3 ko mice. Five Ier3 wt and six Ier3 ko mice with an average
age of 10 weeks (±4 days) received 30 g/l DSS in drinking water ad libitum for nine days to induce
an acute colitis. Mice were prematurely excluded from the experiment if matching at least one abort
criterion.
28.2.3 Chronic DSS colitis in constitutive Ier3 wt and ko mice
Eight Ier3 wt and eight Ier3 ko mice with an average age of 9 weeks were challenged
with three 5 day cycles and one 4 day cycle of 15 g/l DSS in drinking water ad libitum to
induce a chronic colitis. Each cycle was interrupted by a 5 day treatment free interval.
Animals in both cohorts started to loose weight up from the fourth day of the first DSS
cycle (fig. 28.7a). In terms of weight loss, Ier3 wt mice responded much more to the
first DSS cycle (-25 % at day nine) compared to Ier3 ko animals (-13 % at day nine), even
if statistical not significant due to their high intra-cohortal variation. While Ier3 ko
animals did not loose further weight during the second DSS cycle (88 % bw at day 16),
Ier3 wt mice could even gain some weight (85 % bw at day 16). Tough, this is in parts
own to the fact, that respectively two animals from the Ier3 wt group had be excluded
at day 11 and day 16 due to their poor general health condition (fig. 28.7b). Animals
from both genotypes continued to gain weight up to the middle of the third DSS cycle
(day 23: wt: 93 % bw, ko: 98 % bw), before loosing weight again. At day 26, animals
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in both groups had on average 90 % of their initial body weight at day 0. After this
point, animals in both cohorts gained weight until the beginning of the third DSS cycle,
with only minimal differences between genotypes. Weight levels in both groups stayed
approximately constant until the end of the experiment at day 34 (bwwt=bwko=96 %).
As mentioned above, respectively two animals from the Ier3 wt group had be excluded
prematurely at day 11 and day 16 due to their poor general health condition (fig 28.7b).
This led to an overall 34 day survival rate of 50 % in the Ier3 wt cohort, compared to 75 %
in the Ier3 ko group due to two prematurely exclusions at day 17 and 19.
DSS DSS DSS DSS
(a) Body-weight loss during chronic colitis. Shown is the
mean relative body-weight of each cohort in relation to the
absolute body-weight at day 0. Error bars represent relative
standard deviation.
DSS DSS DSS DSS
(b) Kaplan Meyer survival curve of Ier3 wt and ko animals
during chronic colitis.
Figure 28.7: Chronic DSS colitis in Ier3 wt and constitutive Ier3 ko mice. Eight Ier3 wt and eight Ier3 ko
mice with an average age of 9 weeks (±10 days) received three 5-day and one 4-day cycles of
15 g/l DSS in drinking water ad libitum. Each DSS cycle was followed by a 5 day treatment free
interval.
After the end of the experiment at day 34, parameters of immunological relevant organs
were harvested (fig. 28.8). With a median length of 53 mm, colons from Ier3 wt animals
were significant shorter (p=0.033, fig. 28.8a) compared to Ier3 ko animals (61 mm),
indicating an increased inflammation. The increased median cecum weight in ko animals
(3.5 % bw vs. 2.1 % bw, p=0.014, fig. 28.8b) also refers to a higher inflammation score.
Whereas, liver and spleen weights did not differ significant between both genotypes
(fig. 28.8c and 28.8d).
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*
(a) Absolute, median colon length.
*
(b) Relative, median cecum weight, normalized to
body weight.
n.s.
(c) Relative, median liver weight, normalized to
body weight.
n.s.
(d) Relative, median spleen weight, normalized to
body weight.
Figure 28.8: Comparison of immunological relevant organs from Ier3 wt and constitutive Ier3 ko mice
after chronically DSS colitis. Experimental design as described in figure 28.7. Shown are median
values of the analyzed parameters (crossbar within the box) from four Ier3 wt and six Ier3 ko animals
after experimental termination at day 34. Boxes cover the 25 % and 75 % quantiles. Whisker length
corresponds to values with a maximal medial deviation of the 1.5-folds interquartile range, while
extreme values are indicated as bullets. Statistical significance in the difference between the two
cohorts was determined by adjusted WILCOXON-MANN-WHITNEY-test. A p-value ≤ 0.05 is considered
as statistically significant (*).
29 In-vitro differentiation of murine bone-marrow-cells into MΦ
We generated primary macrophages (MΦ) by ex vivo differentiation of bone marrow
cells (BMC) from Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals to further
investigate the effects of myeloid IER3 in vitro.
The differentiated cells (fig. 29.1) were analyzed by flow cytometry for the murine
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macrophage antigens CD11b and F4/80 by (fig. 29.2). Gates to identify CD11b and
F4/80 positive cells were set in reference to corresponding isotype controls (fig. 29.2c and
29.2d). The majority of cells from both genotypes were double positive for CD11b and
F4/80 (Ier3-flox+/+ LysM-Cre-/-: 64.9 %, Ier3-flox+/+ LysM-Cre+/+: 62.9 %). In contrast, 7.5 %
of Ier3-flox+/+ LysM-Cre-/- and 8.7 % of the Ier3-flox+/+ LysM-Cre+/+ cells were negative for
CD11b as well as for F4/80. Interestingly, in both genotypes a population which was
positive for F4/80 but negative for CD11b was identified (Ier3-flox+/+ LysM-Cre-/-: 11.6 %,
Ier3-flox+/+ LysM-Cre+/+: 14.7 %). In the Ier3-flox+/+ LysM-Cre-/- group 15.9 % of all cells
were CD11b+ F4/80−, while in the Ier3-flox+/+ LysM-Cre+/+ group 13.7 % of all cells were
CD11b+ F4/80−.
Overall, 92.1 % of all Ier3-flox+/+ LysM-Cre-/- cells (fig. 29.2a) and 91.3 % of all Ier3-
flox+/+ LysM-Cre+/+ cells (fig. 29.2b) were positive for at least one of the analyzed antigens.
(a) MΦ from Ier3-flox+/+ LysM-Cre-/- animals at day 7. (b) MΦ from Ier3-flox+/+ LysM-Cre+/+ animals at day 7.
Figure 29.1: In vitro differentiation of MΦ from murine BMC. After dissection of femur and tibia, BMCs were
rinsed out under sterile conditions using a syringe containing ice cold PBS. The cell suspension was
centrifuged at 400 g and 4 °C for 10 minutes. The pellet was resuspended in MΦ differentiation
medium containing 50 ng/ml mM-CSF and 50 IU/ml mIFN-γ (MΦdiff.-M.) and adjusted to a concentration
of 5 ⋅ 105 cells/ml. Cells were seeded in uncoated PS culture vessels. At day three, cultures were gently
washed twice using PBS to remove non attached cells and the medium was exchanged against fresh
MΦdiff.-M.. At day 7 cells were fully differentiated into MΦ.
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(a) CD11b and F4/80 staining of cells
from Ier3-flox+/+ LysM-Cre-/- ani-
mals.
(b) CD11b and F4/80 staining of cells
from Ier3-flox+/+ LysM-Cre+/+ ani-
mals.
(c) CD11b and F4/80 isotype con-
trol of cells from Ier3-flox+/+ LysM-
Cre-/- animals.
(d) CD11b and F4/80 isotype con-
trol of cells from Ier3-flox+/+ LysM-
Cre+/+ animals.
Figure 29.2: Flow cytometric analysis of in vitro differentiated MΦ from murine BMC. BMC were harvested
and differentiated into MΦ as described in sec. 14. At day 7 of cultivation, the MΦ were detached
using EDTA and Accutase™. Cell staining was performed as described in sec. 24.2. In short, 5 ⋅ 105
cells each were resuspended in 100 µl cold MACS buffer containing 3 µg/ml FITC conjugated anti-
F4/80 REA™ IgG and/or APC conjugated anti-CD11b REA™ IgG, respectively equal amounts of
appropriate REA™ isotype controls. After incubation for 10 min at 4 °C, cells were washed twice
using cold MACS buffer. The cells were resuspended in 1 ml MACS buffer and analyzed subsequently.
Signal thresholds to identify CD11b and F4/80-positive cells were set in reference to corresponding
isotype controls.
30 mRNA expression in in vitro derived Ier3-flox+/+ MΦ
30.1 Ier3 mRNA expression is up-regulated by LPS
Ier3 mRNA expression of in vitro differentiated MΦ from Ier3-flox+/+ LysM-Cre-/- and
Ier3-flox+/+ LysM-Cre+/+ mice in response to LPS was determined by qPCR (fig. 30.1).
Figure 30.1a shows the results plotted against a linear ordinate, while in figure 30.1b
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the ordinate has a logarithmic scale. In Ier3-flox+/+ LysM-Cre-/- MΦ Ier3 expression is
triggered by LPS in a dose dependent manner. The activation with 0.5 ng/ml LPS increases
the Ier3 expression seven-fold, while an activation with 1.0 ng/ml increases the expression
by factor 12.5 compared to unstimulated MΦ. In Ier3-flox+/+ LysM-Cre-/- MΦ, the basal
Ier3-expression is about 170 times higher compared to Ier3-flox+/+ LysM-Cre+/+ MΦ. This
difference between the genotypes increases after the stimulation with LPS (factor 423 at
0.5 ng/mlLPS, respectively factor 251 at 1.0 ng/ml LPS).
(a) Relative Ier3 mRNA expression of Ier3-flox+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ in response to
LPS (linear ordinate)
(b) Relative Ier3 mRNA expression of Ier3-flox+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ in response to
LPS (logarithmic ordinate)
Figure 30.1: Basal and LPS induced Ier3 mRNA expression of Ier3-flox+/+ MΦ. MΦ were generated as
described in fig. 29.1. At day seven, they were stimulated with with different concentrations of LPS for
6 h. Cells were subsequently harvested and RNA isolation was performed using QiaShredder™ and
RNeasy™ kits (both Qiagen) accordingly to manufacturers instructions. RT-PCR was performed
as described in section 23.2 using 1.0 µg total RNA per sample. Per batch, 50 ng cDNA template
were mixed with 6 µl S’green blue™ qPCR reaction mix (Biozym), primers in an end-concentration
of 400 nmol/l, each and adjusted with water to a total volume of 12 µl. QPCR was conducted using
a BioRad CFX-Connect™ cycler. All samples were measured as triplicates. At least two different
housekeeping genes were used for normalization. Shown are normalized average permeabilities from
a least 3 independent experiments. Bars represent absolute standard deviation.
30.2 mRNA expression of cytokines
Furthermore, the mRNA expression for several anti- and proinflammatory proteins in
Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ was determined (fig. 30.2).
At basal levels, there was no difference in the the expression of Tnf mRNA between
both genotypes (fig. 30.2a). After stimulation with 0.5 ng/ml LPS, in the Ier3-flox+/+ LysM-
Cre-/- group Tnf mRNA levels increased by factor 24, while in the Ier3-flox+/+ LysM-
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Cre+/+ group they increased by factor 46. Due to their standard deviation, these differ-
ences where not significant. In the presence of 1.0 ng/ml LPS, Tnf mRNA expression in
both genotypes increased by factor 65 compared to unstimulated cells.
In the Ier3-flox+/+ LysM-Cre+/+ MΦ, basal expression levels of Il-1β mRNA where 1.8 times
higher compared to Ier3-flox+/+ LysM-Cre-/- cells (fig 30.2b). LPS mediated activation
increased the Il-1β expression in both genotypes to factor 1300 at 0.5 ng/ml LPS, re-
spectively up to factor 3300 at 1.0 ng/ml LPS, compared to the basal expression of
Ier3-flox+/+ LysM-Cre-/- cells.
Even tough basal Il-6 mRNA levels in Ier3-flox+/+ LysM-Cre+/+ cells were 1.7 times
higher compared to Ier3-flox+/+ LysM-Cre-/- cells, the differences were not significant
(fig. 30.2c). In Ier3-flox+/+ LysM-Cre-/- MΦ, LPS augmented the Il-6 expression by factor
1000 (0.5 ng/ml LPS), respectively by factor 3300 (1.0 ng/ml LPS).
In parallel, Ier3-flox+/+ LysM-Cre+/+ MΦ expressed 1 150-fold higher Il-6 levels at
0.5 ng/ml LPS and 3000-fold higher levels at 0.5 ng/ml LPS, compared to unstimulated
Ier3-flox+/+ LysM-Cre-/- cells.
Il-10 expression in both genotypes was triggered by LPS in a dose dependent manner
(fig. 30.2d). However, there were no significant expression differences between Ier3-
flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ detectable.
There was no difference in the basal expression of Tgf-β between both genotypes
(fig. 30.2e). Furthermore, the treatment with 0.5 ng/ml or 1.0 ng/ml LPS did not affect the
Tgf-β expression in Ier3-flox+/+ LysM-Cre-/- as well as in Ier3-flox+/+ LysM-Cre+/+ MΦ.
Although the results revealed a high responsiveness of the generated MΦ even to
small amounts of LPS, it was not possible to evaluate potential differences in cytokine
expression on mRNA level between both genotypes due to the high standard deviation of
the samples. Since the usage of several housekeeping genes as well as a meticulous design
and quality control of the primers and PCR products (see section 23.3.3) did not reveal
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any improvement, the high standard deviation could be ascribed to the heterogeneity
and purity of the specimen.
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(a) Tnf mRNA expression. (b) Il-1βmRNA expression.
(c) Il-6 mRNA expression. (d) IL-10 mRNA expression.
(e) Tgf-β mRNA expression.
Figure 30.2: Basal and LPS-induced mRNA expression of several pro- and anti-inflammatory cytokines
in Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ. MΦwere generated as described
in section 14. At day seven, they were stimulated with with different concentrations of LPS for
6 h and subsequently harvested. RNA isolation and processing was performed as described in
sections23.2 23.1 and . QPCR was conducted using a BioRad CFX-Connect™ cycler as described in
section 23.3. Shown are normalized average expressions from a least 3 independent experiments. All
samples were measured as triplicates. Two different housekeeping genes were used for normalization.
Bars represent absolute standard deviation.
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31 Nitric oxide production and iNOS expression in
Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ
Representing one of the key features of activated MΦ, the expression of inducible nitric
oxide synthase (iNOS) as well as nitric oxide (NOx) production in LPS stimulated Ier3-
flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ was analyzed.
31.1 Ier3-flox+/+ LysM-Cre+/+ MΦ produce less nitric oxide
Nitric oxide (NOx) production of in vitro differentiated macrophages from Ier3-flox
+/+ LysM-
Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals was measured indirectly (as NO –2 ) in the
cell culture supernatant using an assay based on the Griess-reaction [78]. NOx pro-
duction in unstimulated MΦ was below the limit of quantification in both genotypes.
After stimulation with 5 ng/ml LPS, the NOx concentration in the supernatant of Ier3-
flox+/+ LysM-Cre+/+ MΦ was 40 % below the level in the supernatant of Ier3-flox+/+ LysM-
Cre+/+ MΦ (p < 0.002, fig. 31.1a). Interestingly, this difference diminishes at much
higher LPS concentrations (100 ng/ml) (fig 31.1b). A simultaneous treatment with the
iNOS inhibitor 1400W (10 nmol/ml) reduced the LPS induced NOx-production by 94 %
(fig 31.1b).
31.2 LPS induced iNOS expression is attenuated in
Ier3-flox+/+ LysM-Cre+/+ MΦ
INOS expression of in vitro differentiated macrophages from Ier3-flox+/+ LysM-Cre-/- and
Ier3-flox+/+ LysM-Cre+/+ animals was determined by western blot (fig. 31.2). Without
stimulus, iNOS-expression in both genotypes was close to the quantification limit. How-
ever, iNOS-expression in Ier3-flox+/+ LysM-Cre-/- MΦ was 1.75 times higher compared
to Ier3-flox+/+ LysM-Cre+/+ MΦ(fig. 31.2b). LPS induced the iNOS-expression in both
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Ier3-flox⁺⁺
LysM-Cre⁻
Ier3-flox  ⁺⁺
LysM-Cre⁺⁺
(a) Relative NOx production of
Ier3-flox+/+ LysM-Cre-/- and
Ier3-flox+/+ LysM-Cre+/+ MΦ after
stimulation with 5 ng/ml LPS. NOx
production in Ier3-flox+/+ LysM-
Cre-/- MΦ was set to 1.
+ +-
- + +1400W:
LPS:
(b) Relative NOx production (as NO2) in Ier3-flox
+/+ LysM-Cre-/- and Ier3-
flox+/+ LysM-Cre+/+ MΦ after stimulation with 100 ng/ml LPS and/or
10 nmol/ml 1400W. NOx production in LPS stimulated Ier3-flox+/+ LysM-
Cre-/- MΦ without 1400W was set to 1.
Figure 31.1: NOx production of Ier3-flox
+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ in response to
LPS. Primary MΦ were differentiated from BMC as described in fig. 29.1. At day 7, the MΦ were
treated with different concentrations of LPS and/or 1400W for 6 h. Afterwards, the culture medium
was exchanged against normal MΦMM-CSF and the cells were further incubated for 18 h. Nitric
oxide production was measured indirectly by determining the NO –2 concentration in the cultures
supernatant using a photometric assay based on the GRIESS reaction. Values were normalized to
the cell number using a Hoechst 33258 based fluorimetric assay. Shown are normalized average
NO –2 concentrations from a least 3 independent experiments. Error bars represent absolute standard
deviation. Statistical significance was calculated by adjusted WILCOXON-MANN-WHITNEY-test. A
p-value ≤ 0.01 is considered as statistically highly significant (**).
genotypes in a dose dependent manner. At 2 ng/ml LPS, iNOS levels inIer3-flox+/+ LysM-
Cre-/- MΦ raised by factor 33, while 4 ng/ml LPS increased the iNOS-expression 45-fold
compared to the basal level.
Ier3-flox+/+ LysM-Cre+/+ MΦ showed a 13-fold increase of iNOS level in presence of
2 ng/ml LPS, while iNOS levels in Ier3-flox+/+ LysM-Cre-/- MΦ were 33 times higher
compared to unstimulated cells.
In a direct comparison between both genotypes, Ier3-flox+/+ LysM-Cre-/- MΦ showed a
much higher response to LPS than Ier3-flox+/+ LysM-Cre+/+ MΦ. After stimulation with
2 ng/ml LPS, iNOS expression in Ier3-flox+/+ LysM-Cre-/- MΦ was 2.5 times as high as
in Ier3-flox+/+ LysM-Cre+/+ MΦ, while after stimulation with 4 ng/ml LPS the expression
levels differed by factor 1.7.
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250 kDa
iNOS
Tubulin
w/o 2 ng/ml 4 ng/ml
-/- 
LPS:
LysM-Cre: -/- -/- +/+ +/+ +/+ 
(a) Western blot. (b) Densitometric analysis. Relative iNOS expression nor-
malized to tubulin. INOS expression in unstimulated Ier3-
flox+/+ LysM-Cre-/- MΦ is set to 1.
Figure 31.2: INOS protein expression in Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ in re-
sponse to LPS. Primary MΦ were differentiated from BMC as described in fig. 29.1. At day 7,
the MΦ were treated with different concentrations of LPS for 6 h. Subsequently, RIPA lysates of
the cells were generated as described in section 22.1. After adjusting all samples to equal protein
concentrations, SDS-PAGE and western blot were performed as described in section 22. Tubulin
staining served as loading control.
32 Testing enterocyte model system for studying barrier function
To explore the impact of MΦon the barrier function of enterocytes it was necessary to
establish an appropriate enterocyte model system. For this purpose, we first tried to
immortalize freshly prepared murine IECs by employing a combined mTERT/BMI-1
transduction. After having selected immortalized IEC clones it turned out that these cells
have largely lost their epithelial properties. This includes a significant loss of E-cadherin
and villin expression, whereas the expression of vimentin as a mesenchymal marker was
increased. Either, the transduced cell clones were derived from fibroblast contaminations
or the transduction itself resulted in a marked EMT.
Next, two commercially available murine enterocyte cell lines – MODE-K [207] and
YAMC [209] – were tested for their suitability as enterocyte model system. However, both
cell lines also exhibited a considerable loss of epithelial properties, as indicated again by
the loss of E-cadherin and villin expression and a gain of vimentin.
Thus, immortalized murine IECs were not suitable fort he planned experiments that
require a largely maintained epithelial phenotype. Therefore, other cell systems were
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chosen. Fortunately, the rat enterocyte cell line IEC-6 [162] and the well differentiated
human colon cancer cell line Caco2 [61] had been proven suitable as bot cell lines not
only express the epithelial marker at high level but also form intact monolayers in culture
which is a prerequisite for conducting experiments on barrier functions.
33 In vitro permeability of CaCo-2 monolayers to FITC-dextran
Owing to their suitability as model system and their capability to form perfect monolayers,
Caco2 cells were first used for the determination of in vitro permeability in the transwell
setting with MΦ.
33.1 The Ier3 status of MΦ affects the permeability of CaCo-2 monolayers
during direct co-culture
Monolayers of CaCo-2 cells showed on average an 38 % increased permeability (p≤ 0.021)
to FD4 when directly co-cultivated with LPS (5 ng/ml) activated MΦ for 24 h (fig. 33.1a),
independently of the macrophage’s IER3 status (p=0.248). After 48 h of co-cultivation
with Ier3-flox+/+ LysM-Cre-/- MΦ , the FD4 permeability was 3.7 times higher com-
pared to mono-cultured CaCo-2 monolayers, whereas Ier3-flox+/+ LysM-Cre+/+ mac in-
creased the permeability only by factor 2.0. (p≤ 0.034). The FD4 permeability induced
by Ier3-flox+/+ LysM-Cre-/- MΦ was 1.8 times higher compared to Ier3-flox+/+ LysM-
Cre+/+ MΦ (p=0.034).
33.2 Nitric oxide increases the permeability of CaCo-2 monolayers in a dose
dependent manner
The CaCo-2 monolayers revealed an 6-fold increased permeability to FD4 when incubated
in the presence of 5.0 mmol/l of the nitric oxide donor S-Nitroso-N-acetylpenicillamine
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(SNAP) (p=0.003), while a concentration of 2.5 mmol/l SNAP had no effect on their FD4-
permeability (fig 33.1b). Noteworthy, monolayers of the rat intestinal epithelial cell line
IEC-6 partially detached from the transwell insert in the presence of SNAP. Thus, it was
not possible to determine their permeability to FD4 with these cells here.
n.s.
*
*
*
*
*
(a) MΦ induced permeability of CaCo-2 monolayers to
FD4. At day 14 of cultivation, the culture medium was
exchanged against CaCo-2-M.w/o PR medium containing
5 ⋅ 105 MΦ (Ier3-flox+/+ LysM-Cre-/- or Ier3-flox+/+ LysM-
Cre+/+, generated as described in fig. (29.1), 5 ng/ml LPS
and 5 mg/ml FD4 in the apical compartment or phenol red
free CaCo-2 medium without supplements in the basal com-
partment. FD4 concentrations in the basal and apical com-
partments were determined after 24 h and 48 h using a flu-
orimetric assay.
**
n.s.
(b) SNAP induced permeability of CaCo-2 monolayers to
FD4. At day 14 of cultivation, the culture medium was ex-
changed against CaCo-2-M.w/o PR containing SNAP (basal
compartment) or SNAP and 5 mg/ml FD4 (apical compart-
ment). After 24 h FD4 concentrations in the basal and api-
cal compartments were determined using a fluorimetric as-
say.
Figure 33.1: Permeability of CaCo-2 monolayers to FD4. 5 ⋅ 105 CaCo-2 cells were seeded on Transwell TC-
inserts with a pore size of 0.4 µm (Sarstedt). Cells were cultivated for 14 days until a uniform cell
monolayer had established. Medium was exchanged three times a week. At day 13 of cultivation, the
culture medium was exchanged against CaCo-2-M.w/o PR. Permeability experiments were conducted
at day 14 after seeding. Shown are normalized average permeabilities from a least 3 independent
experiments. Error bars represent absolute standard deviation. Statistical significance was calculated
by adjusted WILCOXON-MANN-WHITNEY-test. A p-value ≤ 0.05 is considered as statistically significant
(*), while a p-value ≤ 0.01 is considered as statistically highly significant (**).
34 Expression of tight junction related proteins in IEC-6 and
CaCo-2 monolayers during direct co-culture with activated
macrophages
After having shown that activated macrophages increase the permeability of CaCo-2
monolayers to small molecules, it was next investigated whether and how the expression
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of cell junction related proteins in the enterocyte monolayers were affected during direct
MΦ co-culture.
34.1 IEC-6
In IEC-6, the macrophages IER3-status had a huge impact on the expression of β-catenin
and tubulin during direct co-culture (fig. 34.1a). While Ier3-knockout MΦ did hardly
affect β-catenin expression (97 %, fig. 34.1d), Ier3-sufficient MΦ diminished its expression
by 32 %. The expression of tubulin (fig. 34.1e) is even more affected by the macrophages
Ier3 genotype. Ier3 wt MΦ reduce its expression by 64 %, whereas its expression is even
slightly increased (103 %) during cocultivation with Ier3 ko MΦ. E-Cadherin expression
(fig. 34.1c) was indeed attenuated by MΦ of both genotypes, however the reduction was
more pronounced during co-culture with wt MΦ (-21 % vs. -16 %). In contrast, ZO1
expression (fig. 34.1b) was not altered during co-culture with wt MΦ (102 %), but in
the presence of Ier3 ko MΦ (91 %). Occludin was not detectable in IEC-6 by the used
antibody (fig 34.1a).
34.2 CaCo-2
In CaCo-2 cells, the effects of macrophages on the expression of cell junction related
proteins were much weaker (fig. 34.2a). Furthermore, there were no distinct differences
between Ier3 wt and ko macrophages observable. E-Cadherin expression (fig. 34.2c) was
reduced by 16 % during cocultivation with Ier3 wt MΦ and by 21 % during cocultivation
with Ier3 ko MΦ. The expression of ZO1 (wt: 96 %, ko: 94 %, fig. 34.2b), β-catenin
(wt: 99 %, ko: 96 %, fig. 34.2d) and occludin (wt: 100 %, ko: 97 %, fig. 34.2e) was not
affected by the cocultivation of macrophages. In contrast, the cultivation with Ier3 ko
MΦ increased the tubulin expression (fig. 34.2f) by 11 % compared to normal cultivated
CaCo-2 cells, whereas Ier3 wt MΦ had no effect (101 %).
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Figure 34.1: Expression of tight junction related proteins in IEC-6 cells after direct co-culture with LPS
activated Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ. IEC-6 cells were cultivated
in 6-well-plates over a period of 14 days. Primary MΦ were differentiated from BMC as described
in section 14. At day 7 of differentiation, the MΦ were harvested and counted. They were seeded
on top the IEC-6 monolayer in a concentration of 5 ⋅ 105 cells/ml in MΦ-M. containing 5 ng/ml LPS
(1 ⋅ 106 MΦ in total, NC: only LPS). After 48 h of cocultivation, cells were harvested and RIPA
lysates were generated as described in section 22.1. After adjusting all samples to equal protein
concentrations, SDS-PAGE and western blot were performed as described in section 22. HSP90
staining served as loading control. Relative protein expression normalized to HSP90 was determined
densitometrically. Expression in the negative control was set to 1. Shown is a representative blot from
at least two experiments.
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Figure 34.2: Expression of tight junction related proteins in CaCo-2 cells after direct co-culture with LPS
activated Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ MΦ. CaCo-2 cells were cultivated
in 6-well-plates over a period of 14 days. Primary MΦ were differentiated from BMC as described
in section 14. At day 7 of differentiation, the MΦ were harvested and counted. They were seeded
on top the CaCo-2 monolayer in a concentration of 5 ⋅ 105 cells/ml in MΦ-M. containing 5 ng/ml LPS
(1 ⋅ 106 MΦ in total, NC: only LPS). After 48 h of cocultivation, cells were harvested and RIPA
lysates were generated as described in section 22.1. After adjusting all samples to equal protein
concentrations, SDS-PAGE and western blot were performed as described in section 22. HSP90
staining served as loading control. Relative protein expression normalized to HSP90 was determined
densitometrically. Expression in the negative control (w/o) was set to 1. Shown is a representative
blot from at least two experiments.
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35 Expression of tight junction related proteins in CaCo-2 and
IEC-6 monolayers in response to Nitric oxide
To verify, that the effects of MΦ on the expression of cell junction related proteins, as
described in section 34, are caused by nitric oxide, we cultivated IEC-6 and CaCo-2
monolayers in presence of the NO-donor SNAP.
35.1 IEC-6
In IEC-6, the expression of E-cadherin, β-catenin as well as tubulin was highly attenuated
by SNAP in a dose dependent manner (fig. 35.1a). A concentration of 2.5 mmol/l SNAP
reduced the E-cadherin expression by 24 % (fig. 35.1b), whereas 5.0 mmol/l diminished
its expression by 54 %. The effect of SNAP on expression of tubulin (fig. 35.1d) was
similar, with -20 % at 2.5 mmol/land -49 % at 5.0 mmol/l. β-catenin expression (fig. 35.1c) was
attenuated by 32 % in the presence of 2.5 mmol/l SNAP and by 55 % in the presence of
5.0 mmol/l.
35.2 CaCo-2
In CaCo-2 cells, the expression of β-catenin was also highly affected by SNAP, while
E-cadherin and tubulin showed only a marginal and no response, respectively (fig. 35.2a).
In the presence of 2.5 mmol/l SNAP β-catenin expression (fig. 35.2c) was reduced by 31 %,
whereas a concentration of 5.0 mmol/l SNAP reduced its expression by 51 %. E–Cadherin
expression (fig. 35.2b) was diminished by 5 % and 10 % at 2.5 mmol/l and 5.0 mmol/l SNAP,
respectively. In contrast, tubulin expression (fig. 35.2d) was not affected at all by the
SNAP treatment.
The results of the western blot most closely correspond to the observations from the
immunohistochemically analysis (fig. 35.3). In response to NO, the overall expression
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Figure 35.1: Effects of Nitric oxide on the expression of tight junction related proteins in IEC-6 cells. IEC-6
cells were cultivated in 6-well-plates over a period of 14 days. At day 14, culture medium was
exchanged against freshly prepared medium containing either 2.5 or 5.0 mmol/l of the NO-donor
SNAP or an equivalent amount DMSO in the negative control. After incubated for 24 h, cells were
harvested and RIPA lysates were generated as described in section 22.1. After adjusting all samples
to equal protein concentrations, SDS-PAGE and western blot were performed as described in section
22. HSP90 staining served as loading control. Relative protein expression normalized to HSP90
was determined densitometrically. Expression in the negative control was set to 1. Shown is a
representative blot from at least two experiments.
of E-cadherin and β-catenin is not only down-regulated in general, but the continuous
cell encompassing ring of both proteins exhibits several gaps. Furthermore, a significant
fraction of both proteins is not longer only discretely located at the membraneous sites of
cell-cell contacts, but is also detected diffusely distributed in the cytoplasm.
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Figure 35.2: Effects of Nitric oxide on the expression of tight junction related proteins in CaCo-2 cells –
Western blot. CaCo-2 cells were cultivated in 6-well-plates over a period of 14 days. At day 14, the
culture medium was exchanged against freshly prepared medium containing either 2.5 or 5.0 mmol/l of
the NO-donor SNAP or an equivalent amount DMSO in the negative control. After incubated for 24 h,
cells were harvested and RIPA lysates were generated as described in section 22.1. After adjusting all
samples to equal protein concentrations, SDS-PAGE and western blot were performed as described
in section 22. HSP90 staining served as loading control. Relative protein expression normalized to
HSP90 was determined densitometrically. Expression in the negative control was set to 1. Shown is a
representative blot from at least two experiments.
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Figure 35.3: Effects of Nitric oxide on the expression of E-cadherin and β-catenin in CaCo-2 cells – ICC-F.
CaCo-2 cells were seeded on coverslips and cultivated in 12-well-plates over a period of 14 days.
Culture medium was exchanged with freshly prepared medium containing 5.0 mmol/l of the NO-donor
SNAP or an equivalent amount DMSO in the negative control. After incubated for 24 h, the cells
were fixated and an ICC-F staining against E-cadherin (green) and β-catenin (red) was performed
as described in sec. 18. Cell nuclei were counterstained with Hoechst bisbenzimide H33258 (blue).
Shown are representative pictures from multiple experiments.
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Its ubiquitous expression not only in nearly all tissue compartments of the human
body [14] but also in the majority of all eukaryotes up to drosophila and C. elegans [100],
emphasizes the crucial role of IER3 in the regulation of cellular processes. For the
first time we address the myeloid specific effects of IER3 expression in the context of
AOM/DSS colitis and carcinogenesis in mice.
The infiltration of the lamina propria with M1 polarized MΦ is a critical step not only
during the initial phase of acute and chronic colitis but also during the progression of
inflammation. Thereby, macrophages have an essential role in the course of both IBD in
humans and DSS induced colitis in mice [192].
36 Phenotype differences and similarities between
Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice
In our experiments we did not observe any genotype specific difference in the number of
resident colonic MΦ between genotypes in Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-
Cre+/+ animals or between constitutive Ier3 wt and ko mice. Furthermore, the number of
MΦ infiltrating the mucosa and submucosa during DSS respectively AOM/DSS colitis
did not differ between the respectively genotypes. Hence, two important conclusions can
be drawn from these observations:
First, the macrophage’s IER3 status has no impact on the recruitment of MΦ to the colonic
mucosa under both, physiological and inflammatory conditions. Second, the differential
severity of the DSS as well as AOM/DSS induced colitis seen in Ier3-flox+/+ LysM-Cre-/- and
Ier3-flox+/+ LysM-Cre+/+ animals is not caused by a different number of infiltrating MΦ but
is, instead, the result of their distinct behavior depending on their respective IER3 status.
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Furthermore, our experiments revealed no differences in the integrity of the intestinal
barrier between healthy Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals.
There were not only no differences in their intestinal permeability to orally administered
FITC conjugated dextrans, but we could also not observe any difference in the expression
and localization of the tight junction related proteins E-cadherin and β-catenin in the
colon tissue of both genotypes (results not shown). This leads to the assumption, that
under physiological conditions, the IER3 expression in residual colonic macrophages
does not affect the expression of cellular junction related proteins in adjacent intestinal
epithelial cells. These findings correspond with the results of our in vitro experiments,
where we did not observe any differences in the permeability of CaCo-2 and IEC-6
monolayers to FITC dextran when co-cultivated with unstimulated primary MΦ derived
from BMCs of Ier3-flox+/+ LysM-Cre-/- or Ier3-flox+/+ LysM-Cre+/+ origin.
In contrast to the colon, where the macrophage’s IER3 status had no observable effect on
adjacent cells under physiological conditions, in other tissue compartments it had. As
described in the results, age matched Ier3-flox+/+ LysM-Cre+/+ animals showed on average
an 23 % increased body weight compared to their Ier3-flox+/+ LysM-Cre-/- littermates.
While many studies addressing the interplay of MΦ and mature adipocytes in fat tissue,
little is known about the role of MΦ in the physiological processes during adipogenesis
and adipocyte differentiation. However, there is a huge consensus, that the paracrine
secretion of several pro- and anti-inflammatory factors of tissue MΦ not only affects the
mitochondrial energy metabolism of mature adipocytes but also plays an important role
during the differentiation of their progenitors. Cheng et al. [221] demonstrated, that
the secretion of a typical M1 MΦ associated chemokine profile suppresses adipogenesis
while a more M2 like shifted profile promotes the differentiation into mature adipocytes.
The fat tissue itself secretes a variety of different hormones and cytokines, affecting the
phenotype of adjacent cells in a paracrine manner. It is conceivable that IER3 proficient
and deficient MΦ react differently to these stimuli. Hence, the body-weight differences
between healthy Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ mice, could be an
indicator of a differential cytokine expression profile of the fat tissue associated MΦ in
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these two mouse genotypes. However, it remains unclear whether these differences are
also true for the lamina propria populating MΦ Furthermore, we could not observe any
difference in the expression of typical M1 and M2 markers between genotypes in our
in vitro generated BMC derived MΦ (Results not shown). Shadid et al. [180] reported
an involvement of IER3 in the fat metabolism of mice. However, their results referred to
a genome wide Ier3 depletion in combination with a high-fat diet. Therefore, it seems
reasonable to further characterize the fat tissue as well as the LP populating MΦ in vivo
in prospective experiments.
Interestingly, there were no differences in the body weight between healthy constitutive
Ier3 wt and ko mice.
From all examined organs, only the ceca differed in their relative weight between
genotypes, while the absolute ceca weights were similar. This can be explained by the
fact, that the cecum size is independent of the body fat content, whereas the absolute
liver weight and, to a lesser degree, the spleen weight are.
Keeping in mind the body weight differences between the two mouse genotypes, the
dosages of all agents used in our in vivo experiments were body-weight adjusted to
exclude biases of the results due to body-weight related variations.
37 Myeloid IER3 deficiency protects mice during the initiation of
chronic DSS and AOM/DSS colitis
Mice with a myeloid IER3 depletion showed only very mild signs of inflammation
during the initial phase of both, chronic DSS and combined AOM/DSS colitis. This
obvious protective effect by Ier3 deficiency in MΦ became evident in all analyzed
disease parameters. Most importantly, in all conducted experiments Ier3-flox+/+ LysM-
Cre+/+ animals did not show significant loss of body weight during the initial phase,
whereas Ier3-flox+/+ LysM-Cre-/- lost on average 16 % in the DSS only experiment and
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11 % in the AOM/DSS experiment. The relative standard deviation of body weight
within the Ier3-flox+/+ LysM-Cre-/- cohort was remarkably high in contrast to the group
of Ier3-flox+/+ LysM-Cre+/+ mice, an observation that explains the fast recovery of body
weight in the Ier3-flox+/+ LysM-Cre-/- cohort until day 6 after termination of the DSS
treatment. Moreover, the most severely affected Ier3-flox+/+ LysM-Cre-/- animals had to
be excluded earlier from the experiment due to their poor health condition, so that only
the less affected animals account for the body weight curve during the last third of the
experiment. This also explains the reduced standard deviation in body weight curve of
Ier3-flox+/+ LysM-Cre-/- mice during this period.
The generally higher DSS responsiveness of Ier3-flox+/+ LysM-Cre-/- animals during the
DSS experiment also manifested in their already mentioned poorer overall survival rate
of 50 % compared to 100 % in the Ier3-flox+/+ LysM-Cre+/+ cohort. Interestingly, during the
AOM/DSS experiment non of the animals from both cohorts had to be excluded at this
time point, whereas a lower bleeding score and stool consistency herein clearly revealed
the protective effect of the myeloid IER3 deficiency.
Additionally, relative liver and spleen weights of the animals in the Ier3-flox+/+ LysM-
Cre-/- group were significantly increased compared to Ier3-flox+/+ LysM-Cre+/+ animals.
Both parameters are indicators of intense inflammation and/or a systematic infection.
A potential cause of the divergent DSS responsiveness between the individuals of the
Ier3-flox+/+ LysM-Cre-/- cohort would be a variation of their gut microbiome or other
housing related conditions. However, the responsiveness also varied between animals
in the same cage and deriving from the same mother. Thus, the mice had experienced
an identical vertical transmission (from the mother) of the microbiome, thus excluding
housing or microbiome dependent differences.
On the histological level, all animals in the DSS only experiment exhibited moderate
morphological tissue damages in some colon segments. As mentioned in the results, an
exact grading of the lesions in each colon has proven very difficult. However, colons
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in mice of both genotypes displayed a massive infiltration with MΦ, not only into
segments with visible tissue damage. As MΦ infiltrations take place already in quite
early stages of inflammation and before considerable tissue lesions develop, it is likely,
that the Ier3 deficient MΦ in Ier3-flox+/+ LysM-Cre+/+ animals are more supportive of
maintaining tissue integrity, whereas the Ier3 proficient (wild-type) M1-MΦ enhance
the inflammatory processes in Ier3-flox+/+ LysM-Cre-/- mice and contribute to the DSS
induced tissue damage in a positive feedback loop.
In support of the hypothesis above, in vivo permeability experiments revealed a 2.4-fold
higher intestinal permeability for FD4 (rH ≈ 14 Å) in Ier3-flox+/+ LysM-Cre-/- mice after
24 h treatment with DSS as compared with Ier3-flox+/+ LysM-Cre+/+ animals, whereas both
cohorts revealed only a marginal and statistically not relevant intestinal permeability to
FD10 (rH ≈ 23 Å).
While an effective lesion size of less than 23 Å is to small for whole bacterias to transmi-
grate into the mucosa, it allows the diffusion of soluble factors like LPS fragments from
disintegrated bacteria and other immunogenic antigens.
These findings could also be reproduced in vitro, where a co-cultivation with activated
primary MΦ derived from BMC of Ier3-flox+/+ LysM-Cre-/- animals for 48 h increased the
permeability of CaCo-2 cell monolayers to FD4 by factor 3.7, whereas the co-cultivation
with Ier3-flox+/+ LysM-Cre+/+ MΦ increased the permeability only by factor 2.0 (p=0.034).
38 Myeloid IER3 deficiency affects the expression of cellular
junction associated proteins in mucosal epithelial cells
Several authors reported altered expression profiles of the tight junction associated
proteins E-cadherin and β-catenin in the epithelial cell layer of the colonic mucosa during
both IBD in humans and DSS colitis in mice [130, 81, 44, 114, 156, 200]. We demonstrated,
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that the expression as well as the intracellular localization of these proteins is strongly
affected by the myeloid cells’s IER3 status during AOM/DSS colitis.
As described in the results, the expression level of both proteins was highly variable
per se, even within the colon of each mouse. However, in colon segments with a compa-
rable MΦ infiltration, the overall expression of E-cadherin as well as of β-catenin was
much higher in the Ier3-flox+/+ LysM-Cre+/+ cohort when compared to Ier3-flox+/+ LysM-
Cre-/- animals. These observations are particularly in line with the results from our in
vitro co-culture experiments of activated primary BMC derived IER3pos/neg MΦ and
intestinal epithelial cell monolayers of rat origin (IEC-6). Surprisingly, these IER3 related
differences in the expression of E-cadherin and β-catenin were not observable when the
co-cultivating the MΦ with intestinal epithelial cell monolayers of human adenocarcino-
mal origin (CaCo-2). This leads to the assumption, that at least one species dependent
factor expressed by the MΦ, which is compatible with rat but not with human cells,
is responsible for the altered expression of E-cadherin and β-catenin in the these cells.
Martini et al. [127] and Turner [200] point out the negative effects of increased TNF,
IFN-γ and IL-6 levels on the integrity on cellular junction proteins in IEC during IBD.
While we could not observe differences in the expression of these cytokines between
in vitro generated Ier3 proficient and deficient MΦ, these cytokines do not necessary
arise from them, but are also produced by IEC themselves in response to stimulation by
immune cells [127]. Another explanation could be, that CaCo-2 cells are generally not
affected in their expression of E-cadherin and β-catenin regarding this factor, due to their
transformed genotype as adenocarcinomal cell line.
Not only the intensity but also the intracellular localization of E-cadherin and β-catenin
differed between AOM/DSS challenged Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-
Cre+/+ mice. In segments with a moderate to high E-cadherin and β-catenin expression,
Ier3-flox+/+ LysM-Cre-/- mice revealed a higher grade of cytoplasmic internalization com-
pared to Ier3-flox+/+ LysM-Cre+/+ animals.
This severely altered expression/localization pattern of E-cadherin and β-catenin in
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Ier3-flox+/+ LysM-Cre-/- animals is presumably an essential cause for a disturbed tight
junction integrity as described by other authors [130, 114, 127].
The postulated maintenance of the junctional integrity in Ier3-flox+/+ LysM-Cre+/+ animals
reflects the results of our in-vivo and ex-vivo trans epithelial permeability (TEP) experi-
ments discussed above. Remarkably, the ex-vivo TEP experiments were not affected by
the species dependent differences between the MΦ and the CaCo-2 monolayers which
leads to two possible assumptions:
Either the increased permeability of the CaCo-2 monolayers caused by IER3 proficient
MΦ can be attributed exclusively to their increased release of RNS, which act across
species borders. The other possibility would be, that activated IER3 proficient and
deficient MΦ additionally differ in their expression profile of cellular junction integrity
affecting cytokines. The latter assumption is contradicted by the fact, that the number of
murine cytokines capable of binding to human receptors is limited and that we did not
find any expressional differences between Ier3 proficient and deficient MΦ of the gene
candidate analyzed by us.
However, further evidence could be provided by co-cultivating murine MΦ and human
IEC monolayers in presence of the iNOS inhibitor 1400W.
39 Myeloid IER3 deficiency protects mice from colitis associated
AOM/DSS carcinogenesis
As described in the results, at the end of the experiment all animals suffered from
the formation of colonic neoplasms, which were mostly located in the M2 and distal
quartile. However, with an average number of 3 neoplasms per animal, the number of
tumors in the Ier3-flox+/+ LysM-Cre+/+ cohort was significantly lower compared to the
Ier3-flox+/+ LysM-Cre-/- cohort (8 neoplasms per animal, p=0.009).
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These results clearly prove that the myeloid depletion of IER3 has a protective effect
on the formation of colitis associated neoplasms in the AOM/DSS mouse model. Still,
the underlying mechanisms are not fully clear and further investigations are needed to
elucidate whether the reduced tumor formation in Ier3-flox+/+ LysM-Cre+/+ animals is a
direct result of the attenuated inflammation or whether other mechanisms are involved.
Interestingly, in both cohorts the average size of the tumors did not differ (3 mm, p=0.328)
thus allowing two assumptions. On the one hand, it is possible that the neoplasms in
both genotypes arise at the same time point yielding in equal sizes when explored at
the end of experiment. On the other hand, the tumor formation in Ier3-flox+/+ LysM-
Cre-/- animals commences at an earlier time-point but their growth rate is lower than in
Ier3-flox+/+ LysM-Cre+/+ animals.
While the tumors themselves are mostly free of MΦ infiltrates, they are surrounded by
a huge number of them. It still needs to be investigated, if these surrounding MΦ are
of the same phenotype as the colitis associated M1 polarized MΦ or if they bear the
phenotype of typical M2 polarized tumor associated MΦ . If the tumor surrounding
MΦ should mainly posses the characteristics of the colitis associated MΦ, it could be
envisioned that the same effects which mitigate the inflammatory processes and the
onset of CAC in Ier3-flox+/+ LysM-Cre+/+ animals rather promote the growth of an already
existing neoplasm.
Our results are in accordance with the findings of Ustyugova et al. [202] who also
proposed an CAC protecting effect of IER3 deficiency in an AOM/DSS mouse model.
However, their experimental design differed in several aspects from ours, especially by
using a mouse model with a constitutive Ier3 knockout.
When analyzing the body weight recovery of the Ier3-flox+/+ LysM-Cre-/- animals after
the first DSS cycle, it could be appreciated that both cohorts exhibited similar responses
regarding their body weight during the following DSS cycles. The obviously faster body
weight recovery rate of the Ier3-flox+/+ LysM-Cre-/- cohort after the third DSS cycle, is
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due to the fact, that several Ier3-flox+/+ LysM-Cre-/- animals were at a poor general health
condition during this period and had to be excluded from the experiment.
Despite the reduced inflammatory activity of IER3 deficient MΦ, the initially unaffected
colonic tissue in Ier3-flox+/+ LysM-Cre+/+ animals became more vulnerable of acute toxicity
by the DSS treatment during the third cycle giving rise of some tissue damage at this
later stage. However, except the similar weight loss in both cohorts after the third DSS
cycle, other colitis associated parameters like bleeding scores and stool consistency were
less pronounced in the Ier3-flox+/+ LysM-Cre+/+ cohort. This also reflects in the higher
overall survival rate of 70 % compared to 50 % in the Ier3-flox+/+ LysM-Cre-/- group.
Unexpectedly, the relative spleen weights in the Ier3-flox+/+ LysM-Cre-/- cohort were signif-
icantly lower compared to those in the Ier3-flox+/+ LysM-Cre+/+ group. This observation
could be explained by the fact that the majority of the Ier3-flox+/+ LysM-Cre-/- animals
had to be excluded earlier from the experiment due to their poor health condition, before
a systemic infection could manifest.
40 The tissue protective effect of myeloid IER3 deficiency is less
pronounced in acute high DSS colitis
The body weight loss of Ier3-flox+/+ LysM-Cre+/+ animals after the administration of high
DSS (30 g/l) over a period of 9 days to induce an acute colitis was indeed less pronounced
compared to Ier3-flox+/+ LysM-Cre-/- animals. We assume, that in these experiment the
putative colitis protecting effects of a myeloid IER3-deficiency were mostly prevailed by
the massive disruption of the mucosal epithelial cell barrier caused by the acute toxicity
of high dose DSS. However, in one experiment, the animals of the Ier3-flox+/+ LysM-
Cre-/- cohort exhibited a significantly higher relative spleen weight, indicating a systemic
bacterial infection.
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41 Comparison with effects of Ier3 depletion in other tissue
compartments
Even if statistically significant, the putative protective effects of an epithelial IER3 de-
ficiency during the onset of an acute DSS colitis should not be overestimated, since
they could not be observed during the initial phase of chronic DSS colitis in a second
experiment. Hence, further DSS experiments are necessary to conclusively assess the
impact of epithelial IER3 expression on the outcome of DSS colitis.
In mice with a constitutive IER3 deficiency, differences in the clinical outcome of both,
acute as well chronic DSS colitis are much less pronounced between genotypes compared
to Ier3-flox+/+ LysM-Cre-/- and Ier3-flox+/+ LysM-Cre+/+ animals. This is a strong indicator,
that an IER3 depletion in other tissue compartments than the myeloid exhibits rather
inflammation promoting properties contrasting the protective effects of IER3 deficient
MΦ. This is in line with previous observations of our group, that IER3 in general
attenuates the expression of pro-inflammatory cytokines under control of NF-κB. Sina et
al. even proposed a putative protective effect of a genome wide IER3 expression during
DSS colitis in mice [183]. However, such deviations can be explained not only by genomic
differences between diverse mouse strains but also by different housing conditions and
hereby alterations in the mice’s microbiome, which both have a considerable impact on
the outcome of a DSS experiment.
42 Similarities and differences between IER3 proficient and
deficient in vitro generated BMC derived primary MΦ
42.1 Ier3 mRNA expression
Besides the prove of the specific depletion of the Ier3 gene in the Ier3-flox+/+ LysM-
Cre+/+ mice used in the experiments, we demonstrated a successfully suppression
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of Ier3 on the mRNA level in primary MΦ derived from BMC of Ier3-flox+/+ LysM-
Cre+/+ mice. Furthermore we could show, that the Ier3 mRNA expression in primary
MΦ from Ier3-flox+/+ LysM-Cre-/- mice is triggered by LPS in a dose dependent manner.
These results are in accordance with former findings of our and other groups, describing
a general upregulation of IER3 in response to immunogenic stimuli [183, 160].
42.2 Polarization
As described in the introduction, M1 polarized MΦ are the main subpopulation of
MΦ mostly contributing to inflammatory processes as well as to the induction of
inflammatory associated neoplasm in the gut66. Therefore it was our goal to generate
MΦ with typical M1 characteristics for our ex vivo experiments. Due to the high
number of different protocols described in the literature, we tested several approaches
and characterized the generated cells by flow cytometry (results not shown). Eventually,
we decided to use M-CSF instead of GM-CSF as main cytokine for MΦ differentiation,
because the latter one leads not only to the generation of MΦ but also to a variety of
other cell populations, mainly dendritic cells and granulocytes. The addition of IFN-γ in
combination with M-CSF directed the differentiation of the MΦ towards a M1-like
phenotype. We could observe no differences in the expression of typical M1 markers like
CD80 and MHC II between M-CSF/IFN-γ and GM-CSF differentiated F4/80-positive
cells derived from BMC (results not shown). The same is true for the absence of the M2
marker CD200R. Interestingly, the GM-CSF differentiated bone marrow cells exhibited
greater morphological differences between the genotypes (results not shown), which
were not manifested in M-CSF differentiated MΦ.
An expansion of the M-CSF differentiation period longer than seven days had no effect
on the yield of F4/80-positive cells of ≥ 75 %. A possible explanation is, that a fraction
of the BMC was already in an early differentiated state towards other cell types, which
66In later stages the mostly M2 polarized tumor associated MΦ contribute significantly to the progression
of tumor.
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could not be altered anymore by M-CSF/IFN-γ. This assumption is supported by the
fact, M-CSF triggers not only the differentiation of MΦ but is also involved in the
differentiation of a variety of other cell types.
However, there were no significant differences in the yield of F4/80+/CD11b+, F4/80+/CD11b−
and F4/80−/CD11b+ cells between both genotypes. This is even more remarkably, as
Pietzsch et al. [160] assume the involvement of IER3 in differentiation process from
monocytes to MΦ. It remains to be investigated if our findings from these ex vivo
experiments can be transfered to MΦ under in vivo conditions.
42.3 Cytokine expression
Surprisingly, we did not observe significant differences in the mRNA-expression profile
of inflammation related cytokines between in vitro generated BMC-derived MΦ from
both genotypes on basal level as well as after stimulation with LPS. This, in combination
with the relative high standard deviation, could be an additional indicator for a putative
contamination of the MΦ population with other cell types, masking the effects of a
MΦ specific Ier3 depletion.
Considering the much higher LPS induced mRNA-expression of the pro-inflammatory
cytokines TNF (up to 65-fold), IL-1β (up to 3300-fold), and IL-6 (up to 3000-fold)
compared to the much lower LPS induced expression of the anti-inflammatory cytokines
IL-10 (up to factor 5) and TGF-β (up to factor 1.5) is a further indicator for the M1
polarization of the in vitro generated MΦ.
42.4 IER3 deficient MMΦ produce less RNS in response to immunogenic
stimuli
We demonstrate for the first time, that IER3 has a direct impact on the expression of
the iNOS as well as on the release of RNS in MΦ in response to immunogenic stimuli.
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While previous studies of our group clearly showed an attenuation of the NF-κB cascade
by IER3 in a variety of different cell lines, these mechanism seem to be superimposed
in MΦ from Ier3-flox+/+ LysM-Cre+/+ animals by other effects, leading to a decreased
iNOS expression and a diminished production of RNS. Although the exact mechanisms
underlying these effects are not yet elucidated, we could identify some starting points for
further investigations. The macrophage cell lines RAW264.7 and THP-1 express higher
levels of heme oxygenase in response to LPS when Ier3 is depleted [75]. Furthermore,
it is conceivable that Ier3 deficient MΦexpress lower levels of immunogenic receptors,
which would make them less responsive to certain stimuli. For instance, Akilov et al.
[18] reported a correlation between the expression levels TNF receptor 1 (TNFR1) and
IER3 in patients suffering from the Sézary syndrome.
43 Increased levels of NOx induce in vitro a damage pattern
similar to the one caused by activated wt MΦ
When administered exogenously, the damages nitric oxide causes to CaCo-2 and IEC-6
monolayers resembles the effects of LPS activated Ier3-flox+/+ LysM-Cre-/- BMC derived
MΦ. NOx inhibits the expression of E-cadherin as well as of β-catenin in these cells
in a dose dependent manner. Additionally, we demonstrated for CaCo-2 monolayers
that NOx not only inhibits the expression of these proteins but also but also elicits their
translocation from the cell-cell contact sites towards the cytoplasm.
Furthermore, we demonstrated that these effects result in an increased transepithelial
permeability of CaCo-2 monolayers to FD4, similar to the one caused by Ier3-flox+/+ LysM-
Cre-/- BMC derived MΦ.
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44 Conclusion
When summarizing the results from our in-vivo and in-vitro experiments, one can con-
clude that the reduced severity of an AOM/DSS colitis in Ier3-flox+/+ LysM-Cre+/+ animals
is mainly due to the decreased release of reactive nitrogen species from their intestinal
macrophages in response to immunogenic stimuli. The lower concentration of RNS in
their periphery allows intestinal epithelial cells to maintain their physiological expression
and localization of E-cadherin and β-catenin, thereby preventing the disintegration of the
cellular junction complex (fig. 44.1). Our experiments clearly demonstrate the similarity
between the damage pattern caused by NOx in vitro on the one hand and by infiltrating
proinflammatory MΦ on the other hand. All these effects are distinctly attenuated in
Ier3-flox+/+ LysM-Cre+/+ MΦ which distinguish from Ier3-flox+/+ LysM-Cre-/- MΦ mainly
in their release of RNS in response to LPS.
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Figure 44.1: Proposed effects of myeloid IER3 on the interplay between the colonic microbiome,
macrophages and the integrity of cellular junctions in the mucosa’s epithelial cell layer.
As an important mechanisms of the attenuated NOx release in Ier3 deficient MΦ it
could be shown that in the absence of IER3 the activity of the antioxidant transcription
factor NRF2 increased - due to its elevated AKT mediated derepression - as we already
demonstrated in vitro and in vivo [191, 75]. Under the control of NRF2, its target gene
heme oxygenase 1 (HO1) could interfere with iNOS expression and activation, thus
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resulting in the dampened NOx formation seen in Ier3 deficient MΦ (fig. 44.2).
IER3
HO1
iNOS
ARE
NRF2
NRF2
HO1
Arg NO
Figure 44.2: Hypothesis for the attenuated NOx release of Ier3 deficient MΦ. After data from STACHEL et
al. [191] and GRAEBER [75]. ARE: Antioxidant responsive element; HO1: heme oxygenase 1; NRF2:
Nuclear factor erythroid 2-related factor 2. Dotted line: Indirect impact.
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Appendix
A Figure sources
All figures depicted in this thesis, which were not generated by the author himself are
listed in the table A.1 together with their respectively source. This also includes figures,
which were adapted and modified.
Some of the depicted graphics were generated using the MotifolioTM scientific toolkit
library.
Table A.1: List of adapted and modified figures depicted in this thesis.
Figure Source
1.1 Modified from Blausen cb [39].
3.2 Adapted from Baumgart et al. [30].
3.3 Created after data from Fearon/Vogelstein et al. [59] and Rogler et al. [168].
4.1 Adapted and modified from Arlt et Schaefer [26].
4.2 Adapted from Costello et al. [46].
8.2 Adapted from Sigma-Aldrich [11].
44.2 Created after data from Stachel et al. [191] and Graeber [75].
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Software
B Software
Table B.1 lists the software utilized for acquisition, analysis, processing, validation and
visualization of the data incorporated in this thesis. It further lists the software utilized
to create this thesis itself. References are given if available. Inquired databases are not
listed.
Table B.1: List of software utilized for this thesis. Scientific references are listed if available. Otherwise the
developers/distributors URL is listed.
Software Version
Developer/ Reference/
distributor URL
Alpha ViewTM 3.0 AlphaInnotec [3]
Axio VisionTM 2.8 Carl Zeiss [6]
BZ-ViewerTM 2.0 Keyence [8]
CFX MaestroTM 4.1 BioRad [5]
FACSuiteTM 1.0.5 BD [4]
Fiji/ImageJ 1.52 The Fiji project∗∗ [172]
GIMP 2.8.22 The GIMP project∗∗ [187]
Gnome Chem Utils 0.14.16 The Gnome project∗∗ [1]
Gnumeric 1.12.35 The Gnumeric project∗∗ [203]
iControlTM 1.6 Tecan [12]
Inkscape 0.92 The Inkscape project∗∗ [49]
LibreOffice suite 6.0.7.3 The LibreOffice project∗∗ [9]
Lyx / LaTex 2.3.3 The Lyx project∗∗ [216]
MotifolioTM toolkit library n/a Motifolio [10]
ND-1000 3.3 Thermo [13]
Primer-BLAST rr NCBI [217]
Quantity OneTM 4.5 BioRad [5]
RevelationTM 4.25 Dynex [7]
Ubuntu GNU/Linux∗ 16.04 / 18.04 Canonical [137]
ZenTM software suite 2.0 Carl Zeiss [6]
Zotero 5.0.82 The Zotero project∗∗ [108]
Legend:
∗: Debian based
∗∗: Community based open source project
NCBI: National Center of Biotechnology Information
rr: rolling release
URL: Uniform resource locator
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Animal experiments
C Animal experiments
All animals were housed and bred under S1 conditions in the central animal housing
facility of the Christan Albrechts University Kiel (Building U39, UKSH Campus Kiel)
pursuant to the European and German animal welfare regulations.
All experiments were conducted in accordance with the European and German animal
welfare regulations and were approved by the admission authorities of the Federal State
of Schleswig-Holstein (File no. 155-11/13).
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